{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:20:04Z","timestamp":1775607604948,"version":"3.50.1"},"reference-count":401,"publisher":"Bentham Science Publishers Ltd.","issue":"27","funder":[{"DOI":"10.13039\/501100018786","name":"Deanship of Scientific Research at Al-Zaytoonah University of Jordan","doi-asserted-by":"publisher","award":["2020-2019\/17\/03"],"award-info":[{"award-number":["2020-2019\/17\/03"]}],"id":[{"id":"10.13039\/501100018786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Vaccines are instrumental tools to fight against novel and re-emerging pathogens and\ncurb pandemics. Vaccination has been an integral part of the multifaceted public health response to\nthe COVID-19 pandemic. Diverse vaccine platforms have been designed and are currently at different stages of development. Some vaccines are still in early biological testing, while others have\nbeen launched after being approved by regulatory agencies worldwide. Genomic vaccines that deliver parts of the viral DNA or RNA to host cells have gained popularity recently due to their high\nefficiency and fast manufacture. Furthermore, recent clinical studies encouraged the use of different vaccine platforms within the primary vaccination course to enhance the efficacy of vaccination.\nHerein, we discuss COVID-19 genomic vaccines, which deliver viral genetic material to host cells\nthrough diverse biotechnology platforms, including viral vector vaccines, messenger RNA nucleic\nacid vaccines, and DNA nucleic acid vaccines. We compare and contrast vaccine characteristics,\ncomposition, and pros and cons among different genomic vaccine platforms as well as non-genomic vaccines. This review summarizes all current knowledge about COVID-19 genomic vaccines,\nwhich could be highly valuable to researchers interested in public health and vaccine development.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026623666230825094341","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:52:02Z","timestamp":1692964322000},"page":"2552-2589","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Critical Assessment of COVID-19 Genomic Vaccines"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-5097","authenticated-orcid":true,"given":"Dima A.","family":"Sabbah","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, 11733, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-5425","authenticated-orcid":true,"given":"Rima","family":"Hajjo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, 11733, Jordan"},{"name":"Laboratory\nfor Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy,\nThe University of North Carlina at Chapel Hill, Chapel Hill, NC, 27599, USA"},{"name":"National Center for Epidemics and\nCommunicable Disease Control (JCDC), Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-1390","authenticated-orcid":true,"given":"Suhair","family":"Sunoqrot","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, 11733, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46405\/ejms.v2i1.38","volume":"2","author":"Sajed A.N.","year":"2020","unstructured":"Sajed A.N.; Amgain K.; Corona virus disease (COVID-19) outbreak and the strategy for prevention. Eur J Med Sci 2020,2(1),1-3","journal-title":"Eur J Med Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1620\/tjem.250.271","volume":"250","author":"Baloch S.","year":"2020","unstructured":"Baloch S.; Baloch M.A.; Zheng T.; Pei X.; The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med 2020,250(4),271-278","journal-title":"Tohoku J Exp Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/1995-7645.281612","volume":"13","author":"Anjorin A.","year":"2020","unstructured":"Anjorin A.; The coronavirus disease 2019 (COVID-19) pandemic: A review and an update on cases in Africa. Asian Pac J Trop Med 2020,13(5),199","journal-title":"Asian Pac J Trop Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/microorganisms11041048","volume":"11","author":"Contini C.","year":"2023","unstructured":"Contini C.; Rotondo J.C.; Perna B.; Guarino M.; De Giorgio R.; Special issue: Advances in SARS-CoV-2 infection. Microorganisms 2023,11(4),1048","journal-title":"Microorganisms"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.37201\/req\/122.2022","volume":"36","author":"Mart\u00edn-S\u00e1nchez F.J.","year":"2023","unstructured":"Mart\u00edn-S\u00e1nchez F.J.; Mart\u00ednez-Sell\u00e9s M.; Molero Garc\u00eda J.M.; Moreno Guill\u00e9n S.; Rodr\u00edguez-Artalejo F.; Ruiz-Galiana J.; Cant\u00f3n R.; De Lucas Ramos P.; Garc\u00eda-Botella A.; Garc\u00eda-Lled\u00f3 A.; Hern\u00e1ndez-Sampelayo T.; G\u00f3mez-Pav\u00f3n J.; Gonz\u00e1lez del Castillo J.; Mart\u00edn-Delgado M.C.; Bouza E.; Insights for COVID-19 in 2023. Rev Esp Quimioter 2023,36(2),114-124","journal-title":"Rev Esp Quimioter"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14787210.2021.1863146","volume":"19","author":"Tsang H.F.","year":"2021","unstructured":"Tsang H.F.; Chan L.W.C.; Cho W.C.S.; Yu A.C.S.; Yim A.K.Y.; Chan A.K.C.; Ng L.P.W.; Wong Y.K.E.; Pei X.M.; Li M.J.W.; Wong S.C.C.; An update on COVID-19 pandemic: The epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther 2021,19(7),877-888","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/microorganisms10061193","volume":"10","author":"Rotondo J.C.","year":"2022","unstructured":"Rotondo J.C.; Martini F.; Maritati M.; Caselli E.; Gallenga C.E.; Guarino M.; De Giorgio R.; Mazziotta C.; Tramarin M.L.; Badiale G.; Tognon M.; Contini C.; Advanced molecular and immunological diagnostic methods to detect SARS-CoV-2 infection. Microorganisms 2022,10(6),1193","journal-title":"Microorganisms"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/molecules26010039","volume":"26","author":"Khan M.","year":"2020","unstructured":"Khan M.; Adil S.F.; Alkhathlan H.Z.; Tahir M.N.; Saif S.; Khan M.; Khan S.T.; COVID-19: A global challenge with old history, epidemiology and progress so far. Molecules 2020,26(1),39","journal-title":"Molecules"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.accpm.2020.10.008","volume":"39","author":"Rello J.","year":"2020","unstructured":"Rello J.; Belliato M.; Dimopoulos M.A.; Giamarellos-Bourboulis E.J.; Jaksic V.; Martin-Loeches I.; Mporas I.; Pelosi P.; Poulakou G.; Pournaras S.; Tamae-Kakazu M.; Timsit J.F.; Waterer G.; Tejada S.; Dimopoulos G.; Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesth Crit Care Pain Med 2020,39(6),723-730","journal-title":"Anaesth Crit Care Pain Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11606-022-07908-4","volume":"38","author":"Danesh V.","year":"2023","unstructured":"Danesh V.; Arroliga A.C.; Bourgeois J.A.; Boehm L.M.; McNeal M.J.; Widmer A.J.; McNeal T.M.; Kesler S.R.; Symptom clusters seen in adult COVID-19 recovery clinic care seekers. J Gen Intern Med 2023,38(2),442-449","journal-title":"J Gen Intern Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"Davis H.E.","year":"2021","unstructured":"Davis H.E.; Assaf G.S.; McCorkell L.; Wei H.; Low R.J.; Re\u2019em Y.; Redfield S.; Austin J.P.; Akrami A.; Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021,38,101019","journal-title":"EClinicalMedicine"},{"key":"ref=12","year":"2021","unstructured":"A detailed study of patients with long-haul COVID\u2014an analysis of private healthcare claims 2021","journal-title":"A detailed study of patients with long-haul COVID\u2014an analysis of private healthcare claims"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(23)00810-3","volume":"401","author":"Huang C.","year":"2023","unstructured":"Huang C.; Huang L.; Wang Y.; Li X.; Ren L.; Gu X.; Kang L.; Guo L.; Liu M.; Zhou X.; Luo J.; Huang Z.; Tu S.; Zhao Y.; Chen L.; Xu D.; Li Y.; Li C.; Peng L.; Li Y.; Xie W.; Cui D.; Shang L.; Fan G.; Xu J.; Wang G.; Wang Y.; Zhong J.; Wang C.; Wang J.; Zhang D.; Cao B.; 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 2023,401(10393),e21-e33","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"104413","DOI":"10.1016\/j.ebiom.2022.104413","volume":"87","author":"Reese J.T.","year":"2023","unstructured":"Reese J.T.; Blau H.; Casiraghi E.; Bergquist T.; Loomba J.J.; Callahan T.J.; Laraway B.; Antonescu C.; Coleman B.; Gargano M.; Wilkins K.J.; Cappelletti L.; Fontana T.; Ammar N.; Antony B.; Murali T.M.; Caufield J.H.; Karlebach G.; McMurry J.A.; Williams A.; Moffitt R.; Banerjee J.; Solomonides A.E.; Davis H.; Kostka K.; Valentini G.; Sahner D.; Chute C.G.; Madlock-Brown C.; Haendel M.A.; Robinson P.N.; Spratt H.; Visweswaran S.; Flack J.E.; Yoo Y.J.; Gabriel D.; Alexander G.C.; Mehta H.B.; Liu F.; Miller R.T.; Wong R.; Hill E.L.; Thorpe L.E.; Divers J.; Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes. EBioMedicine 2023,87,104413","journal-title":"EBioMedicine"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2023.8823","volume":"329","author":"Thaweethai T.","year":"2023","unstructured":"Thaweethai T.; Jolley S.E.; Karlson E.W.; Levitan E.B.; Levy B.; McComsey G.A.; McCorkell L.; Nadkarni G.N.; Parthasarathy S.; Singh U.; Walker T.A.; Selvaggi C.A.; Shinnick D.J.; Schulte C.C.M.; Atchley-Challenner R.; Alba G.A.; Alicic R.; Altman N.; Anglin K.; Argueta U.; Ashktorab H.; Baslet G.; Bassett I.V.; Bateman L.; Bedi B.; Bhattacharyya S.; Bind M.A.; Blomkalns A.L.; Bonilla H.; Bush P.A.; Castro M.; Chan J.; Charney A.W.; Chen P.; Chibnik L.B.; Chu H.Y.; Clifton R.G.; Costantine M.M.; Cribbs S.K.; Davila Nieves S.I.; Deeks S.G.; Duven A.; Emery I.F.; Erdmann N.; Erlandson K.M.; Ernst K.C.; Farah-Abraham R.; Farner C.E.; Feuerriegel E.M.; Fleurimont J.; Fonseca V.; Franko N.; Gainer V.; Gander J.C.; Gardner E.M.; Geng L.N.; Gibson K.S.; Go M.; Goldman J.D.; Grebe H.; Greenway F.L.; Habli M.; Hafner J.; Han J.E.; Hanson K.A.; Heath J.; Hernandez C.; Hess R.; Hodder S.L.; Hoffman M.K.; Hoover S.E.; Huang B.; Hughes B.L.; Jagannathan P.; John J.; Jordan M.R.; Katz S.D.; Kaufman E.S.; Kelly J.D.; Kelly S.W.; Kemp M.M.; Kirwan J.P.; Klein J.D.; Knox K.S.; Krishnan J.A.; Kumar A.; Laiyemo A.O.; Lambert A.A.; Lanca M.; Lee-Iannotti J.K.; Logarbo B.P.; Longo M.T.; Luciano C.A.; Lutrick K.; Maley J.H.; Marathe J.G.; Marconi V.; Marshall G.D.; Martin C.F.; Matusov Y.; Mehari A.; Mendez-Figueroa H.; Mermelstein R.; Metz T.D.; Morse R.; Mosier J.; Mouchati C.; Mullington J.; Murphy S.N.; Neuman R.B.; Nikolich J.Z.; Ofotokun I.; Ojemakinde E.; Palatnik A.; Palomares K.; Parimon T.; Parry S.; Patterson J.E.; Patterson T.F.; Patzer R.E.; Peluso M.J.; Pemu P.; Pettker C.M.; Plunkett B.A.; Pogreba-Brown K.; Poppas A.; Quigley J.G.; Reddy U.; Reece R.; Reeder H.; Reeves W.B.; Reiman E.M.; Rischard F.; Rosand J.; Rouse D.J.; Ruff A.; Saade G.; Sandoval G.J.; Schlater S.M.; Shepherd F.; Sherif Z.A.; Simhan H.; Singer N.G.; Skupski D.W.; Sowles A.; Sparks J.A.; Sukhera F.I.; Taylor B.S.; Teunis L.; Thomas R.J.; Thorp J.M.; Thuluvath P.; Ticotsky A.; Tita A.T.; Tuttle K.R.; Urdaneta A.E.; Valdivieso D.; VanWagoner T.M.; Vasey A.; Verduzco-Gutierrez M.; Wallace Z.S.; Ward H.D.; Warren D.E.; Weiner S.J.; Welch S.; Whiteheart S.W.; Wiley Z.; Wisnivesky J.P.; Yee L.M.; Zisis S.; Horwitz L.I.; Foulkes A.S.; Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023,329(22),1934-1946","journal-title":"JAMA"},{"key":"ref=16","first-page":"103","volume":"5","author":"Schang L.M.","year":"2003","unstructured":"Schang L.M.; The cell cycle, cyclin-dependent kinases, and viral infections: New horizons and unexpected connections. Prog Cell Cycle Res 2003,5,103-124","journal-title":"Prog Cell Cycle Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","volume":"395","author":"Brisson M.","year":"2020","unstructured":"Brisson M.; Kim J.J.; Canfell K.; Drolet M.; Gingras G.; Burger E.A.; Martin D.; Simms K.T.; B\u00e9nard \u00c9.; Boily M.C.; Sy S.; Regan C.; Keane A.; Caruana M.; Nguyen D.T.N.; Smith M.A.; Laprise J.F.; Jit M.; Alary M.; Bray F.; Fidarova E.; Elsheikh F.; Bloem P.J.N.; Broutet N.; Hutubessy R.; Impact of HPV vaccination and cervical screening on cervical cancer elimination: A comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 2020,395(10224),575-590","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","volume":"8","author":"Zou Z.","year":"2020","unstructured":"Zou Z.; Fairley C.K.; Ong J.J.; Hocking J.; Canfell K.; Ma X.; Chow E.P.F.; Xu X.; Zhang L.; Zhuang G.; Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: A cost-effectiveness analysis. Lancet Glob Health 2020,8(10),e1335-e1344","journal-title":"Lancet Glob Health"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1017\/S0950268815002198","volume":"144","author":"Castle P.E.","year":"2016","unstructured":"Castle P.E.; Maza M.; Prophylactic HPV vaccination: Past, present, and future. Epidemiol Infect 2016,144(3),449-468","journal-title":"Epidemiol Infect"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"de Martel C.","year":"2017","unstructured":"de Martel C.; Plummer M.; Vignat J.; Franceschi S.; Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017,141(4),664-670","journal-title":"Int J Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"de Martel C.","year":"2020","unstructured":"de Martel C.; Georges D.; Bray F.; Ferlay J.; Clifford G.M.; Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health 2020,8(2),e180-e190","journal-title":"Lancet Glob Health"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"100836","DOI":"10.1016\/j.eclinm.2021.100836","volume":"34","author":"Dorji T.","year":"2021","unstructured":"Dorji T.; Nopsopon T.; Tamang S.T.; Pongpirul K.; Human papillomavirus vaccination uptake in low-and middle-income countries: A meta-analysis. EClinicalMedicine 2021,34,100836","journal-title":"EClinicalMedicine"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1056\/NEJMsr1513109","volume":"375","author":"Agua-Agum J.","year":"2016","unstructured":"Agua-Agum J.; Allegranzi B.; Ariyarajah A.; Aylward R.; Blake I.M.; Barboza P.; Bausch D.; Brennan R.J.; Clement P.; Coffey P.; Cori A.; Donnelly C.A.; Dorigatti I.; Drury P.; Durski K.; Dye C.; Eckmanns T.; Ferguson N.M.; Fraser C.; Garcia E.; Garske T.; Gasasira A.; Gurry C.; Hamblion E.; Hinsley W.; Holden R.; Holmes D.; Hugonnet S.; Jaramillo Gutierrez G.; Jombart T.; Kelley E.; Santhana R.; Mahmoud N.; Mills H.L.; Mohamed Y.; Musa E.; Naidoo D.; Nedjati-Gilani G.; Newton E.; Norton I.; Nouvellet P.; Perkins D.; Perkins M.; Riley S.; Schumacher D.; Shah A.; Tang M.; Varsaneux O.; Van Kerkhove M.D.; After Ebola in West Africa-unpredictable risks, preventable epidemics. N Engl J Med 2016,375(6),587-596","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"S698","DOI":"10.1093\/infdis\/jiy213","volume":"218","author":"Huber C.","year":"2018","unstructured":"Huber C.; Finelli L.; Stevens W.; The economic and social burden of the 2014 Ebola outbreak in West Africa. J Infect Dis 2018,218(Suppl. 5),S698-S704","journal-title":"J Infect Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"Jones S.M.","year":"2005","unstructured":"Jones S.M.; Feldmann H.; Str\u00f6her U.; Geisbert J.B.; Fernando L.; Grolla A.; Klenk H.D.; Sullivan N.J.; Volchkov V.E.; Fritz E.A.; Daddario K.M.; Hensley L.E.; Jahrling P.B.; Geisbert T.W.; Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005,11(7),786-790","journal-title":"Nat Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"Henao-Restrepo A.M.","year":"2017","unstructured":"Henao-Restrepo A.M.; Camacho A.; Longini I.M.; Watson C.H.; Edmunds W.J.; Egger M.; Carroll M.W.; Dean N.E.; Diatta I.; Doumbia M.; Draguez B.; Duraffour S.; Enwere G.; Grais R.; Gunther S.; Gsell P.S.; Hossmann S.; Watle S.V.; Kond\u00e9 M.K.; K\u00e9\u00efta S.; Kone S.; Kuisma E.; Levine M.M.; Mandal S.; Mauget T.; Norheim G.; Riveros X.; Soumah A.; Trelle S.; Vicari A.S.; R\u00f8ttingen J.A.; Kieny M.P.; Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 2017,389(10068),505-518","journal-title":"Lancet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17512433.2021.1902303","volume":"14","author":"Rahman S.","year":"2021","unstructured":"Rahman S.; Montero M.T.V.; Rowe K.; Kirton R.; Kunik F.; Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: A review of current evidence. Expert Rev Clin Pharmacol 2021,14(5),601-621","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","volume":"6","author":"Mendon\u00e7a S.A.","year":"2021","unstructured":"Mendon\u00e7a S.A.; Lorincz R.; Boucher P.; Curiel D.T.; Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 2021,6(1),97","journal-title":"NPJ Vaccines"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1523\/JNEUROSCI.13-04-01676.1993","volume":"13","author":"Pike C.J.","year":"1993","unstructured":"Pike C.J.; Burdick D.; Walencewicz A.J.; Glabe C.G.; Cotman C.W.; Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 1993,13(4),1676-1687","journal-title":"J Neurosci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1101\/gad.851100","volume":"14","author":"Jeffrey P.D.","year":"2000","unstructured":"Jeffrey P.D.; Tong L.; Pavletich N.P.; Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev 2000,14(24),3115-3125","journal-title":"Genes Dev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","volume":"19","author":"Nagy A.","year":"2021","unstructured":"Nagy A.; Alhatlani B.; An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J 2021,19,2508-2517","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/35106065","volume":"1","author":"Malumbres M.","year":"2001","unstructured":"Malumbres M.; Barbacid M.; To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 2001,1(3),222-231","journal-title":"Nat Rev Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/microorganisms10071450","volume":"10","author":"Deng S.","year":"2022","unstructured":"Deng S.; Liang H.; Chen P.; Li Y.; Li Z.; Fan S.; Wu K.; Li X.; Chen W.; Qin Y.; Yi L.; Chen J.; Viral vector vaccine development and application during the COVID-19 pandemic. Microorganisms 2022,10(7),1450","journal-title":"Microorganisms"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2018.02.002","volume":"29","author":"Baron M.D.","year":"2018","unstructured":"Baron M.D.; Iqbal M.; Nair V.; Recent advances in viral vectors in veterinary vaccinology. Curr Opin Virol 2018,29,1-7","journal-title":"Curr Opin Virol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMe2112543","volume":"385","author":"Lee G.M.","year":"2021","unstructured":"Lee G.M.; The importance of context in Covid-19 vaccine safety. N Engl J Med 2021,385(12),1138-1140","journal-title":"N Engl J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.15585\/mmwr.mm7032e3","volume":"70","author":"Moline H.L.","year":"2021","unstructured":"Moline H.L.; Whitaker M.; Deng L.; Rhodes J.C.; Milucky J.; Pham H.; Patel K.; Anglin O.; Reingold A.; Chai S.J.; Alden N.B.; Kawasaki B.; Meek J.; Yousey-Hindes K.; Anderson E.J.; Farley M.M.; Ryan P.A.; Kim S.; Nunez V.T.; Como-Sabetti K.; Lynfield R.; Sosin D.M.; McMullen C.; Muse A.; Barney G.; Bennett N.M.; Bushey S.; Shiltz J.; Sutton M.; Abdullah N.; Talbot H.K.; Schaffner W.; Chatelain R.; Ortega J.; Murthy B.P.; Zell E.; Schrag S.J.; Taylor C.; Shang N.; Verani J.R.; Havers F.P.; Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged\u2265 65 years\u2014COVID-NET, 13 states, February\u2013April 2021. MMWR Morb Mortal Wkly Rep 2021,70(32),1088-1093","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","volume":"70","author":"Rosenblum H.G.","year":"2021","unstructured":"Rosenblum H.G.; Hadler S.C.; Moulia D.; Shimabukuro T.T.; Su J.R.; Tepper N.K.; Ess K.C.; Woo E.J.; Mba-Jonas A.; Alimchandani M.; Nair N.; Klein N.P.; Hanson K.E.; Markowitz L.E.; Wharton M.; McNally V.V.; Romero J.R.; Talbot H.K.; Lee G.M.; Daley M.F.; Mbaeyi S.A.; Oliver S.E.; Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson and Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices-United States, July 2021. MMWR Morb Mortal Wkly Rep 2021,70(32),1094-1099","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.15585\/mmwr.mm7017e4","volume":"70","author":"MacNeil J.R.","year":"2021","unstructured":"MacNeil J.R.; Su J.R.; Broder K.R.; Guh A.Y.; Gargano J.W.; Wallace M.; Hadler S.C.; Scobie H.M.; Blain A.E.; Moulia D.; Daley M.F.; McNally V.V.; Romero J.R.; Talbot H.K.; Lee G.M.; Bell B.P.; Oliver S.E.; Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson and Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients\u2014United States, April 2021. MMWR Morb Mortal Wkly Rep 2021,70(17),651-656","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1097\/MJT.0000000000001431","volume":"28","author":"Banerjee S.","year":"2021","unstructured":"Banerjee S.; Sandhu M.; Tonzi E.; Tambe A.; Gambhir H.S.; Immune-mediated thrombocytopenia associated with Ad26.COV2.S (Janssen; Johnson and Johnson) vaccine. Am J Ther 2021,28(5),e604-e606","journal-title":"Am J Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbi.2022.04.013","volume":"103","author":"Taquet M.","year":"2022","unstructured":"Taquet M.; Dercon Q.; Harrison P.J.; Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 2022,103,154-162","journal-title":"Brain Behav Immun"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/bioengineering9020072","volume":"9","author":"Kudlay D.","year":"2022","unstructured":"Kudlay D.; Svistunov A.; COVID-19 vaccines: An overview of different platforms. Bioengineering 2022,9(2),72","journal-title":"Bioengineering"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2021-0170","author":"Shafaati M.","year":"2021","unstructured":"Shafaati M.; Saidijam M.; Soleimani M.; Hazrati F.; Mirzaei R.; Amirheidari B.; Tanzadehpanah H.; Karampoor S.; Kazemi S.; Yavari B.; Mahaki H.; Safaei M.; Rahbarizadeh F.; Samadi P.; Ahmadyousefi Y.; A brief review on DNA vaccines in the era of COVID-19. Future Virol 2021","journal-title":"Future Virol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/biologics1030020","volume":"1","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Hossain M.K.; Beladiya J.; Apostolopoulos V.; Nucleic acid vaccines for COVID-19: A paradigm shift in the vaccine development arena. Biologics 2021,1(3),337-356","journal-title":"Biologics"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11596-021-2395-1","volume":"41","author":"Forchette L.","year":"2021","unstructured":"Forchette L.; Sebastian W.; Liu T.; A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci 2021,41(6),1037-1051","journal-title":"Curr Med Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.micinf.2020.09.004","volume":"22","author":"de Queiroz N.M.G.P.","year":"2020","unstructured":"de Queiroz N.M.G.P.; Marinho F.V.; Chagas M.A.; Leite L.C.C.; Homan E.J.; de Magalh\u00e3es M.T.Q.; Oliveira S.C.; Vaccines for COVID-19: Perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes Infect 2020,22(10),515-524","journal-title":"Microbes Infect"},{"key":"ref=46","first-page":"43","volume":"35","author":"Koirala A.","year":"2020","unstructured":"Koirala A.; Joo Y.J.; Khatami A.; Chiu C.; Britton P.N.; Vaccines for COVID-19: The current state of play. Paediatr Respir Rev 2020,35,43-49","journal-title":"Paediatr Respir Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4155\/tde-2020-0129","volume":"12","author":"Shahcheraghi S.H.","year":"2021","unstructured":"Shahcheraghi S.H.; Ayatollahi J.; Aljabali A.A.A.; Shastri M.D.; Shukla S.D.; Chellappan D.K.; Jha N.K.; Anand K.; Katari N.K.; Mehta M.; Satija S.; Dureja H.; Mishra V.; Almutary A.G.; Alnuqaydan A.M.; Charbe N.; Prasher P.; Gupta G.; Dua K.; Lotfi M.; Bakshi H.A.; Tambuwala M.M.; An overview of vaccine development for COVID-19. Ther Deliv 2021,12(3),235-244","journal-title":"Ther Deliv"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"106455","DOI":"10.1016\/j.intimp.2020.106455","volume":"83","author":"AminJafari A.","year":"2020","unstructured":"AminJafari A.; Ghasemi S.; The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol 2020,83,106455","journal-title":"Int Immunopharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijbiomac.2021.08.076","volume":"188","author":"Fathizadeh H.","year":"2021","unstructured":"Fathizadeh H.; Afshar S.; Masoudi M.R.; Gholizadeh P.; Asgharzadeh M.; Ganbarov K.; K\u00f6se \u015e.; Yousefi M.; Kafil H.S.; SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. Int J Biol Macromol 2021,188,740-750","journal-title":"Int J Biol Macromol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/vaccines9121387","volume":"9","author":"Khandker S.S.","year":"2021","unstructured":"Khandker S.S.; Godman B.; Jawad M.I.; Meghla B.A.; Tisha T.A.; Khondoker M.U.; Haq M.A.; Charan J.; Talukder A.A.; Azmuda N.; Sharmin S.; Jamiruddin M.R.; Haque M.; Adnan N.; A systematic review on COVID-19 vaccine strategies, their effectiveness, and issues. Vaccines 2021,9(12),1387","journal-title":"Vaccines"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"108634","DOI":"10.1016\/j.clim.2020.108634","volume":"222","author":"Izda V.","year":"2021","unstructured":"Izda V.; Jeffries M.A.; Sawalha A.H.; COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol 2021,222,108634","journal-title":"Clin Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/vaccines9101086","volume":"9","author":"Shah S.M.","year":"2021","unstructured":"Shah S.M.; Alsaab H.O.; Rawas-Qalaji M.M.; Uddin M.N.; A review on current COVID-19 vaccines and evaluation of particulate vaccine delivery systems. Vaccines 2021,9(10),1086","journal-title":"Vaccines"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.11604\/pamj.2020.37.124.24973","volume":"37","author":"Sanicas M.","year":"2020","unstructured":"Sanicas M.; Sanicas M.; Diop D.; Montomoli E.; A review of COVID-19 vaccines in development: 6 months into the pandemic. Pan Afr Med J 2020,37,124","journal-title":"Pan Afr Med J"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13417","volume":"144","author":"Lu L.","year":"2021","unstructured":"Lu L.; Xiong W.; Mu J.; Zhang Q.; Zhang H.; Zou L.; Li W.; He L.; Sander J.W.; Zhou D.; The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol Scand 2021,144(1),3-12","journal-title":"Acta Neurol Scand"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bj.2020.05.021","volume":"43","author":"Shih H.I.","year":"2020","unstructured":"Shih H.I.; Wu C.J.; Tu Y.F.; Chi C.Y.; Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J 2020,43(4),341-354","journal-title":"Biomed J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e2313","DOI":"10.1002\/rmv.2313","volume":"32","author":"Hadj Hassine I.","year":"2022","unstructured":"Hadj Hassine I.; Covid-19 vaccines and variants of concern: A review. Rev Med Virol 2022,32(4),e2313","journal-title":"Rev Med Virol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"585354","DOI":"10.3389\/fimmu.2020.585354","volume":"11","author":"Sharma O.","year":"2020","unstructured":"Sharma O.; Sultan A.A.; Ding H.; Triggle C.R.; A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020,11,585354","journal-title":"Front Immunol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s42269-021-00607-w","volume":"45","author":"Iheanacho C.O.","year":"2021","unstructured":"Iheanacho C.O.; Eze U.I.H.; Adida E.A.; A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population. Bull Natl Res Cent 2021,45(1),150","journal-title":"Bull Natl Res Cent"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.vacun.2020.05.002","volume":"21","author":"Belete T.M.","year":"2020","unstructured":"Belete T.M.; A review on Promising vaccine development progress for COVID-19 disease. Vacunas 2020,21(2),121-128","journal-title":"Vacunas"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/IDR.S288877","volume":"14","author":"Belete T.M.","year":"2021","unstructured":"Belete T.M.; Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist 2021,14,151-161","journal-title":"Infect Drug Resist"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"Krammer F.","year":"2020","unstructured":"Krammer F.; SARS-CoV-2 vaccines in development. Nature 2020,586(7830),516-527","journal-title":"Nature"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40779-021-00360-1","volume":"8","author":"Peng X.L.","year":"2021","unstructured":"Peng X.L.; Cheng J.S.Y.; Gong H.L.; Yuan M.D.; Zhao X.H.; Li Z.; Wei D.X.; Advances in the design and development of SARS-CoV-2 vaccines. Mil Med Res 2021,8(1),67","journal-title":"Mil Med Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Gao Q.","year":"2020","unstructured":"Gao Q.; Bao L.; Mao H.; Wang L.; Xu K.; Yang M.; Li Y.; Zhu L.; Wang N.; Lv Z.; Gao H.; Ge X.; Kan B.; Hu Y.; Liu J.; Cai F.; Jiang D.; Yin Y.; Qin C.; Li J.; Gong X.; Lou X.; Shi W.; Wu D.; Zhang H.; Zhu L.; Deng W.; Li Y.; Lu J.; Li C.; Wang X.; Yin W.; Zhang Y.; Qin C.; Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020,369(6499),77-81","journal-title":"Science"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"669339","DOI":"10.3389\/fimmu.2021.669339","volume":"12","author":"He Q.","year":"2021","unstructured":"He Q.; Mao Q.; Zhang J.; Bian L.; Gao F.; Wang J.; Xu M.; Liang Z.; COVID-19 vaccines: Current understanding on immunogenicity, safety, and further considerations. Front Immunol 2021,12,669339","journal-title":"Front Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"Wang H.","year":"2020","unstructured":"Wang H.; Zhang Y.; Huang B.; Deng W.; Quan Y.; Wang W.; Xu W.; Zhao Y.; Li N.; Zhang J.; Liang H.; Bao L.; Xu Y.; Ding L.; Zhou W.; Gao H.; Liu J.; Niu P.; Zhao L.; Zhen W.; Fu H.; Yu S.; Zhang Z.; Xu G.; Li C.; Lou Z.; Xu M.; Qin C.; Wu G.; Gao G.F.; Tan W.; Yang X.; Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 2020,182(3),713-721.e9","journal-title":"Cell"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coi.2021.07.003","volume":"71","author":"Ndwandwe D.","year":"2021","unstructured":"Ndwandwe D.; Wiysonge C.S.; COVID-19 vaccines. Curr Opin Immunol 2021,71,111-116","journal-title":"Curr Opin Immunol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"328","DOI":"10.53854\/liim-2903-3","volume":"29","author":"Vanaparthy R.","year":"2021","unstructured":"Vanaparthy R.; Mohan G.; Vasireddy D.; Atluri P.; Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez Med 2021,29(3),328-338","journal-title":"Infez Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/v13020317","volume":"13","author":"Lundstrom K.","year":"2021","unstructured":"Lundstrom K.; Viral vectors for COVID-19 vaccine development. Viruses 2021,13(2),317","journal-title":"Viruses"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1517\/14712598.2015.993374","volume":"15","author":"Appaiahgari M.B.","year":"2015","unstructured":"Appaiahgari M.B.; Vrati S.; Adenoviruses as gene\/vaccine delivery vectors: Promises and pitfalls. Expert Opin Biol Ther 2015,15(3),337-351","journal-title":"Expert Opin Biol Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.addr.2021.01.014","volume":"172","author":"Chakraborty S.","year":"2021","unstructured":"Chakraborty S.; Mallajosyula V.; Tato C.M.; Tan G.S.; Wang T.T.; SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? Adv Drug Deliv Rev 2021,172,314-338","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.4110\/in.2021.21.e5","volume":"21","author":"Chakraborty C.","year":"2021","unstructured":"Chakraborty C.; Sharma A.R.; Bhattacharya M.; Sharma G.; Saha R.P.; Lee S.S.; Ongoing clinical trials of vaccines to fight against COVID-19 pandemic. Immune Netw 2021,21(1),e5","journal-title":"Immune Netw"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"e24418","DOI":"10.1002\/jcla.24418","volume":"36","author":"Khoshnood S.","year":"2022","unstructured":"Khoshnood S.; Arshadi M.; Akrami S.; Koupaei M.; Ghahramanpour H.; Shariati A.; Sadeghifard N.; Heidary M.; An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. J Clin Lab Anal 2022,36(5),e24418","journal-title":"J Clin Lab Anal"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e127042","DOI":"10.5812\/ijpr-127042","volume":"21","author":"Sharifzadeh M.","year":"2022","unstructured":"Sharifzadeh M.; Mottaghi-Dastjerdi N.; Soltany Rezae Raad M.; A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases. Iran J Pharm Res 2022,21(1),e127042","journal-title":"Iran J Pharm Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"Fang E.","year":"2022","unstructured":"Fang E.; Liu X.; Li M.; Zhang Z.; Song L.; Zhu B.; Wu X.; Liu J.; Zhao D.; Li Y.; Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther 2022,7(1),94","journal-title":"Signal Transduct Target Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/jmv.27463","volume":"94","author":"Rashedi R.","year":"2022","unstructured":"Rashedi R.; Samieefar N.; Masoumi N.; Mohseni S.; Rezaei N.; COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. J Med Virol 2022,94(4),1294-1299","journal-title":"J Med Virol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12929-022-00853-8","volume":"29","author":"Chi W.Y.","year":"2022","unstructured":"Chi W.Y.; Li Y.D.; Huang H.C.; Chan T.E.H.; Chow S.Y.; Su J.H.; Ferrall L.; Hung C.F.; Wu T.C.; COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 2022,29(1),82","journal-title":"J Biomed Sci"},{"key":"ref=77","first-page":"1","volume":"98","author":"Francis A.I.","year":"2021","unstructured":"Francis A.I.; Ghany S.; Gilkes T.; Umakanthan S.; Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J 2021,98(1159),1-6","journal-title":"Postgrad Med J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"118919","DOI":"10.1016\/j.lfs.2020.118919","volume":"267","author":"Silveira M.M.","year":"2021","unstructured":"Silveira M.M.; Moreira G.M.S.G.; Mendon\u00e7a M.; DNA vaccines against COVID-19: Perspectives and challenges. Life Sci 2021,267,118919","journal-title":"Life Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"e23937","DOI":"10.1002\/jcla.23937","volume":"35","author":"Han X.","year":"2021","unstructured":"Han X.; Xu P.; Ye Q.; Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal 2021,35(9),e23937","journal-title":"J Clin Lab Anal"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14760584.2021.1875824","volume":"20","author":"Soleimanpour S.","year":"2021","unstructured":"Soleimanpour S.; Yaghoubi A.; COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines 2021,20(1),23-44","journal-title":"Expert Rev Vaccines"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/tmi.13503","volume":"26","author":"Wibawa T.","year":"2021","unstructured":"Wibawa T.; COVID-19 vaccine research and development: Ethical issues. Trop Med Int Health 2021,26(1),14-19","journal-title":"Trop Med Int Health"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.aivir.2016.08.004","volume":"Vol. 96","author":"Hulswit R.","year":"2016","unstructured":"Hulswit R.; de Haan C.; Bosch B-J.; Coronavirus spike protein and tropism changes. Advances in Virus Research 2016,Vol. 96,29-57","journal-title":"Advances in Virus Research"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-1-4899-1531-3_10","author":"Brown T.","year":"1995","unstructured":"Brown T.; Brierley I.; The coronavirus nonstructural proteins. The Coronaviridae 1995,191-217","journal-title":"The Coronaviridae"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1196\/annals.1408.002","volume":"1102","author":"Satija N.","year":"2007","unstructured":"Satija N.; Lal S.K.; The molecular biology of SARS coronavirus. Ann N Y Acad Sci 2007,1102(1),26-38","journal-title":"Ann N Y Acad Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0065-7743(06)41011-3","volume":"41","author":"Ghosh A.K.","year":"2006","unstructured":"Ghosh A.K.; Xi K.; Johnson M.E.; Baker S.C.; Mesecar A.D.; Progress in anti-SARS coronavirus chemistry, biology and chemotherapy. Annu Rep Med Chem 2006,41,183-196","journal-title":"Annu Rep Med Chem"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(08)60286-9","volume":"Vol. 48","author":"Lai M.M.","year":"1997","unstructured":"Lai M.M.; Cavanagh D.; The molecular biology of coronaviruses. Advances in virus research 1997,Vol. 48,1-100","journal-title":"Advances in virus research"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","volume":"66","author":"Masters P.S.","year":"2006","unstructured":"Masters P.S.; The molecular biology of coronaviruses. Adv Virus Res 2006,66,193-292","journal-title":"Adv Virus Res"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-3527(08)60721-6","volume":"Vol. 28","author":"Sturman L.S.","year":"1983","unstructured":"Sturman L.S.; Holmes K.V.; The molecular biology of coronaviruses. Advances in virus research 1983,Vol. 28,35-112","journal-title":"Advances in virus research"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-642-68528-6_5","author":"Wege H.","year":"1982","unstructured":"Wege H.; Ter Meulen V.; The biology and pathogenesis of coronaviruses. Current topics in microbiology and immunology 1982,165-200","journal-title":"Current topics in microbiology and immunology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nrmicro3143","volume":"11","author":"Graham R.L.","year":"2013","unstructured":"Graham R.L.; Donaldson E.F.; Baric R.S.; A decade after SARS: Strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013,11(12),836-848","journal-title":"Nat Rev Microbiol"},{"key":"ref=91","author":"Lai M.M.","year":"2001","unstructured":"Lai M.M.;  Coronaviridae: The viruses and their replication 2001","journal-title":"Coronaviridae: The viruses and their replication"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1128\/JVI.01358-06","volume":"81","author":"Sawicki S.G.","year":"2007","unstructured":"Sawicki S.G.; Sawicki D.L.; Siddell S.G.; A contemporary view of coronavirus transcription. J Virol 2007,81(1),20-29","journal-title":"J Virol"},{"key":"ref=93","unstructured":"Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. National Library of Medicine (NIH)Available from: (Accessed on 26 June 2023)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12964-023-01104-5","volume":"21","author":"Kakavandi S.","year":"2023","unstructured":"Kakavandi S.; Zare I.; VaezJalali M.; Dadashi M.; Azarian M.; Akbari A.; Ramezani Farani M.; Zalpoor H.; Hajikhani B.; Structural and non-structural proteins in SARS-CoV-2: Potential aspects to COVID-19 treatment or prevention of progression of related diseases. Cell Commun Signal 2023,21(1),110","journal-title":"Cell Commun Signal"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","volume":"28","author":"Trougakos I.P.","year":"2021","unstructured":"Trougakos I.P.; Stamatelopoulos K.; Terpos E.; Tsitsilonis O.E.; Aivalioti E.; Paraskevis D.; Kastritis E.; Pavlakis G.N.; Dimopoulos M.A.; Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci 2021,28(1),9","journal-title":"J Biomed Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s15010-020-01486-5","volume":"48","author":"Rossi G.A.","year":"2020","unstructured":"Rossi G.A.; Sacco O.; Mancino E.; Cristiani L.; Midulla F.; Differences and similarities between SARS-CoV and SARS-CoV-2: Spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases. Infection 2020,48(5),665-669","journal-title":"Infection"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40199-022-00446-8","volume":"30","author":"Abdolmaleki G.","year":"2022","unstructured":"Abdolmaleki G.; Taheri M.A.; Paridehpour S.; Mohammadi N.M.; Tabatabaei Y.A.; Mousavi T.; Amin M.; A comparison between SARS-CoV-1 and SARS-CoV2: An update on current COVID-19 vaccines. Daru 2022,30(2),379-406","journal-title":"Daru"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/v12030254","volume":"12","author":"Ahmed S.F.","year":"2020","unstructured":"Ahmed S.F.; Quadeer A.A.; McKay M.R.; Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020,12(3),254","journal-title":"Viruses"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"594495","DOI":"10.3389\/fmed.2020.594495","volume":"7","author":"Salamanna F.","year":"2020","unstructured":"Salamanna F.; Maglio M.; Landini M.P.; Fini M.; Body localization of ace-2: on the trail of the keyhole of SARS-CoV-2. Front Med 2020,7,594495","journal-title":"Front Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/fvl-2020-0050","volume":"15","author":"Fani M.","year":"2020","unstructured":"Fani M.; Teimoori A.; Ghafari S.; Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virol 2020,15(5),317-323","journal-title":"Future Virol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/v12020244","volume":"12","author":"Xu J.","year":"2020","unstructured":"Xu J.; Zhao S.; Teng T.; Abdalla A.E.; Zhu W.; Xie L.; Wang Y.; Guo X.; Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 2020,12(2),244","journal-title":"Viruses"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","volume":"26","author":"Petrosillo N.","year":"2020","unstructured":"Petrosillo N.; Viceconte G.; Ergonul O.; Ippolito G.; Petersen E.; COVID-19, SARS and MERS: Are they closely related? Clin Microbiol Infect 2020,26(6),729-734","journal-title":"Clin Microbiol Infect"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"108737","DOI":"10.1016\/j.celrep.2021.108737","volume":"34","author":"Bates T.A.","year":"2021","unstructured":"Bates T.A.; Weinstein J.B.; Farley S.; Leier H.C.; Messer W.B.; Tafesse F.G.; Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep 2021,34(7),108737","journal-title":"Cell Rep"},{"key":"ref=104","unstructured":"Cortellis drug discovery intelligenceAvailable from:"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"Rauch S.","year":"2018","unstructured":"Rauch S.; Jasny E.; Schmidt K.E.; Petsch B.; New vaccine technologies to combat outbreak situations. Front Immunol 2018,9,1963","journal-title":"Front Immunol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.109.163444","volume":"333","author":"French K.J.","year":"2010","unstructured":"French K.J.; Zhuang Y.; Maines L.W.; Gao P.; Wang W.; Beljanski V.; Upson J.J.; Green C.L.; Keller S.N.; Smith C.D.; Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010,333(1),129-139","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1053\/j.gastro.2020.05.056","volume":"159","author":"Chai C.","year":"2020","unstructured":"Chai C.; Cox B.; Yaish D.; Gross D.; Rosenberg N.; Amblard F.; Shemuelian Z.; Gefen M.; Korach A.; Tirosh O.; Lanton T.; Link H.; Tam J.; Permyakova A.; Ozhan G.; Citrin J.; Liao H.; Tannous M.; Hahn M.; Axelrod J.; Arretxe E.; Alonso C.; Martinez-Arranz I.; Bet\u00e9s P.O.; Safadi R.; Salhab A.; Amer J.; Tber Z.; Mengshetti S.; Giladi H.; Schinazi R.F.; Galun E.; Agonist of RORA attenuates nonalcoholic fatty liver progression in mice via Up-regulation of MicroRNA 122. Gastroenterology 2020,159(3),999-1014.e9","journal-title":"Gastroenterology"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"Li J.X.","year":"2022","unstructured":"Li J.X.; Wu S.P.; Guo X.L.; Tang R.; Huang B.Y.; Chen X.Q.; Chen Y.; Hou L.H.; Liu J.X.; Zhong J.; Pan H.X.; Shi F.J.; Xu X.Y.; Li Z.P.; Zhang X.Y.; Cui L.B.; Tan W.J.; Chen W.; Zhu F.C.; Li J-X.; Wu S-P.; Guo X-L.; Tang R.; Huang B-Y.; Chen X-Q.; Chen Y.; Hou L-H.; Liu J-X.; Zhong J.; Pan H-X.; Shi F-J.; Xu X-Y.; Li Z-P.; Zhang X-Y.; Cui L-B.; Tan W-J.; Chen W.; Zhu F-C.; Huang H-T.; Gou J-B.; Si W-X.; Wang X.; Zhao X-L.; Zhu T.; Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial. Lancet Respir Med 2022,10(8),739-748","journal-title":"Lancet Respir Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1080\/14760584.2022.2119133","volume":"21","author":"Li Z.P.","year":"2022","unstructured":"Li Z.P.; Shi Y.F.; Hou L.H.; Jin P.F.; Ma S.H.; Pan H.X.; Zhang J.L.; Shan Y.M.; Huang H.T.; Wu S.P.; Du P.; Wang X.; Wang L.L.; Wang R.J.; Wang Y.; Wang X.W.; Zhu F.C.; Li J.X.; Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above. Expert Rev Vaccines 2022,21(12),1843-1849","journal-title":"Expert Rev Vaccines"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1128\/MMBR.00049-13","volume":"78","author":"Koonin E.V.","year":"2014","unstructured":"Koonin E.V.; Dolja V.V.; Virus world as an evolutionary network of viruses and capsidless selfish elements. Microbiol Mol Biol Rev 2014,78(2),278-303","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1128\/jvi.41.1.51-65.1982","volume":"41","author":"Galibert F.","year":"1982","unstructured":"Galibert F.; Chen T.N.; Mandart E.; Nucleotide sequence of a cloned woodchuck hepatitis virus genome: Comparison with the hepatitis B virus sequence. J Virol 1982,41(1),51-65","journal-title":"J Virol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.virusres.2007.02.021","volume":"127","author":"Kay A.","year":"2007","unstructured":"Kay A.; Zoulim F.; Hepatitis B virus genetic variability and evolution. Virus Res 2007,127(2),164-176","journal-title":"Virus Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"Wu S.","year":"2021","unstructured":"Wu S.; Huang J.; Zhang Z.; Wu J.; Zhang J.; Hu H.; Zhu T.; Zhang J.; Luo L.; Fan P.; Wang B.; Chen C.; Chen Y.; Song X.; Wang Y.; Si W.; Sun T.; Wang X.; Hou L.; Chen W.; Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis 2021,21(12),1654-1664","journal-title":"Lancet Infect Dis"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1021\/acs.jmedchem.1c00302","volume":"65","author":"Garc\u00eda-C\u00e1rceles J.","year":"2022","unstructured":"Garc\u00eda-C\u00e1rceles J.; Caballero E.; Gil C.; Mart\u00ednez A.; Kinase inhibitors as underexplored antiviral agents. J Med Chem 2022,65(2),935-954","journal-title":"J Med Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"Cohen P.","year":"2002","unstructured":"Cohen P.; Protein kinases \u2014 the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002,1(4),309-315","journal-title":"Nat Rev Drug Discov"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nrg2707","volume":"11","author":"Lahiry P.","year":"2010","unstructured":"Lahiry P.; Torkamani A.; Schork N.J.; Hegele R.A.; Kinase mutations in human disease: Interpreting genotype\u2013phenotype relationships. Nat Rev Genet 2010,11(1),60-74","journal-title":"Nat Rev Genet"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"ra98","DOI":"10.1126\/scisignal.aaf5132","volume":"9","author":"Ye J.","year":"2016","unstructured":"Ye J.; Zhang H.; He W.; Zhu B.; Zhou D.; Chen Z.; Ashraf U.; Wei Y.; Liu Z.; Fu Z.F.; Chen H.; Cao S.; Quantitative phosphoproteomic analysis identifies the critical role of JNK1 in neuroinflammation induced by Japanese encephalitis virus. Sci Signal 2016,9(448),ra98","journal-title":"Sci Signal"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(22)00770-X","volume":"399","author":"Li G.","year":"2022","unstructured":"Li G.; Cappuccini F.; Marchevsky N.G.; Aley P.K.; Aley R.; Anslow R.; Bibi S.; Cathie K.; Clutterbuck E.; Faust S.N.; Feng S.; Heath P.T.; Kerridge S.; Lelliott A.; Mujadidi Y.; Ng K.F.; Rhead S.; Roberts H.; Robinson H.; Roderick M.R.; Singh N.; Smith D.; Snape M.D.; Song R.; Tang K.; Yao A.; Liu X.; Lambe T.; Pollard A.J.; Aboagye J.; Ambihapathy W.; Baker J.F.; Beales E.R.; Boon A.; Brampton R.; Branch N.M.; Cooper R.; Cornish E.L.; Cuevas-Asturias S.; Danos Z.; Davies S.; de Luna George L.; Drury R.; Flaxman A.; Fowler J.; Galiza E.; Godfrey L.; Haskell L.; Hillson K.; Hultin C.L.; Koleva S.; Lees E.; Mabbett R.; Muller J.; Munro A.P.S.; Oliver A.L.; Owens D.R.; Pearce J.P.; Rajan M.; Ratcliffe H.; Rowbotham I.; Salter S.; Sanders H.; Sapuan S.S.; Sharpe H.; Sheehan E.; Sutton N.; Thaygaraja G.; Thomson-Hill S.; Ulaszewska M.; Woods D.; Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6\u201317 years: A preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet 2022,399(10342),2212-2225","journal-title":"Lancet"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"Manning G.","year":"2002","unstructured":"Manning G.; Whyte D.B.; Martinez R.; Hunter T.; Sudarsanam S.; The protein kinase complement of the human genome. Science 2002,298(5600),1912-1934","journal-title":"Science"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"Falsey A.R.","year":"2021","unstructured":"Falsey A.R.; Sobieszczyk M.E.; Hirsch I.; Sproule S.; Robb M.L.; Corey L.; Neuzil K.M.; Hahn W.; Hunt J.; Mulligan M.J.; McEvoy C.; DeJesus E.; Hassman M.; Little S.J.; Pahud B.A.; Durbin A.; Pickrell P.; Daar E.S.; Bush L.; Solis J.; Carr Q.O.; Oyedele T.; Buchbinder S.; Cowden J.; Vargas S.L.; Guerreros Benavides A.; Call R.; Keefer M.C.; Kirkpatrick B.D.; Pullman J.; Tong T.; Brewinski Isaacs M.; Benkeser D.; Janes H.E.; Nason M.C.; Green J.A.; Kelly E.J.; Maaske J.; Mueller N.; Shoemaker K.; Takas T.; Marshall R.P.; Pangalos M.N.; Villafana T.; Gonzalez-Lopez A.; Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med 2021,385(25),2348-2360","journal-title":"N Engl J Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"24946","DOI":"10.1074\/jbc.M102108200","volume":"276","author":"Zhang F.","year":"2001","unstructured":"Zhang F.; Romano P.R.; Nagamura-Inoue T.; Tian B.; Dever T.E.; Mathews M.B.; Ozato K.; Hinnebusch A.G.; Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop. J Biol Chem 2001,276(27),24946-24958","journal-title":"J Biol Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"re2","DOI":"10.1126\/stke.2001.89.re2","volume":"2001","author":"Williams B.R.G.","year":"2001","unstructured":"Williams B.R.G.; Signal integration via PKR. Sci STKE 2001,2001(89),re2","journal-title":"Sci STKE"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/jir.2010.0099","volume":"31","author":"Pindel A.","year":"2011","unstructured":"Pindel A.; Sadler A.; The role of protein kinase R in the interferon response. J Interferon Cytokine Res 2011,31(1),59-70","journal-title":"J Interferon Cytokine Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1073\/pnas.82.16.5300","volume":"82","author":"Twardzik D.R.","year":"1985","unstructured":"Twardzik D.R.; Brown J.P.; Ranchalis J.E.; Todaro G.J.; Moss B.; Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc Natl Acad Sci 1985,82(16),5300-5304","journal-title":"Proc Natl Acad Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"Sadoff J.","year":"2021","unstructured":"Sadoff J.; Gray G.; Vandebosch A.; C\u00e1rdenas V.; Shukarev G.; Grinsztejn B.; Goepfert P.A.; Truyers C.; Fennema H.; Spiessens B.; Offergeld K.; Scheper G.; Taylor K.L.; Robb M.L.; Treanor J.; Barouch D.H.; Stoddard J.; Ryser M.F.; Marovich M.A.; Neuzil K.M.; Corey L.; Cauwenberghs N.; Tanner T.; Hardt K.; Ruiz-Gui\u00f1az\u00fa J.; Le Gars M.; Schuitemaker H.; Van Hoof J.; Struyf F.; Douoguih M.; Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021,384(23),2187-2201","journal-title":"N Engl J Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMoa2117608","volume":"386","author":"Sadoff J.","year":"2022","unstructured":"Sadoff J.; Gray G.; Vandebosch A.; C\u00e1rdenas V.; Shukarev G.; Grinsztejn B.; Goepfert P.A.; Truyers C.; Van Dromme I.; Spiessens B.; Vingerhoets J.; Custers J.; Scheper G.; Robb M.L.; Treanor J.; Ryser M.F.; Barouch D.H.; Swann E.; Marovich M.A.; Neuzil K.M.; Corey L.; Stoddard J.; Hardt K.; Ruiz-Gui\u00f1az\u00fa J.; Le Gars M.; Schuitemaker H.; Van Hoof J.; Struyf F.; Douoguih M.; Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med 2022,386(9),847-860","journal-title":"N Engl J Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1039\/C4NP00085D","volume":"32","author":"Martinez J.P.","year":"2015","unstructured":"Martinez J.P.; Sasse F.; Br\u00f6nstrup M.; Diez J.; Meyerhans A.; Antiviral drug discovery: Broad-spectrum drugs from nature. Nat Prod Rep 2015,32(1),29-48","journal-title":"Nat Prod Rep"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"116356","DOI":"10.1016\/j.bmc.2021.116356","volume":"46","author":"Mahajan S.","year":"2021","unstructured":"Mahajan S.; Choudhary S.; Kumar P.; Tomar S.; Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. Bioorg Med Chem 2021,46,116356","journal-title":"Bioorg Med Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","volume":"99","author":"Lin K.","year":"2013","unstructured":"Lin K.; Gallay P.; Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Res 2013,99(1),68-77","journal-title":"Antiviral Res"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12967-020-02476-9","volume":"18","author":"Chitalia V.C.","year":"2020","unstructured":"Chitalia V.C.; Munawar A.H.; A painful lesson from the COVID-19 pandemic: The need for broad-spectrum, host-directed antivirals. J Transl Med 2020,18(1),390","journal-title":"J Transl Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s13346-021-01001-9","volume":"12","author":"Kumar A.","year":"2022","unstructured":"Kumar A.; Kumar A.; Mucosal and transdermal vaccine delivery strategies against COVID-19. Drug Deliv Transl Res 2022,12(5),968-972","journal-title":"Drug Deliv Transl Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/vaccines9020171","volume":"9","author":"Ashraf M.U.","year":"2021","unstructured":"Ashraf M.U.; Kim Y.; Kumar S.; Seo D.; Ashraf M.; Bae Y.S.; COVID-19 vaccines (revisited) and oral-mucosal vector system as a potential vaccine platform. Vaccines 2021,9(2),171","journal-title":"Vaccines"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/j.1572-0241.2008.01876.x","volume":"103","author":"Bader T.","year":"2008","unstructured":"Bader T.; Fazili J.; Madhoun M.; Aston C.; Hughes D.; Rizvi S.; Seres K.; Hasan M.; Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008,103(6),1383-1389","journal-title":"Am J Gastroenterol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000213504","volume":"52","author":"Sezaki H.","year":"2009","unstructured":"Sezaki H.; Suzuki F.; Akuta N.; Yatsuji H.; Hosaka T.; Kobayashi M.; Suzuki Y.; Arase Y.; Ikeda K.; Miyakawa Y.; Kumada H.; An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009,52(1),43-48","journal-title":"Intervirology"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/10409238.2016.1215406","volume":"51","author":"Jayaraman B.","year":"2016","unstructured":"Jayaraman B.; Smith A.M.; Fernandes J.D.; Frankel A.D.; Oligomeric viral proteins: Small in size, large in presence. Crit Rev Biochem Mol Biol 2016,51(5),379-394","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coviro.2020.07.001","volume":"45","author":"Schlicksup C.J.","year":"2020","unstructured":"Schlicksup C.J.; Zlotnick A.; Viral structural proteins as targets for antivirals. Curr Opin Virol 2020,45,43-50","journal-title":"Curr Opin Virol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"14365","DOI":"10.1073\/pnas.0804461105","volume":"105","author":"Legiewicz M.","year":"2008","unstructured":"Legiewicz M.; Badorrek C.S.; Turner K.B.; Fabris D.; Hamm T.E.; Rekosh D.; Hammarskj\u00f6ld M.L.; Le Grice S.F.J.; Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element. Proc Natl Acad Sci 2008,105(38),14365-14370","journal-title":"Proc Natl Acad Sci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cld.2010.05.004","volume":"14","author":"Locarnini S.","year":"2010","unstructured":"Locarnini S.; Bowden S.; Drug resistance in antiviral therapy. Clin Liver Dis 2010,14(3),439-459","journal-title":"Clin Liver Dis"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3389\/fgene.2019.00696","volume":"10","author":"Zhang Z.","year":"2019","unstructured":"Zhang Z.; Wang C.; Liu Z.; Zou G.; Li J.; Lu M.; Host genetic determinants of hepatitis B virus infection. Front Genet 2019,10,696","journal-title":"Front Genet"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/rmv.722","volume":"22","author":"Keating J.A.","year":"2012","unstructured":"Keating J.A.; Striker R.; Phosphorylation events during viral infections provide potential therapeutic targets. Rev Med Virol 2012,22(3),166-181","journal-title":"Rev Med Virol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1186\/s12889-022-14016-9","volume":"22","author":"Zhang Y.","year":"2022","unstructured":"Zhang Y.; Belayachi J.; Yang Y.; Fu Q.; Rodewald L.; Li H.; Yan B.; Wang Y.; Shen Y.; Yang Q.; Mu W.; Tang R.; Su C.; Xu T.; Obtel M.; Mhayi A.; Razine R.; Abouqal R.; Zhang Y.; Yang X.; Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health 2022,22(1),1584","journal-title":"BMC Public Health"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1038\/s41467-022-31379-0","volume":"13","author":"Kaabi N.A.","year":"2022","unstructured":"Kaabi N.A.; Yang Y.K.; Du L.F.; Xu K.; Shao S.; Liang Y.; Kang Y.; Su J.G.; Zhang J.; Yang T.; Hussein S.; ElDein M.S.; Yang S.S.; Lei W.; Gao X.J.; Jiang Z.; Cong X.; Tan Y.; Wang H.; Li M.; Mekki H.M.; Zaher W.; Mahmoud S.; Zhang X.; Qu C.; Liu D.Y.; Zhang J.; Yang M.; Eltantawy I.; Hou J.W.; Lei Z.H.; Xiao P.; Wang Z.N.; Yin J.L.; Mao X.Y.; Zhang J.; Qu L.; Zhang Y.T.; Yang X.M.; Wu G.; Li Q.M.; Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun 2022,13(1),3654","journal-title":"Nat Commun"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"e26910","DOI":"10.7554\/eLife.26910","volume":"6","author":"Mondal A.","year":"2017","unstructured":"Mondal A.; Dawson A.R.; Potts G.K.; Freiberger E.C.; Baker S.F.; Moser L.A.; Bernard K.A.; Coon J.J.; Mehle A.; Influenza virus recruits host protein kinase C to control assembly and activity of its replication machinery. eLife 2017,6,e26910","journal-title":"eLife"},{"key":"ref=144","year":"2022","unstructured":"Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. 2022"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1093\/ofid\/ofab466.775","volume":"8","author":"Kushnir A.","year":"2021","unstructured":"Kushnir A.; Mueller S.; Tasker S.; Robert Coleman J.; 577. COVI-VAC\u2122, a live attenuated COVID-19 vaccine, provides single dose protection against heterologous challenge with SARS-CoV-2 Beta (B.1.351) in the syrian golden hamster model. Open Forum Infect Dis 2021,8(Suppl. 1),S390","journal-title":"Open Forum Infect Dis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1038\/s41467-022-31930-z","volume":"13","author":"Liu Y.","year":"2022","unstructured":"Liu Y.; Zhang X.; Liu J.; Xia H.; Zou J.; Muruato A.E.; Periasamy S.; Kurhade C.; Plante J.A.; Bopp N.E.; Kalveram B.; Bukreyev A.; Ren P.; Wang T.; Menachery V.D.; Plante K.S.; Xie X.; Weaver S.C.; Shi P.Y.; A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat Commun 2022,13(1),4337","journal-title":"Nat Commun"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.3390\/ijms19102848","volume":"19","author":"Ja\u015bkiewicz A.","year":"2018","unstructured":"Ja\u015bkiewicz A.; Paj\u0105k B.; Orzechowski A.; The many faces of rap1 GTPase. Int J Mol Sci 2018,19(10),2848","journal-title":"Int J Mol Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"Heath P.T.","year":"2021","unstructured":"Heath P.T.; Galiza E.P.; Baxter D.N.; Boffito M.; Browne D.; Burns F.; Chadwick D.R.; Clark R.; Cosgrove C.; Galloway J.; Goodman A.L.; Heer A.; Higham A.; Iyengar S.; Jamal A.; Jeanes C.; Kalra P.A.; Kyriakidou C.; McAuley D.F.; Meyrick A.; Minassian A.M.; Minton J.; Moore P.; Munsoor I.; Nicholls H.; Osanlou O.; Packham J.; Pretswell C.H.; San Francisco Ramos A.; Saralaya D.; Sheridan R.P.; Smith R.; Soiza R.L.; Swift P.A.; Thomson E.C.; Turner J.; Viljoen M.E.; Albert G.; Cho I.; Dubovsky F.; Glenn G.; Rivers J.; Robertson A.; Smith K.; Toback S.; Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021,385(13),1172-1183","journal-title":"N Engl J Med"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/fcp.12794","volume":"36","author":"Montastruc J.L.","year":"2022","unstructured":"Montastruc J.L.; Biron P.; Sommet A.; NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression. Fundam Clin Pharmacol 2022,36(6),1125-1127","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/v13102068","volume":"13","author":"Kleinehr J.","year":"2021","unstructured":"Kleinehr J.; Wilden J.J.; Boergeling Y.; Ludwig S.; Hrincius E.R.; Metabolic modifications by common respiratory viruses and their potential as new antiviral targets. Viruses 2021,13(10),2068","journal-title":"Viruses"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","volume":"386","author":"Dunkle L.M.","year":"2022","unstructured":"Dunkle L.M.; Kotloff K.L.; Gay C.L.; \u00c1\u00f1ez G.; Adelglass J.M.; Barrat Hern\u00e1ndez A.Q.; Harper W.L.; Duncanson D.M.; McArthur M.A.; Florescu D.F.; McClelland R.S.; Garcia-Fragoso V.; Riesenberg R.A.; Musante D.B.; Fried D.L.; Safirstein B.E.; McKenzie M.; Jeanfreau R.J.; Kingsley J.K.; Henderson J.A.; Lane D.C.; Ru\u00edz-Palacios G.M.; Corey L.; Neuzil K.M.; Coombs R.W.; Greninger A.L.; Hutter J.; Ake J.A.; Smith K.; Woo W.; Cho I.; Glenn G.M.; Dubovsky F.; Efficacy and safety of NVX-CoV2373 in adults in the united states and mexico. N Engl J Med 2022,386(6),531-543","journal-title":"N Engl J Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"Gordon D.E.","year":"2020","unstructured":"Gordon D.E.; Jang G.M.; Bouhaddou M.; Xu J.; Obernier K.; White K.M.; O\u2019Meara M.J.; Rezelj V.V.; Guo J.Z.; Swaney D.L.; Tummino T.A.; H\u00fcttenhain R.; Kaake R.M.; Richards A.L.; Tutuncuoglu B.; Foussard H.; Batra J.; Haas K.; Modak M.; Kim M.; Haas P.; Polacco B.J.; Braberg H.; Fabius J.M.; Eckhardt M.; Soucheray M.; Bennett M.J.; Cakir M.; McGregor M.J.; Li Q.; Meyer B.; Roesch F.; Vallet T.; Mac Kain A.; Miorin L.; Moreno E.; Naing Z.Z.C.; Zhou Y.; Peng S.; Shi Y.; Zhang Z.; Shen W.; Kirby I.T.; Melnyk J.E.; Chorba J.S.; Lou K.; Dai S.A.; Barrio-Hernandez I.; Memon D.; Hernandez-Armenta C.; Lyu J.; Mathy C.J.P.; Perica T.; Pilla K.B.; Ganesan S.J.; Saltzberg D.J.; Rakesh R.; Liu X.; Rosenthal S.B.; Calviello L.; Venkataramanan S.; Liboy-Lugo J.; Lin Y.; Huang X.P.; Liu Y.; Wankowicz S.A.; Bohn M.; Safari M.; Ugur F.S.; Koh C.; Savar N.S.; Tran Q.D.; Shengjuler D.; Fletcher S.J.; O\u2019Neal M.C.; Cai Y.; Chang J.C.J.; Broadhurst D.J.; Klippsten S.; Sharp P.P.; Wenzell N.A.; Kuzuoglu-Ozturk D.; Wang H.Y.; Trenker R.; Young J.M.; Cavero D.A.; Hiatt J.; Roth T.L.; Rathore U.; Subramanian A.; Noack J.; Hubert M.; Stroud R.M.; Frankel A.D.; Rosenberg O.S.; Verba K.A.; Agard D.A.; Ott M.; Emerman M.; Jura N.; von Zastrow M.; Verdin E.; Ashworth A.; Schwartz O.; d\u2019Enfert C.; Mukherjee S.; Jacobson M.; Malik H.S.; Fujimori D.G.; Ideker T.; Craik C.S.; Floor S.N.; Fraser J.S.; Gross J.D.; Sali A.; Roth B.L.; Ruggero D.; Taunton J.; Kortemme T.; Beltrao P.; Vignuzzi M.; Garc\u00eda-Sastre A.; Shokat K.M.; Shoichet B.K.; Krogan N.J.; A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020,583(7816),459-468","journal-title":"Nature"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/13543776.2021.1924150","volume":"31","author":"Sabbah D.A.","year":"2021","unstructured":"Sabbah D.A.; Hajjo R.; Bardaweel S.K.; Zhong H.A.; Phosphatidylinositol 3-kinase (PI3K) inhibitors: A recent update on inhibitor design and clinical trials (2016\u20132020). Expert Opin Ther Pat 2021,31(10),877-892","journal-title":"Expert Opin Ther Pat"},{"key":"ref=154","year":"2022","unstructured":"Safety and Immunogenicity of EXG-5003. 2022"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"Cohen P.","year":"2021","unstructured":"Cohen P.; Cross D.; J\u00e4nne P.A.; Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat Rev Drug Discov 2021,20(7),551-569","journal-title":"Nat Rev Drug Discov"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2174\/1568026615666150915115823","volume":"16","author":"Sabbah D.A.","year":"2016","unstructured":"Sabbah D.A.; Hu J.; Zhong H.A.; Advances in the development of class I phosphoinositide 3-kinase (PI3K) inhibitors. Curr Top Med Chem 2016,16(13),1413-1426","journal-title":"Curr Top Med Chem"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","volume":"54","author":"Bok K.","year":"2021","unstructured":"Bok K.; Sitar S.; Graham B.S.; Mascola J.R.; Accelerated COVID-19 vaccine development: Milestones, lessons, and prospects. Immunity 2021,54(8),1636-1651","journal-title":"Immunity"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"111254","DOI":"10.1016\/j.biopha.2021.111254","volume":"137","author":"Malik J.A.","year":"2021","unstructured":"Malik J.A.; Mulla A.H.; Farooqi T.; Pottoo F.H.; Anwar S.; Rengasamy K.R.R.; Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother 2021,137,111254","journal-title":"Biomed Pharmacother"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"173751","DOI":"10.1016\/j.ejphar.2020.173751","volume":"892","author":"Rawat K.","year":"2021","unstructured":"Rawat K.; Kumari P.; Saha L.; COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021,892,173751","journal-title":"Eur J Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"947-951","DOI":"10.1177\/08971900211009650","volume":"1-5","author":"Teo S.P.","year":"2021","unstructured":"Teo S.P.; Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract 2021,1-5,947-951","journal-title":"J Pharm Pract"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.2174\/092986711798347298","volume":"18","author":"Sabbah D.A.","year":"2011","unstructured":"Sabbah D.A.; Brattain M.G.; Zhong H.; Dual inhibitors of PI3K\/mTOR or mTOR-selective inhibitors: Which way shall we go? Curr Med Chem 2011,18(36),5528-5544","journal-title":"Curr Med Chem"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/18734294MTEy0MDk6w","volume":"21","author":"Sabbah D.A.","year":"2021","unstructured":"Sabbah D.A.; Hajjo R.; Bardaweel S.K.; Zhong H.A.; An updated review on SARS-CoV-2 main proteinase (M): Protein structure and small-molecule inhibitors. Curr Top Med Chem 2021,21(6),442-460","journal-title":"Curr Top Med Chem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/1568026621666210119111409","volume":"21","author":"Sabbah D.A.","year":"2021","unstructured":"Sabbah D.A.; Hajjo R.; Bardaweel S.K.; Zhong H.A.; An updated review on betacoronavirus viral entry inhibitors: Learning from past discoveries to advance COVID-19 drug discovery. Curr Top Med Chem 2021,21(7),571-596","journal-title":"Curr Top Med Chem"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"29765","DOI":"10.1021\/acsomega.0c03597","volume":"5","author":"Hajjo R.","year":"2020","unstructured":"Hajjo R.; Sabbah D.A.; Bardaweel S.K.; Chemocentric informatics analysis: Dexamethasone versus combination therapy for COVID-19. ACS Omega 2020,5(46),29765-29779","journal-title":"ACS Omega"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/vaccines9101186","volume":"9","author":"Hajjo R.","year":"2021","unstructured":"Hajjo R.; Sabbah D.A.; Bardaweel S.K.; Tropsha A.; Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients. Vaccines (Basel) 2021,9(10),1186","journal-title":"Vaccines (Basel)"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/pathogens11070743","volume":"11","author":"Hajjo R.","year":"2022","unstructured":"Hajjo R.; Sabbah D.; Tropsha A.; Analyzing the systems biology effects of COVID-19 mRNA vaccines to assess their safety and putative side effects. Pathogens 2022,11(7),743","journal-title":"Pathogens"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/ph15060696","volume":"15","author":"Khirfan F.","year":"2022","unstructured":"Khirfan F.; Jarrar Y.; Al-Qirim T.; Goh K.W.; Jarrar Q.; Ardianto C.; Awad M.; Al-Ameer H.J.; Al-Awaida W.; Moshawih S.; Ming L.C.; Analgesics induce alterations in the expression of SARS-CoV-2 entry and arachidonic-acid-metabolizing genes in the mouse lungs. Pharmaceuticals (Basel) 2022,15(6),696","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2478\/acph-2021-0013","volume":"71","author":"Bardaweel S.K.","year":"2021","unstructured":"Bardaweel S.K.; Hajjo R.; Sabbah D.A.; Sitagliptin: A potential drug for the treatment of COVID-19? Acta Pharm 2021,71(2),175-184","journal-title":"Acta Pharm"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1017\/dmp.2020.437","volume":"16","author":"Ikhmais B.","year":"2022","unstructured":"Ikhmais B.; Hammad A.M.; Al-Qerem W.; Abusara O.H.; Ling J.; Conducting COVID-19-related research in Jordan: Are we ready? Disaster Med Public Health Prep 2022,16(3),967-974","journal-title":"Disaster Med Public Health Prep"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"Baden L.R.","year":"2021","unstructured":"Baden L.R.; El Sahly H.M.; Essink B.; Kotloff K.; Frey S.; Novak R.; Diemert D.; Spector S.A.; Rouphael N.; Creech C.B.; McGettigan J.; Khetan S.; Segall N.; Solis J.; Brosz A.; Fierro C.; Schwartz H.; Neuzil K.; Corey L.; Gilbert P.; Janes H.; Follmann D.; Marovich M.; Mascola J.; Polakowski L.; Ledgerwood J.; Graham B.S.; Bennett H.; Pajon R.; Knightly C.; Leav B.; Deng W.; Zhou H.; Han S.; Ivarsson M.; Miller J.; Zaks T.; Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021,384(5),403-416","journal-title":"N Engl J Med"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"El Sahly H.M.","year":"2021","unstructured":"El Sahly H.M.; Baden L.R.; Essink B.; Doblecki-Lewis S.; Martin J.M.; Anderson E.J.; Campbell T.B.; Clark J.; Jackson L.A.; Fichtenbaum C.J.; Zervos M.; Rankin B.; Eder F.; Feldman G.; Kennelly C.; Han-Conrad L.; Levin M.; Neuzil K.M.; Corey L.; Gilbert P.; Janes H.; Follmann D.; Marovich M.; Polakowski L.; Mascola J.R.; Ledgerwood J.E.; Graham B.S.; August A.; Clouting H.; Deng W.; Han S.; Leav B.; Manzo D.; Pajon R.; Sch\u00f6del F.; Tomassini J.E.; Zhou H.; Miller J.; Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021,385(19),1774-1785","journal-title":"N Engl J Med"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","volume":"385","author":"Ali K.","year":"2021","unstructured":"Ali K.; Berman G.; Zhou H.; Deng W.; Faughnan V.; Coronado-Voges M.; Ding B.; Dooley J.; Girard B.; Hillebrand W.; Pajon R.; Miller J.M.; Leav B.; McPhee R.; Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med 2021,385(24),2241-2251","journal-title":"N Engl J Med"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"Gilbert P.B.","year":"2022","unstructured":"Gilbert P.B.; Montefiori D.C.; McDermott A.B.; Fong Y.; Benkeser D.; Deng W.; Zhou H.; Houchens C.R.; Martins K.; Jayashankar L.; Castellino F.; Flach B.; Lin B.C.; O\u2019Connell S.; McDanal C.; Eaton A.; Sarzotti-Kelsoe M.; Lu Y.; Yu C.; Borate B.; van der Laan L.W.P.; Hejazi N.S.; Huynh C.; Miller J.; El Sahly H.M.; Baden L.R.; Baron M.; De La Cruz L.; Gay C.; Kalams S.; Kelley C.F.; Andrasik M.P.; Kublin J.G.; Corey L.; Neuzil K.M.; Carpp L.N.; Pajon R.; Follmann D.; Donis R.O.; Koup R.A.; Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022,375(6576),43-50","journal-title":"Science"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2217\/fvl-2016-0070","volume":"11","author":"Morris S.J.","year":"2016","unstructured":"Morris S.J.; Sebastian S.; Spencer A.J.; Gilbert S.C.; Simian adenoviruses as vaccine vectors. Future Virol 2016,11(9),649-659","journal-title":"Future Virol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1016\/j.vaccine.2019.04.056","volume":"37","author":"Fedosyuk S.","year":"2019","unstructured":"Fedosyuk S.; Merritt T.; Peralta-Alvarez M.P.; Morris S.J.; Lam A.; Laroudie N.; Kangokar A.; Wright D.; Warimwe G.M.; Angell-Manning P.; Ritchie A.J.; Gilbert S.C.; Xenopoulos A.; Boumlic A.; Douglas A.D.; Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components. Vaccine 2019,37(47),6951-6961","journal-title":"Vaccine"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1016\/S2666-5247(22)00126-4","volume":"3","author":"Jenkin D.","year":"2022","unstructured":"Jenkin D.; Ritchie A.J.; Aboagye J.; Fedosyuk S.; Thorley L.; Provstgaad-Morys S.; Sanders H.; Bellamy D.; Makinson R.; Xiang Z.Q.; Bolam E.; Tarrant R.; Ramos Lopez F.; Platt A.; Poulton I.; Green C.; Ertl H.C.J.; Ewer K.J.; Douglas A.D.; Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: An open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. Lancet Microbe 2022,3(9),e663-e671","journal-title":"Lancet Microbe"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","volume":"22","author":"Kremsner P.G.","year":"2022","unstructured":"Kremsner P.G.; Ahuad Guerrero R.A.; Arana-Arri E.; Aroca Martinez G.J.; Bonten M.; Chandler R.; Corral G.; De Block E.J.L.; Ecker L.; Gabor J.J.; Garcia Lopez C.A.; Gonzales L.; Granados Gonz\u00e1lez M.A.; Gorini N.; Grobusch M.P.; Hrabar A.D.; Junker H.; Kimura A.; Lanata C.F.; Lehmann C.; Leroux-Roels I.; Mann P.; Martinez-Res\u00e9ndez M.F.; Ochoa T.J.; Poy C.A.; Reyes Fentanes M.J.; Rivera Mejia L.M.; Ruiz Herrera V.V.; S\u00e1ez-Llorens X.; Sch\u00f6nborn-Kellenberger O.; Schunk M.; Sierra Garcia A.; Vergara I.; Verstraeten T.; Vico M.; Oostvogels L.; Lovesio L.; Diez F.; Grazziani F.; Ganaha M.C.; Zalatnik V.J.; Dittrich R.J.; Esp\u00ednola L.; Lambert S.; Longhi A.; Vecchio C.; Mastruzzo M.; Fernandez A.; Borchowiek S.; Potito R.; Ahuad Guerrero R.A.; Guardiani F.M.; Castella S.; Foccoli M.; Pedernera A.; Braida A.; Durigan V.; Martella C.; Bobat A.; Boggia B.E.; Nemi S.A.; Tartaglione J.G.; Piedimonte F.C.; De Bie J.; Reynales Londo\u00f1o H.; Rodr\u00edguez Ordo\u00f1ez P.A.; Garc\u00eda Cruz J.M.; Bautista Toloza L.; Ladino Gonz\u00e1lez M.C.; Zambrano Ochoa A.P.; Prieto Pradera I.; Torres Hernandez D.; Mazo Elorza D.P.; Collazos Lennis M.F.; Vanegas Dominguez B.; Solano Mosquera L.M.; Fendel R.; Fleischmann W.A.; Koehne E.; Kreidenweiss A.; K\u00f6hler C.; Esen M.; Horn C.; Eberts S.; Kroidl A.; Huber K.; Thiel V.; Mazara Rosario S.; Reyes G.; Rivera L.; Donastorg Y.; Lantigua F.; Torres Almanzar D.; Candelario R.; Pe\u00f1a Mendez L.; Rosario Gomez N.; Portol\u00e9s-P\u00e9rez A.; Ascaso del R\u00edo A.; Laredo Velasco L.; Bustinduy Odriozola M.J.; Larrea Arranz I.; Mart\u00ednez Alcorta L.I.; Dur\u00e1n Lavi\u00f1a M.I.; Imaz-Ayo N.; Meijide S.; Garc\u00eda-de-Vicu\u00f1a A.; Santorcuato A.; Gallego M.; Aguirre-Garc\u00eda G.M.; Olmos Vega J.; Gonz\u00e1lez Lim\u00f3n P.; V\u00e1zquez Villar A.; Ch\u00e1vez Bar\u00f3n J.; Arredondo Salda\u00f1a F.; Luj\u00e1n Palacios J.D.; Camacho Choza L.J.; V\u00e1zquez Salda\u00f1a E.G.; Ortega Dominguez S.J.; Vega Orozco K.S.; Torres Quiroz I.A.; Martinez Avenda\u00f1o A.; Herrera Sanchez J.; Guzman E.; Castro Castrezana L.; Ruiz Palacios y Santos G.M.; de Winter R.F.J.; de Jonge H.K.; Schnyder J.L.; Boersma W.; Hessels L.; Djamin R.; van der Sar S.; DeAntonio R.; Pe\u00f1a M.; Rebollon G.; Rojas M.; Escobar J.; Hammerschlag Icaza B.; Wong T D.Y.; Barrera Perigault P.; Ruiz S.; Chan M.; Arias Hoo D.J.; Gil A.I.; Celis C.R.; Balmaceda M.P.; Flores O.; Ochoa M.; Pe\u00f1a B.; de la Flor C.; Webb C.M.; Cornejo E.; Sanes F.; Mayorga V.; Valdiviezo G.; Ram\u00edrez Lamas S.P.; Grandez Castillo G.A.; Lama J.R.; Matta Aguirre M.E.; Arancibia Luna L.A.; Carbajal Paulet \u00d3.; Zambrano Ortiz J.; Camara A.; Guzman Quintanilla F.; Diaz-Parra C.; Morales-Oliva J.; Cornejo R.E.; Ricalde S.A.; Vidal J.; Rios Nogales L.; Cheatham-Seitz D.; Gregoraci G.; Brecx A.; Walz L.; Vahrenhorst D.; Seibel T.; Quintini G.; Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): A randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis 2022,22(3),329-340","journal-title":"Lancet Infect Dis"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12249-020-01744-7","volume":"21","author":"Wang J.","year":"2020","unstructured":"Wang J.; Peng Y.; Xu H.; Cui Z.; Williams R.O.; The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation. AAPS PharmSciTech 2020,21(6),225","journal-title":"AAPS PharmSciTech"},{"key":"ref=179","first-page":"1","volume":"\u2022","author":"Samaranayake L.P.","year":"2021","unstructured":"Samaranayake L.P.; Seneviratne C.J.; Fakhruddin K.S.; Coronavirus disease 2019 (COVID-19) vaccines: A concise review. Oral Dis 2021,\u2022,1-11","journal-title":"Oral Dis"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"e1345","DOI":"10.1002\/cti2.1345","volume":"10","author":"Elkashif A.","year":"2021","unstructured":"Elkashif A.; Alhashimi M.; Sayedahmed E.E.; Sambhara S.; Mittal S.K.; Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Clin Transl Immunology 2021,10(10),e1345","journal-title":"Clin Transl Immunology"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.vaccine.2022.02.030","volume":"40","author":"Masuda T.","year":"2022","unstructured":"Masuda T.; Murakami K.; Sugiura K.; Sakui S.; Philip Schuring R.; Mori M.; A phase 1\/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. Vaccine 2022,40(13),2044-2052","journal-title":"Vaccine"},{"key":"ref=182","unstructured":"Clinical evaluation of new vaccinesAvailable from: (accessed on 14 October 2022)"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","volume":"3","author":"Chen G.L.","year":"2022","unstructured":"Chen G.L.; Li X.F.; Dai X.H.; Li N.; Cheng M.L.; Huang Z.; Shen J.; Ge Y.H.; Shen Z.W.; Deng Y.Q.; Yang S.Y.; Zhao H.; Zhang N.N.; Zhang Y.F.; Wei L.; Wu K.Q.; Zhu M.F.; Peng C.G.; Jiang Q.; Cao S.C.; Li Y.H.; Zhao D.H.; Wu X.H.; Ni L.; Shen H.H.; Dong C.; Ying B.; Sheng G.P.; Qin C.F.; Gao H.N.; Li L.J.; Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 2022,3(3),e193-e202","journal-title":"Lancet Microbe"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00401-020-02249-0","volume":"141","author":"Sepulveda-Falla D.","year":"2021","unstructured":"Sepulveda-Falla D.; Chavez-Gutierrez L.; Portelius E.; V\u00e9lez J.I.; Dujardin S.; Barrera-Ocampo A.; Dinkel F.; Hagel C.; Puig B.; Mastronardi C.; Lopera F.; Hyman B.T.; Blennow K.; Arcos-Burgos M.; de Strooper B.; Glatzel M.; A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer\u2019s disease. Acta Neuropathol 2021,141(2),217-233","journal-title":"Acta Neuropathol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","volume":"6","author":"Kalnin K.V.","year":"2021","unstructured":"Kalnin K.V.; Plitnik T.; Kishko M.; Zhang J.; Zhang D.; Beauvais A.; Anosova N.G.; Tibbitts T.; DiNapoli J.; Ulinski G.; Piepenhagen P.; Cummings S.M.; Bangari D.S.; Ryan S.; Huang P.W.D.; Huleatt J.; Vincent D.; Fries K.; Karve S.; Goldman R.; Gopani H.; Dias A.; Tran K.; Zacharia M.; Gu X.; Boeglin L.; Abysalh J.; Vargas J.; Beaulieu A.; Shah M.; Jeannotte T.; Gillis K.; Chivukula S.; Swearingen R.; Landolfi V.; Fu T.M.; DeRosa F.; Casimiro D.; Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 2021,6(1),61","journal-title":"NPJ Vaccines"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"e2133012","DOI":"10.1001\/jamanetworkopen.2021.33012","volume":"4","author":"Tehrani Z.R.","year":"2021","unstructured":"Tehrani Z.R.; Sajadi M.M.; Single-dose Ad26.COV2.S vaccine\u2014room for improvement. JAMA Netw Open 2021,4(11),e2133012","journal-title":"JAMA Netw Open"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Fong Y.","year":"2022","unstructured":"Fong Y.; McDermott A.B.; Benkeser D.; Roels S.; Stieh D.J.; Vandebosch A.; Le Gars M.; Van Roey G.A.; Houchens C.R.; Martins K.; Jayashankar L.; Castellino F.; Amoa-Awua O.; Basappa M.; Flach B.; Lin B.C.; Moore C.; Naisan M.; Naqvi M.; Narpala S.; O\u2019Connell S.; Mueller A.; Serebryannyy L.; Castro M.; Wang J.; Petropoulos C.J.; Luedtke A.; Hyrien O.; Lu Y.; Yu C.; Borate B.; van der Laan L.W.P.; Hejazi N.S.; Kenny A.; Carone M.; Wolfe D.N.; Sadoff J.; Gray G.E.; Grinsztejn B.; Goepfert P.A.; Little S.J.; Paiva de Sousa L.; Maboa R.; Randhawa A.K.; Andrasik M.P.; Hendriks J.; Truyers C.; Struyf F.; Schuitemaker H.; Douoguih M.; Kublin J.G.; Corey L.; Neuzil K.M.; Carpp L.N.; Follmann D.; Gilbert P.B.; Koup R.A.; Donis R.O.; Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat Microbiol 2022,7(12),1996-2010","journal-title":"Nat Microbiol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41564-022-01271-0","volume":"7","author":"Gatechompol S.","year":"2022","unstructured":"Gatechompol S.; Kittanamongkolchai W.; Ketloy C.; Prompetchara E.; Thitithanyanont A.; Jongkaewwattana A.; Buranapraditkun S.; Alameh M.G.; Ubolyam S.; Sophonphan J.; Apornpong T.; Kerr S.; Kamarulzaman A.; Siwamogsatham S.; Kroon E.; Puthanakit T.; Patarakul K.; Palaga T.; Wijagkanalan W.; Carpenter A.; Hong L.; Weissman D.; Ruxrungtham K.; Chula V.A.C.; Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: A phase I trial. Nat Microbiol 2022,7(12),1987-1995","journal-title":"Nat Microbiol"},{"key":"ref=189","year":"2021","unstructured":"Study of sputnik V COVID-19 vaccination in adults in Kazakhstan. 2021"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"Khoury D.S.","year":"2021","unstructured":"Khoury D.S.; Cromer D.; Reynaldi A.; Schlub T.E.; Wheatley A.K.; Juno J.A.; Subbarao K.; Kent S.J.; Triccas J.A.; Davenport M.P.; Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021,27(7),1205-1211","journal-title":"Nat Med"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"Jones I.","year":"2021","unstructured":"Jones I.; Roy P.; Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 2021,397(10275),642-643","journal-title":"Lancet"},{"key":"ref=192","year":"2021","unstructured":"A Ph 2 trial with an oral tableted COVID-19 vaccine. 2021"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"eabj9815","DOI":"10.1126\/sciadv.abj9815","volume":"8","author":"Liu J.","year":"2022","unstructured":"Liu J.; Budylowski P.; Samson R.; Griffin B.D.; Babuadze G.; Rathod B.; Colwill K.; Abioye J.A.; Schwartz J.A.; Law R.; Yip L.; Ahn S.K.; Chau S.; Naghibosadat M.; Arita Y.; Hu Q.; Yue F.Y.; Banerjee A.; Hardy W.R.; Mossman K.; Mubareka S.; Kozak R.A.; Pollanen M.S.; Martin Orozco N.; Gingras A.C.; Marcusson E.G.; Ostrowski M.A.; Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Sci Adv 2022,8(3),eabj9815","journal-title":"Sci Adv"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","volume":"67","author":"Chen J.","year":"2022","unstructured":"Chen J.; Wang P.; Yuan L.; Zhang L.; Zhang L.; Zhao H.; Chen C.; Wang X.; Han J.; Chen Y.; Jia J.; Lu Z.; Hong J.; Lu Z.; Wang Q.; Chen R.; Qi R.; Ma J.; Zhou M.; Yu H.; Zhuang C.; Liu X.; Han Q.; Wang G.; Su Y.; Yuan Q.; Cheng T.; Wu T.; Ye X.; Zhang T.; Li C.; Zhang J.; Zhu H.; Chen Y.; Chen H.; Xia N.; A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bull (Beijing) 2022,67(13),1372-1387","journal-title":"Sci Bull (Beijing)"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"101262","DOI":"10.1016\/j.eclinm.2021.101262","volume":"44","author":"Pollock K.M.","year":"2022","unstructured":"Pollock K.M.; Cheeseman H.M.; Szubert A.J.; Libri V.; Boffito M.; Owen D.; Bern H.; McFarlane L.R.; O\u2019Hara J.; Lemm N.M.; McKay P.; Rampling T.; Yim Y.T.N.; Milinkovic A.; Kingsley C.; Cole T.; Fagerbrink S.; Aban M.; Tanaka M.; Mehdipour S.; Robbins A.; Budd W.; Faust S.; Hassanin H.; Cosgrove C.A.; Winston A.; Fidler S.; Dunn D.; McCormack S.; Shattock R.J.; Adams K.; Amini F.; Atako N.B.; Bakri A.; Barclay W.; Brodnicki E.; Brown J.C.; Byrne R.; Chilvers R.; Coelho S.; Day S.; Desai M.; Dorman E.; Elliott T.; Flight K.E.; Fletcher J.; Galang J.; Gohil J.; Gupta A.; Harlow C.; Hu K.; Kalyan M.; Lagrue D.; Liscano E.; Njenga C.; Polra K.; Powlette D.A.; Randell P.; Rauchenberger M.; Redknap I.; Ricamara M.; Rogers P.; Sallah H.; Samnuan K.; Schumacher M.; Shah Z.; Shaw R.; Shaw T.; Sivapatham S.; Slater S.; Sorley K.; Storch R.; Tan E.; Tan T.; Thielemans L.; Whitely S.; Valentine C.; Varghese J.; Vikraman A.; Wilkins M.; Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine 2022,44,101262","journal-title":"EClinicalMedicine"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","volume":"118","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Yang C.; Song Y.; Coleman J.R.; Stawowczyk M.; Tafrova J.; Tasker S.; Boltz D.; Baker R.; Garcia L.; Seale O.; Kushnir A.; Wimmer E.; Mueller S.; Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci 2021,118(29),e2102775118","journal-title":"Proc Natl Acad Sci"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"Wang P.","year":"2021","unstructured":"Wang P.; Nair M.S.; Liu L.; Iketani S.; Luo Y.; Guo Y.; Wang M.; Yu J.; Zhang B.; Kwong P.D.; Graham B.S.; Mascola J.R.; Chang J.Y.; Yin M.T.; Sobieszczyk M.; Kyratsous C.A.; Shapiro L.; Sheng Z.; Huang Y.; Ho D.D.; Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021,593(7857),130-135","journal-title":"Nature"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/vaccines10070984","volume":"10","author":"Matveeva O.","year":"2022","unstructured":"Matveeva O.; Ershov A.; Retrospective cohort study of the effectiveness of the sputnik V and EpiVacCorona vaccines against the SARS-CoV-2 Delta variant in Moscow (June\u2013July 2021). Vaccines 2022,10(7),984","journal-title":"Vaccines"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"198857","DOI":"10.1016\/j.virusres.2022.198857","volume":"319","author":"Abdoli M.","year":"2022","unstructured":"Abdoli M.; Shafaati M.; Ghamsari L.K.; Abdoli A.; Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2. Virus Res 2022,319,198857","journal-title":"Virus Res"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.3390\/ijerph19074136","volume":"19","author":"Briko N.I.","year":"2022","unstructured":"Briko N.I.; Korshunov V.A.; Mindlina A.Y.; Polibin R.V.; Antipov M.O.; Brazhnikov A.I.; Vyazovichenko Y.E.; Glushkova E.V.; Lomonosov K.S.; Lomonosova A.V.; Lopukhov P.D.; Pozdnyakov A.A.; Saltykova T.S.; Torchinsky N.V.; Tsapkova N.N.; Chernyavskaya O.P.; Shamis A.V.; Healthcare workers\u2019 acceptance of COVID-19 vaccination in Russia. Int J Environ Res Public Health 2022,19(7),4136","journal-title":"Int J Environ Res Public Health"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"e61312","DOI":"10.7554\/eLife.61312","volume":"9","author":"Weisblum Y.","year":"2020","unstructured":"Weisblum Y.; Schmidt F.; Zhang F.; DaSilva J.; Poston D.; Lorenzi J.C.C.; Muecksch F.; Rutkowska M.; Hoffmann H.H.; Michailidis E.; Gaebler C.; Agudelo M.; Cho A.; Wang Z.; Gazumyan A.; Cipolla M.; Luchsinger L.; Hillyer C.D.; Caskey M.; Robbiani D.F.; Rice C.M.; Nussenzweig M.C.; Hatziioannou T.; Bieniasz P.D.; Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 2020,9,e61312","journal-title":"eLife"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41541-021-00384-7","volume":"6","author":"Andrade V.M.","year":"2021","unstructured":"Andrade V.M.; Christensen-Quick A.; Agnes J.; Tur J.; Reed C.; Kalia R.; Marrero I.; Elwood D.; Schultheis K.; Purwar M.; Reuschel E.; McMullan T.; Pezzoli P.; Kraynyak K.; Sylvester A.; Mammen M.P.; Tebas P.; Joseph Kim J.; Weiner D.B.; Smith T.R.F.; Ramos S.J.; Humeau L.M.; Boyer J.D.; Broderick K.E.; INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. NPJ Vaccines 2021,6(1),121","journal-title":"NPJ Vaccines"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","volume":"31","author":"Tebas P.","year":"2021","unstructured":"Tebas P.; Yang S.; Boyer J.D.; Reuschel E.L.; Patel A.; Christensen-Quick A.; Andrade V.M.; Morrow M.P.; Kraynyak K.; Agnes J.; Purwar M.; Sylvester A.; Pawlicki J.; Gillespie E.; Maricic I.; Zaidi F.I.; Kim K.Y.; Dia Y.; Frase D.; Pezzoli P.; Schultheis K.; Smith T.R.F.; Ramos S.J.; McMullan T.; Buttigieg K.; Carroll M.W.; Ervin J.; Diehl M.C.; Blackwood E.; Mammen M.P.; Lee J.; Dallas M.J.; Brown A.S.; Shea J.E.; Kim J.J.; Weiner D.B.; Broderick K.E.; Humeau L.M.; Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 2021,31,100689","journal-title":"EClinicalMedicine"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","volume":"225","author":"Kraynyak K.A.","year":"2022","unstructured":"Kraynyak K.A.; Blackwood E.; Agnes J.; Tebas P.; Giffear M.; Amante D.; Reuschel E.L.; Purwar M.; Christensen-Quick A.; Liu N.; Andrade V.M.; Diehl M.C.; Wani S.; Lupicka M.; Sylvester A.; Morrow M.P.; Pezzoli P.; McMullan T.; Kulkarni A.J.; Zaidi F.I.; Frase D.; Liaw K.; Smith T.R.F.; Ramos S.J.; Ervin J.; Adams M.; Lee J.; Dallas M.; Shah Brown A.; Shea J.E.; Kim J.J.; Weiner D.B.; Broderick K.E.; Humeau L.M.; Boyer J.D.; Mammen M.P.; SARS-CoV-2 DNA Vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial. J Infect Dis 2022,225(11),1923-1932","journal-title":"J Infect Dis"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"815389","DOI":"10.3389\/fmed.2022.815389","volume":"9","author":"Thakur S.","year":"2022","unstructured":"Thakur S.; Sasi S.; Pillai S.G.; Nag A.; Shukla D.; Singhal R.; Phalke S.; Velu G.S.K.; SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines. Front Med 2022,9,815389","journal-title":"Front Med"},{"key":"ref=206","year":"2022","unstructured":"Annexes to the interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ) against COVID-19. WHOAvailable from: (accessed on 19 November 2022) 2022"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.eclinm.2021.101020","volume":"38","author":"Momin T.","year":"2021","unstructured":"Momin T.; Kansagra K.; Patel H.; Sharma S.; Sharma B.; Patel J.; Mittal R.; Sanmukhani J.; Maithal K.; Dey A.; Chandra H.; Rajanathan C.T.M.; Pericherla H.P.R.; Kumar P.; Narkhede A.; Parmar D.; Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine 2021,38,101020","journal-title":"EClinicalMedicine"},{"key":"ref=208","year":"2022","unstructured":"Study to monitor the occurrence of viral variants in patients with compromised immune systems being treated for COVID-19 (LUNAR). 2022"},{"key":"ref=209","year":"2020","unstructured":"Ascending dose study of investigational SARS-CoV-2 vaccine ARCT-021 in healthy adult subjects. 2020"},{"key":"ref=210","year":"2022","unstructured":"Booster superiority study of PTX-COVID19-B compared to vaxzevria in adults aged 18 years and older. 2022"},{"key":"ref=211","year":"2022","unstructured":"A study of the safety of and immune response to varying doses of a vaccine against COVID-19 in healthy adults. 2022"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ymthe.2021.09.011","volume":"30","author":"Conforti A.","year":"2022","unstructured":"Conforti A.; Marra E.; Palombo F.; Roscilli G.; Rav\u00e0 M.; Fumagalli V.; Muzi A.; Maffei M.; Luberto L.; Lione L.; Salvatori E.; Compagnone M.; Pinto E.; Pavoni E.; Bucci F.; Vitagliano G.; Stoppoloni D.; Pacello M.L.; Cappelletti M.; Ferrara F.F.; D\u2019Acunto E.; Chiarini V.; Arriga R.; Nyska A.; Di Lucia P.; Marotta D.; Bono E.; Giustini L.; Sala E.; Perucchini C.; Paterson J.; Ryan K.A.; Challis A.R.; Matusali G.; Colavita F.; Caselli G.; Criscuolo E.; Clementi N.; Mancini N.; Gro\u00df R.; Seidel A.; Wettstein L.; M\u00fcnch J.; Donnici L.; Conti M.; De Francesco R.; Kuka M.; Ciliberto G.; Castilletti C.; Capobianchi M.R.; Ippolito G.; Guidotti L.G.; Rovati L.; Iannacone M.; Aurisicchio L.; COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther 2022,30(1),311-326","journal-title":"Mol Ther"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jama.2021.2927","volume":"325","author":"Livingston E.H.","year":"2021","unstructured":"Livingston E.H.; Malani P.N.; Creech C.B.; The johnson and johnson vaccine for COVID-19. JAMA 2021,325(15),1575-1575","journal-title":"JAMA"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"n970","DOI":"10.1136\/bmj.n970","volume":"373","author":"Mahase E.","year":"2021","unstructured":"Mahase E.; Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots. BMJ 2021,373(970),n970","journal-title":"BMJ"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"n1046","DOI":"10.1136\/bmj.n1046","volume":"373","author":"Mahase E.","year":"2021","unstructured":"Mahase E.; Covid-19: Unusual blood clots are \u201cvery rare side effect\u201d of Janssen vaccine, says EMA. BMJ 2021,373(1046),n1046","journal-title":"BMJ"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/neurolint13030040","volume":"13","author":"Prasad A.","year":"2021","unstructured":"Prasad A.; Hurlburt G.; Podury S.; Tandon M.; Kingree S.; Sriwastava S.; A novel case of bifacial diplegia variant of guillain-Barr\u00e9 syndrome following Janssen COVID-19 vaccination. Neurol Int 2021,13(3),404-409","journal-title":"Neurol Int"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","volume":"70","author":"Shay D.K.","year":"2021","unstructured":"Shay D.K.; Gee J.; Su J.R.; Myers T.R.; Marquez P.; Liu R.; Zhang B.; Licata C.; Clark T.A.; Shimabukuro T.T.; Safety monitoring of the janssen (Johnson and Johnson) COVID-19 vaccine \u2014 United States, March\u2013April 2021. MMWR Morb Mortal Wkly Rep 2021,70(18),680-684","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","volume":"69","author":"Oliver S.E.","year":"2020","unstructured":"Oliver S.E.; Gargano J.W.; Marin M.; Wallace M.; Curran K.G.; Chamberland M.; McClung N.; Campos-Outcalt D.; Morgan R.L.; Mbaeyi S.; Romero J.R.; Talbot H.K.; Lee G.M.; Bell B.P.; Dooling K.; The advisory committee on immunization practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States, December 2020. MMWR Morb Mortal Wkly Rep 2020,69(50),1922-1924","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jama.2021.2828","volume":"325","author":"Murray C.J.L.","year":"2021","unstructured":"Murray C.J.L.; Piot P.; The potential future of the COVID-19 pandemic: will SARS-CoV-2 become a recurrent seasonal infection? JAMA 2021,325(13),1249-1250","journal-title":"JAMA"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","volume":"70","author":"Self W.H.","year":"2021","unstructured":"Self W.H.; Tenforde M.W.; Rhoads J.P.; Gaglani M.; Ginde A.A.; Douin D.J.; Olson S.M.; Talbot H.K.; Casey J.D.; Mohr N.M.; Zepeski A.; McNeal T.; Ghamande S.; Gibbs K.W.; Files D.C.; Hager D.N.; Shehu A.; Prekker M.E.; Erickson H.L.; Gong M.N.; Mohamed A.; Henning D.J.; Steingrub J.S.; Peltan I.D.; Brown S.M.; Martin E.T.; Monto A.S.; Khan A.; Hough C.L.; Busse L.W.; ten Lohuis C.C.; Duggal A.; Wilson J.G.; Gordon A.J.; Qadir N.; Chang S.Y.; Mallow C.; Rivas C.; Babcock H.M.; Kwon J.H.; Exline M.C.; Halasa N.; Chappell J.D.; Lauring A.S.; Grijalva C.G.; Rice T.W.; Jones I.D.; Stubblefield W.B.; Baughman A.; Womack K.N.; Lindsell C.J.; Hart K.W.; Zhu Y.; Mills L.; Lester S.N.; Stumpf M.M.; Naioti E.A.; Kobayashi M.; Verani J.R.; Thornburg N.J.; Patel M.M.; Calhoun N.; Murthy K.; Herrick J.; McKillop A.; Hoffman E.; Zayed M.; Smith M.; Seattle N.; Ettlinger J.; Priest E.; Thomas J.; Arroliga A.; Beeram M.; Kindle R.; Kozikowski L-A.; De Souza L.; Ouellette S.; Thornton-Thompson S.; Mehkri O.; Ashok K.; Gole S.; King A.; Poynter B.; Stanley N.; Hendrickson A.; Maruggi E.; Scharber T.; Jorgensen J.; Bowers R.; King J.; Aston V.; Armbruster B.; Rothman R.E.; Nair R.; Chen J-T.T.; Karow S.; Robart E.; Maldonado P.N.; Khan M.; So P.; Levitt J.; Perez C.; Visweswaran A.; Roque J.; Rivera A.; Angeles L.; Frankel T.; Angeles L.; Goff J.; Huynh D.; Howell M.; Friedel J.; Tozier M.; Driver C.; Carricato M.; Foster A.; Nassar P.; Stout L.; Sibenaller Z.; Walter A.; Mares J.; Olson L.; Clinansmith B.; Rivas C.; Gershengorn H.; McSpadden E.J.; Truscon R.; Kaniclides A.; Thomas L.; Bielak R.; Valvano W.D.; Fong R.; Fitzsimmons W.J.; Blair C.; Valesano A.L.; Gilbert J.; Crider C.D.; Steinbock K.A.; Paulson T.C.; Anderson L.A.; Kampe C.; Johnson J.; McHenry R.; Blair M.; Conway D.; LaRose M.; Landreth L.; Hicks M.; Parks L.; Bongu J.; McDonald D.; Cass C.; Seiler S.; Park D.; Hink T.; Wallace M.; Burnham C-A.; Arter O.G.; Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson and Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March\u2013August 2021. MMWR Morb Mortal Wkly Rep 2021,70(38),1337-1343","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1097\/TP.0000000000003850","volume":"105","author":"Boyarsky B.J.","year":"2021","unstructured":"Boyarsky B.J.; Chiang T.P.Y.; Ou M.T.; Werbel W.A.; Massie A.B.; Segev D.L.; Garonzik-Wang J.M.; Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients. Transplantation 2021,105(8),e82-e83","journal-title":"Transplantation"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1136\/annrheumdis-2021-221145","volume":"80","author":"Chiang T.P.Y.","year":"2021","unstructured":"Chiang T.P.Y.; Connolly C.M.; Ruddy J.A.; Boyarsky B.J.; Alejo J.L.; Werbel W.A.; Massie A.; Christopher-Stine L.; Garonzik-Wang J.; Segev D.L.; Paik J.J.; Antibody response to the Janssen\/Johnson and Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021,80(10),1365-1366","journal-title":"Ann Rheum Dis"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"Folegatti P.M.","year":"2020","unstructured":"Folegatti P.M.; Ewer K.J.; Aley P.K.; Angus B.; Becker S.; Belij-Rammerstorfer S.; Bellamy D.; Bibi S.; Bittaye M.; Clutterbuck E.A.; Dold C.; Faust S.N.; Finn A.; Flaxman A.L.; Hallis B.; Heath P.; Jenkin D.; Lazarus R.; Makinson R.; Minassian A.M.; Pollock K.M.; Ramasamy M.; Robinson H.; Snape M.; Tarrant R.; Voysey M.; Green C.; Douglas A.D.; Hill A.V.S.; Lambe T.; Gilbert S.C.; Pollard A.J.; Aboagye J.; Adams K.; Ali A.; Allen E.; Allison J.L.; Anslow R.; Arbe-Barnes E.H.; Babbage G.; Baillie K.; Baker M.; Baker N.; Baker P.; Baleanu I.; Ballaminut J.; Barnes E.; Barrett J.; Bates L.; Batten A.; Beadon K.; Beckley R.; Berrie E.; Berry L.; Beveridge A.; Bewley K.R.; Bijker E.M.; Bingham T.; Blackwell L.; Blundell C.L.; Bolam E.; Boland E.; Borthwick N.; Bower T.; Boyd A.; Brenner T.; Bright P.D.; Brown-O\u2019Sullivan C.; Brunt E.; Burbage J.; Burge S.; Buttigieg K.R.; Byard N.; Cabera Puig I.; Calvert A.; Camara S.; Cao M.; Cappuccini F.; Carr M.; Carroll M.W.; Carter V.; Cathie K.; Challis R.J.; Charlton S.; Chelysheva I.; Cho J-S.; Cicconi P.; Cifuentes L.; Clark H.; Clark E.; Cole T.; Colin-Jones R.; Conlon C.P.; Cook A.; Coombes N.S.; Cooper R.; Cosgrove C.A.; Coy K.; Crocker W.E.M.; Cunningham C.J.; Damratoski B.E.; Dando L.; Datoo M.S.; Davies H.; De Graaf H.; Demissie T.; Di Maso C.; Dietrich I.; Dong T.; Donnellan F.R.; Douglas N.; Downing C.; Drake J.; Drake-Brockman R.; Drury R.E.; Dunachie S.J.; Edwards N.J.; Edwards F.D.L.; Edwards C.J.; Elias S.C.; Elmore M.J.; Emary K.R.W.; English M.R.; Fagerbrink S.; Felle S.; Feng S.; Field S.; Fixmer C.; Fletcher C.; Ford K.J.; Fowler J.; Fox P.; Francis E.; Frater J.; Furze J.; Fuskova M.; Galiza E.; Gbesemete D.; Gilbride C.; Godwin K.; Gorini G.; Goulston L.; Grabau C.; Gracie L.; Gray Z.; Guthrie L.B.; Hackett M.; Halwe S.; Hamilton E.; Hamlyn J.; Hanumunthadu B.; Harding I.; Harris S.A.; Harris A.; Harrison D.; Harrison C.; Hart T.C.; Haskell L.; Hawkins S.; Head I.; Henry J.A.; Hill J.; Hodgson S.H.C.; Hou M.M.; Howe E.; Howell N.; Hutlin C.; Ikram S.; Isitt C.; Iveson P.; Jackson S.; Jackson F.; James S.W.; Jenkins M.; Jones E.; Jones K.; Jones C.E.; Jones B.; Kailath R.; Karampatsas K.; Keen J.; Kelly S.; Kelly D.; Kerr D.; Kerridge S.; Khan L.; Khan U.; Killen A.; Kinch J.; King T.B.; King L.; King J.; Kingham-Page L.; Klenerman P.; Knapper F.; Knight J.C.; Knott D.; Koleva S.; Kupke A.; Larkworthy C.W.; Larwood J.P.J.; Laskey A.; Lawrie A.M.; Lee A.; Ngan Lee K.Y.; Lees E.A.; Legge H.; Lelliott A.; Lemm N-M.; Lias A.M.; Linder A.; Lipworth S.; Liu X.; Liu S.; Lopez Ramon R.; Lwin M.; Mabesa F.; Madhavan M.; Mallett G.; Mansatta K.; Marcal I.; Marinou S.; Marlow E.; Marshall J.L.; Martin J.; McEwan J.; McInroy L.; Meddaugh G.; Mentzer A.J.; Mirtorabi N.; Moore M.; Moran E.; Morey E.; Morgan V.; Morris S.J.; Morrison H.; Morshead G.; Morter R.; Mujadidi Y.F.; Muller J.; Munera-Huertas T.; Munro C.; Munro A.; Murphy S.; Munster V.J.; Mweu P.; No\u00e9 A.; Nugent F.L.; Nuthall E.; O\u2019Brien K.; O\u2019Connor D.; Oguti B.; Oliver J.L.; Oliveira C.; O\u2019Reilly P.J.; Osborn M.; Osborne P.; Owen C.; Owens D.; Owino N.; Pacurar M.; Parker K.; Parracho H.; Patrick-Smith M.; Payne V.; Pearce J.; Peng Y.; Peralta Alvarez M.P.; Perring J.; Pfafferott K.; Pipini D.; Plested E.; Pluess-Hall H.; Pollock K.; Poulton I.; Presland L.; Provstgaard-Morys S.; Pulido D.; Radia K.; Ramos Lopez F.; Rand J.; Ratcliffe H.; Rawlinson T.; Rhead S.; Riddell A.; Ritchie A.J.; Roberts H.; Robson J.; Roche S.; Rohde C.; Rollier C.S.; Romani R.; Rudiansyah I.; Saich S.; Sajjad S.; Salvador S.; Sanchez Riera L.; Sanders H.; Sanders K.; Sapaun S.; Sayce C.; Schofield E.; Screaton G.; Selby B.; Semple C.; Sharpe H.R.; Shaik I.; Shea A.; Shelton H.; Silk S.; Silva-Reyes L.; Skelly D.T.; Smee H.; Smith C.C.; Smith D.J.; Song R.; Spencer A.J.; Stafford E.; Steele A.; Stefanova E.; Stockdale L.; Szigeti A.; Tahiri-Alaoui A.; Tait M.; Talbot H.; Tanner R.; Taylor I.J.; Taylor V.; Te Water Naude R.; Thakur N.; Themistocleous Y.; Themistocleous A.; Thomas M.; Thomas T.M.; Thompson A.; Thomson-Hill S.; Tomlins J.; Tonks S.; Towner J.; Tran N.; Tree J.A.; Truby A.; Turkentine K.; Turner C.; Turner N.; Turner S.; Tuthill T.; Ulaszewska M.; Varughese R.; Van Doremalen N.; Veighey K.; Verheul M.K.; Vichos I.; Vitale E.; Walker L.; Watson M.E.E.; Welham B.; Wheat J.; White C.; White R.; Worth A.T.; Wright D.; Wright S.; Yao X.L.; Yau Y.; Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 2020,396(10249),467-478","journal-title":"Lancet"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","volume":"7","author":"Watanabe Y.","year":"2021","unstructured":"Watanabe Y.; Mendon\u00e7a L.; Allen E.R.; Howe A.; Lee M.; Allen J.D.; Chawla H.; Pulido D.; Donnellan F.; Davies H.; Ulaszewska M.; Belij-Rammerstorfer S.; Morris S.; Krebs A.S.; Dejnirattisai W.; Mongkolsapaya J.; Supasa P.; Screaton G.R.; Green C.M.; Lambe T.; Zhang P.; Gilbert S.C.; Crispin M.; Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19\/AZD1222 vaccine. ACS Cent Sci 2021,7(4),594-602","journal-title":"ACS Cent Sci"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","volume":"398","author":"Flaxman A.","year":"2021","unstructured":"Flaxman A.; Marchevsky N.G.; Jenkin D.; Aboagye J.; Aley P.K.; Angus B.; Belij-Rammerstorfer S.; Bibi S.; Bittaye M.; Cappuccini F.; Cicconi P.; Clutterbuck E.A.; Davies S.; Dejnirattisai W.; Dold C.; Ewer K.J.; Folegatti P.M.; Fowler J.; Hill A.V.S.; Kerridge S.; Minassian A.M.; Mongkolsapaya J.; Mujadidi Y.F.; Plested E.; Ramasamy M.N.; Robinson H.; Sanders H.; Sheehan E.; Smith H.; Snape M.D.; Song R.; Woods D.; Screaton G.; Gilbert S.C.; Voysey M.; Pollard A.J.; Lambe T.; Adlou S.; Aley R.; Ali A.; Anslow R.; Baker M.; Baker P.; Barrett J.R.; Bates L.; Beadon K.; Beckley R.; Bell J.; Bellamy D.; Beveridge A.; Bissett C.; Blackwell L.; Bletchly H.; Boyd A.; Bridges-Webb A.; Brown C.; Byard N.; Camara S.; Cifuentes Gutierrez L.; Collins A.M.; Cooper R.; Crocker W.E.M.; Darton T.C.; Davies H.; Davies J.; Demissie T.; Di Maso C.; Dinesh T.; Donnellan F.R.; Douglas A.D.; Drake-Brockman R.; Duncan C.J.A.; Elias S.C.; Emary K.R.W.; Ghulam Farooq M.; Faust S.N.; Felle S.; Ferreira D.; Ferreira Da Silva C.; Finn A.; Ford K.J.; Francis E.; Furze J.; Fuskova M.; Galiza E.; Gibertoni Cruz A.; Godfrey L.; Goodman A.L.; Green C.; Green C.A.; Greenwood N.; Harrison D.; Hart T.C.; Hawkins S.; Heath P.T.; Hill H.; Hillson K.; Horsington B.; Hou M.M.; Howe E.; Howell N.; Joe C.; Jones E.; Kasanyinga M.; Keen J.; Kelly S.; Kerr D.; Khan L.; Khozoee B.; Kinch J.; Kinch P.; Koleva S.; Kwok J.; Larkworthy C.W.; Lawrie A.M.; Lazarus R.; Lees E.A.; Li G.; Libri V.; Lillie P.J.; Linder A.; Long F.; Lopez Ramon R.; Mabbett R.; Makinson R.; Marinou S.; Marlow E.; Marshall J.L.; Mazur O.; McEwan J.; McGregor A.C.; Mokaya J.; Morey E.; Morshead G.; Morter R.; Muller J.; Mweu P.; Noristani R.; Owino N.; Polo Peralta Alvarez M.; Platt A.; Pollock K.M.; Poulton I.; Provstgaard-Morys S.; Pulido-Gomez D.; Rajan M.; Ramos Lopez F.; Ritchie A.; Roberts H.; Rollier C.; Rudiansyah I.; Sanders K.; Saunders J.E.; Seddiqi S.; Sharpe H.R.; Shaw R.; Silva-Reyes L.; Singh N.; Smith D.J.; Smith C.C.; Smith A.; Spencer A.J.; Stuart A.S.V.; Sutherland R.; Szigeti A.; Tang K.; Thomas M.; Thomas T.M.; Thompson A.; Thomson E.C.; T\u00f6r\u00f6k E.M.; Toshner M.; Tran N.; Trivett R.; Turnbull I.; Turner C.; Turner D.P.J.; Ulaszewska M.; Vichos I.; Walker L.; Watson M.E.; Whelan C.; White R.; Williams S.J.; Williams C.J.A.; Wright D.; Yao A.; Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002). Lancet 2021,398(10304),981-990","journal-title":"Lancet"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","volume":"5","author":"Bos R.","year":"2020","unstructured":"Bos R.; Rutten L.; van der Lubbe J.E.M.; Bakkers M.J.G.; Hardenberg G.; Wegmann F.; Zuijdgeest D.; de Wilde A.H.; Koornneef A.; Verwilligen A.; van Manen D.; Kwaks T.; Vogels R.; Dalebout T.J.; Myeni S.K.; Kikkert M.; Snijder E.J.; Li Z.; Barouch D.H.; Vellinga J.; Langedijk J.P.M.; Zahn R.C.; Custers J.; Schuitemaker H.; Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020,5(1),91","journal-title":"NPJ Vaccines"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/POR.S381836","volume":"13","author":"Alshakka M.","year":"2022","unstructured":"Alshakka M.; Hatem N.A.H.; Badullah W.; Alsakaf R.; Rageh A.; Yousef S.A.; Mohamed Ibrahim M.I.; Detection of short-term side effects of ChAdOx1 nCoV-19 vaccine: A cross-sectional study in a war-torn country. Pragmat Obs Res 2022,13,85-91","journal-title":"Pragmat Obs Res"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"106569","DOI":"10.1016\/j.rmed.2021.106569","volume":"187","author":"Cazzola M.","year":"2021","unstructured":"Cazzola M.; Rogliani P.; Mazzeo F.; Matera M.G.; Controversy surrounding the Sputnik V vaccine. Respir Med 2021,187,106569","journal-title":"Respir Med"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"Logunov D.Y.","year":"2020","unstructured":"Logunov D.Y.; Dolzhikova I.V.; Zubkova O.V.; Tukhvatulin A.I.; Shcheblyakov D.V.; Dzharullaeva A.S.; Grousova D.M.; Erokhova A.S.; Kovyrshina A.V.; Botikov A.G.; Izhaeva F.M.; Popova O.; Ozharovskaya T.A.; Esmagambetov I.B.; Favorskaya I.A.; Zrelkin D.I.; Voronina D.V.; Shcherbinin D.N.; Semikhin A.S.; Simakova Y.V.; Tokarskaya E.A.; Lubenets N.L.; Egorova D.A.; Shmarov M.M.; Nikitenko N.A.; Morozova L.F.; Smolyarchuk E.A.; Kryukov E.V.; Babira V.F.; Borisevich S.V.; Naroditsky B.S.; Gintsburg A.L.; Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia. Lancet 2020,396(10255),887-897","journal-title":"Lancet"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2021.3465","volume":"325","author":"Moore J.P.","year":"2021","unstructured":"Moore J.P.; Approaches for optimal use of different COVID-19 Vaccines. JAMA 2021,325(13),1251-1252","journal-title":"JAMA"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"Logunov D.Y.","year":"2021","unstructured":"Logunov D.Y.; Dolzhikova I.V.; Shcheblyakov D.V.; Tukhvatulin A.I.; Zubkova O.V.; Dzharullaeva A.S.; Kovyrshina A.V.; Lubenets N.L.; Grousova D.M.; Erokhova A.S.; Botikov A.G.; Izhaeva F.M.; Popova O.; Ozharovskaya T.A.; Esmagambetov I.B.; Favorskaya I.A.; Zrelkin D.I.; Voronina D.V.; Shcherbinin D.N.; Semikhin A.S.; Simakova Y.V.; Tokarskaya E.A.; Egorova D.A.; Shmarov M.M.; Nikitenko N.A.; Gushchin V.A.; Smolyarchuk E.A.; Zyryanov S.K.; Borisevich S.V.; Naroditsky B.S.; Gintsburg A.L.; Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021,397(10275),671-681","journal-title":"Lancet"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"100359","DOI":"10.1016\/j.xcrm.2021.100359","volume":"2","author":"Rossi A.H.","year":"2021","unstructured":"Rossi A.H.; Ojeda D.S.; Varese A.; Sanchez L.; Gonzalez Lopez Ledesma M.M.; Mazzitelli I.; Alvarez Juli\u00e1 A.; Oviedo Rouco S.; Pallar\u00e9s H.M.; Costa Navarro G.S.; Rasetto N.B.; Garcia C.I.; Wenker S.D.; Ramis L.Y.; Bialer M.G.; de Leone M.J.; Hernando C.E.; Sosa S.; Bianchimano L.; Rios A.S.; Treffinger Cienfuegos M.S.; Caramelo J.J.; Longueira Y.; Laufer N.; Alvarez D.E.; Carradori J.; Pedrozza D.; Rima A.; Echegoyen C.; Ercole R.; Gelpi P.; Marchetti S.; Zubieta M.; Docena G.; Kreplak N.; Yanovsky M.; Geffner J.; Pifano M.; Gamarnik A.V.; Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Rep Med 2021,2(8),100359","journal-title":"Cell Rep Med"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"101027","DOI":"10.1016\/j.eclinm.2021.101027","volume":"38","author":"Montalti M.","year":"2021","unstructured":"Montalti M.; Sold\u00e0 G.; Di Valerio Z.; Salussolia A.; Lenzi J.; Forcellini M.; Barvas E.; Guttmann S.; Messina R.; Poluzzi E.; Raschi E.; Riccardi R.; Fantini M.P.; La Fauci G.; Gori D.; ROCCA observational study: Early results on safety of sputnik V vaccine (Gam-COVID-Vac) in the republic of san marino using active surveillance. EClinicalMedicine 2021,38,101027","journal-title":"EClinicalMedicine"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/inthealth\/ihab010","volume":"13","author":"James E.R.","year":"2021","unstructured":"James E.R.; Disrupting vaccine logistics. Int Health 2021,13(3),211-214","journal-title":"Int Health"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0262-4079(21)00671-0","volume":"250","author":"Lawton G.","year":"2021","unstructured":"Lawton G.; Sputnik V vaccine goes global. New Sci 2021,250(3331),10-11","journal-title":"New Sci"},{"key":"ref=236","year":"2020","unstructured":"Pfizer's COVID-19 vaccine distribution will be a \"logistical nightmare\". CBC NewsAvailable from: (updated on 17 November 2020)2020"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2018.09.009","volume":"156","author":"Ahmadyousefi Y.","year":"2019","unstructured":"Ahmadyousefi Y.; Malih S.; Mirzaee Y.; Saidijam M.; Nucleic acid aptamers in diagnosis of colorectal cancer. Biochimie 2019,156,1-11","journal-title":"Biochimie"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","volume":"65","author":"Gary E.N.","year":"2020","unstructured":"Gary E.N.; Weiner D.B.; DNA vaccines: Prime time is now. Curr Opin Immunol 2020,65,21-27","journal-title":"Curr Opin Immunol"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"Jackson L.A.","year":"2020","unstructured":"Jackson L.A.; Anderson E.J.; Rouphael N.G.; Roberts P.C.; Makhene M.; Coler R.N.; McCullough M.P.; Chappell J.D.; Denison M.R.; Stevens L.J.; Pruijssers A.J.; McDermott A.; Flach B.; Doria-Rose N.A.; Corbett K.S.; Morabito K.M.; O\u2019Dell S.; Schmidt S.D.; Swanson P.A.; Padilla M.; Mascola J.R.; Neuzil K.M.; Bennett H.; Sun W.; Peters E.; Makowski M.; Albert J.; Cross K.; Buchanan W.; Pikaart-Tautges R.; Ledgerwood J.E.; Graham B.S.; Beigel J.H.; An mRNA vaccine against SARS-CoV-preliminary report. N Engl J Med 2020,383(20),1920-1931","journal-title":"N Engl J Med"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"Mulligan M.J.","year":"2020","unstructured":"Mulligan M.J.; Lyke K.E.; Kitchin N.; Absalon J.; Gurtman A.; Lockhart S.; Neuzil K.; Raabe V.; Bailey R.; Swanson K.A.; Li P.; Koury K.; Kalina W.; Cooper D.; Fontes-Garfias C.; Shi P.Y.; T\u00fcreci \u00d6.; Tompkins K.R.; Walsh E.E.; Frenck R.; Falsey A.R.; Dormitzer P.R.; Gruber W.C.; \u015eahin U.; Jansen K.U.; Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020,586(7830),589-593","journal-title":"Nature"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","volume":"110","author":"Crommelin D.J.A.","year":"2021","unstructured":"Crommelin D.J.A.; Anchordoquy T.J.; Volkin D.B.; Jiskoot W.; Mastrobattista E.; Addressing the cold reality of mRNA vaccine stability. J Pharm Sci 2021,110(3),997-1001","journal-title":"J Pharm Sci"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jiph.2020.12.025","volume":"14","author":"ElBagoury M.","year":"2021","unstructured":"ElBagoury M.; Tolba M.M.; Nasser H.A.; Jabbar A.; Elagouz A.M.; Aktham Y.; Hutchinson A.; The find of COVID-19 vaccine: Challenges and opportunities. J Infect Public Health 2021,14(3),389-416","journal-title":"J Infect Public Health"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"104811","DOI":"10.1016\/j.micinf.2021.104811","volume":"23","author":"Hotez P.J.","year":"2021","unstructured":"Hotez P.J.; Nuzhath T.; Callaghan T.; Colwell B.; COVID-19 vaccine decisions: Considering the choices and opportunities. Microbes Infect 2021,23(4-5),104811","journal-title":"Microbes Infect"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41579-020-00462-y","volume":"19","author":"Su S.","year":"2021","unstructured":"Su S.; Du L.; Jiang S.; Learning from the past: Development of safe and effective COVID-19 vaccines. Nat Rev Microbiol 2021,19(3),211-219","journal-title":"Nat Rev Microbiol"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"2000147","DOI":"10.1002\/biot.202000147","volume":"15","author":"Wu S.C.","year":"2020","unstructured":"Wu S.C.; Progress and concept for COVID-19 vaccine development. Biotechnol J 2020,15(6),2000147","journal-title":"Biotechnol J"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","volume":"597","author":"Dolgin E.","year":"2021","unstructured":"Dolgin E.; The tangled history of mRNA vaccines. Nature 2021,597(7876),318-324","journal-title":"Nature"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","volume":"14","author":"Chung Y.H.","year":"2020","unstructured":"Chung Y.H.; Beiss V.; Fiering S.N.; Steinmetz N.F.; COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano 2020,14(10),12522-12537","journal-title":"ACS Nano"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","volume":"14","author":"Astuti I.","year":"2020","unstructured":"Astuti I.; Ysrafil ; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020,14(4),407-412","journal-title":"Diabetes Metab Syndr"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/eji.202048663","volume":"50","author":"Lv H.","year":"2020","unstructured":"Lv H.; Wu N.C.; Mok C.K.P.; COVID-19 vaccines: Knowing the unknown. Eur J Immunol 2020,50(7),939-943","journal-title":"Eur J Immunol"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"Wrapp D.","year":"2020","unstructured":"Wrapp D.; Wang N.; Corbett K.S.; Goldsmith J.A.; Hsieh C.L.; Abiona O.; Graham B.S.; McLellan J.S.; Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020,367(6483),1260-1263","journal-title":"Science"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"Schoenmaker L.","year":"2021","unstructured":"Schoenmaker L.; Witzigmann D.; Kulkarni J.A.; Verbeke R.; Kersten G.; Jiskoot W.; Crommelin D.J.A.; mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm 2021,601,120586","journal-title":"Int J Pharm"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4161\/rna.20206","volume":"9","author":"Dalpke A.H.","year":"2012","unstructured":"Dalpke A.H.; Helm M.; RNA mediated toll-like receptor stimulation in health and disease. RNA Biol 2012,9(6),828-842","journal-title":"RNA Biol"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"Heil F.","year":"2004","unstructured":"Heil F.; Hemmi H.; Hochrein H.; Ampenberger F.; Kirschning C.; Akira S.; Lipford G.; Wagner H.; Bauer S.; Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004,303(5663),1526-1529","journal-title":"Science"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"Zhang C.","year":"2019","unstructured":"Zhang C.; Maruggi G.; Shan H.; Li J.; Advances in mRNA vaccines for infectious diseases. Front Immunol 2019,10,594","journal-title":"Front Immunol"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.antiviral.2009.12.005","volume":"85","author":"Pulido M.R.","year":"2010","unstructured":"Pulido M.R.; Sobrino F.; Borrego B.; S\u00e1iz M.; RNA immunization can protect mice against foot-and-mouth disease virus. Antiviral Res 2010,85(3),556-558","journal-title":"Antiviral Res"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","volume":"25","author":"VanBlargan L.A.","year":"2018","unstructured":"VanBlargan L.A.; Himansu S.; Foreman B.M.; Ebel G.D.; Pierson T.C.; Diamond M.S.; An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell Rep 2018,25,3382-3392. e3383","journal-title":"Cell Rep"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vetmic.2008.10.030","volume":"136","author":"Saxena S.","year":"2009","unstructured":"Saxena S.; Sonwane A.A.; Dahiya S.S.; Patel C.L.; Saini M.; Rai A.; Gupta P.K.; Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein. Vet Microbiol 2009,136(1-2),36-44","journal-title":"Vet Microbiol"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/all.14722","volume":"76","author":"Krantz M.S.","year":"2021","unstructured":"Krantz M.S.; Liu Y.; Phillips E.J.; Stone C.A.; COVID-19 vaccine anaphylaxis: PEG or not? Allergy 2021,76(6),1934-1937","journal-title":"Allergy"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"Walsh E.E.","year":"2020","unstructured":"Walsh E.E.; Frenck R.W.; Falsey A.R.; Kitchin N.; Absalon J.; Gurtman A.; Lockhart S.; Neuzil K.; Mulligan M.J.; Bailey R.; Swanson K.A.; Li P.; Koury K.; Kalina W.; Cooper D.; Fontes-Garfias C.; Shi P.Y.; T\u00fcreci \u00d6.; Tompkins K.R.; Lyke K.E.; Raabe V.; Dormitzer P.R.; Jansen K.U.; \u015eahin U.; Gruber W.C.; Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med 2020,383(25),2439-2450","journal-title":"N Engl J Med"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"Karik\u00f3 K.","year":"2008","unstructured":"Karik\u00f3 K.; Muramatsu H.; Welsh F.A.; Ludwig J.; Kato H.; Akira S.; Weissman D.; Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008,16(11),1833-1840","journal-title":"Mol Ther"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1021\/ja01096a050","volume":"87","author":"Naylor R.","year":"1965","unstructured":"Naylor R.; Ho N.W.Y.; Gilham P.T.; Selective chemical modifications of uridine and pseudouridine in polynucleotides and their effect on the specificities of ribonuclease and phosphodiesterases. J Am Chem Soc 1965,87(18),4209-4210","journal-title":"J Am Chem Soc"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1093\/nar\/23.24.5020","volume":"23","author":"Davis D.R.","year":"1995","unstructured":"Davis D.R.; Stabilization of RNA stacking by pseudouridine. Nucleic Acids Res 1995,23(24),5020-5026","journal-title":"Nucleic Acids Res"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"Polack F.P.","year":"2020","unstructured":"Polack F.P.; Thomas S.J.; Kitchin N.; Absalon J.; Gurtman A.; Lockhart S.; Perez J.L.; P\u00e9rez Marc G.; Moreira E.D.; Zerbini C.; Bailey R.; Swanson K.A.; Roychoudhury S.; Koury K.; Li P.; Kalina W.V.; Cooper D.; Frenck R.W.; Hammitt L.L.; T\u00fcreci \u00d6.; Nell H.; Schaefer A.; \u00dcnal S.; Tresnan D.B.; Mather S.; Dormitzer P.R.; \u015eahin U.; Jansen K.U.; Gruber W.C.; Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020,383(27),2603-2615","journal-title":"N Engl J Med"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","volume":"499","author":"Tai W.","year":"2016","unstructured":"Tai W.; Zhao G.; Sun S.; Guo Y.; Wang Y.; Tao X.; Tseng C.T.K.; Li F.; Jiang S.; Du L.; Zhou Y.; A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 2016,499,375-382","journal-title":"Virology"},{"key":"ref=265","first-page":"1663","volume":"25","author":"Meo S.A.","year":"2021","unstructured":"Meo S.A.; Bukhari I.A.; Akram J.; Meo A.S.; Klonoff D.C.; COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 2021,25(3),1663-1669","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","volume":"69","author":"Oliver S.E.","year":"2021","unstructured":"Oliver S.E.; Gargano J.W.; Marin M.; Wallace M.; Curran K.G.; Chamberland M.; McClung N.; Campos-Outcalt D.; Morgan R.L.; Mbaeyi S.; Romero J.R.; Talbot H.K.; Lee G.M.; Bell B.P.; Dooling K.; The advisory committee on immunization practices\u2019 interim recommendation for use of moderna COVID-19 vaccine-United States, December 2020. MMWR Morb Mortal Wkly Rep 2021,69(5152),1653-1656","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1111\/jdv.17248","volume":"35","author":"Ackerman M.","year":"2021","unstructured":"Ackerman M.; Henry D.; Finon A.; Binois R.; Esteve E.; Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol 2021,35(7),e423-e425","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjd.19163","volume":"183","author":"Galv\u00e1n Casas C.","year":"2020","unstructured":"Galv\u00e1n Casas C.; Catal\u00e0 A.; Carretero Hern\u00e1ndez G.; Rodr\u00edguez-Jim\u00e9nez P.; Fern\u00e1ndez-Nieto D.; Rodr\u00edguez-Villa Lario A.; Navarro Fern\u00e1ndez I.; Ruiz-Villaverde R.; Falkenhain-L\u00f3pez D.; Llamas Velasco M.; Garc\u00eda-Gav\u00edn J.; Baniandr\u00e9s O.; Gonz\u00e1lez-Cruz C.; Morillas-Lahuerta V.; Cubir\u00f3 X.; Figueras Nart I.; Selda-Enriquez G.; Roman\u00ed J.; Fust\u00e0-Novell X.; Melian-Olivera A.; Roncero Riesco M.; Burgos-Blasco P.; Sola Ortigosa J.; Feito Rodriguez M.; Garc\u00eda-Doval I.; Classification of the cutaneous manifestations of  -19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020,183(1),71-77","journal-title":"Br J Dermatol"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijwd.2021.01.007","volume":"7","author":"Rice S.M.","year":"2021","unstructured":"Rice S.M.; Ferree S.D.; Mesinkovska N.A.; Kourosh A.S.; The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int J Womens Dermatol 2021,7(2),209-212","journal-title":"Int J Womens Dermatol"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"Pardi N.","year":"2015","unstructured":"Pardi N.; Tuyishime S.; Muramatsu H.; Kariko K.; Mui B.L.; Tam Y.K.; Madden T.D.; Hope M.J.; Weissman D.; Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015,217,345-351","journal-title":"J Control Release"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"749","DOI":"10.15585\/mmwr.mm7020e1","volume":"70","author":"Wallace M.","year":"2021","unstructured":"Wallace M.; Woodworth K.R.; Gargano J.W.; Scobie H.M.; Blain A.E.; Moulia D.; Chamberland M.; Reisman N.; Hadler S.C.; MacNeil J.R.; Campos-Outcalt D.; Morgan R.L.; Daley M.F.; Romero J.R.; Talbot H.K.; Lee G.M.; Bell B.P.; Oliver S.E.; The advisory committee on immunization practices\u2019 interim recommendation for use of pfizer-bioNTech COVID-19 vaccine in adolescents aged 12\u201315 Years - United States, May 2021. MMWR Morb Mortal Wkly Rep 2021,70(20),749-752","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/vim.2020.0119","volume":"34","author":"Sumirtanurdin R.","year":"2021","unstructured":"Sumirtanurdin R.; Barliana M.I.; Coronavirus disease 2019 vaccine development: An overview. Viral Immunol 2021,34(3),134-144","journal-title":"Viral Immunol"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"Richner J.M.","year":"2017","unstructured":"Richner J.M.; Himansu S.; Dowd K.A.; Butler S.L.; Salazar V.; Fox J.M.; Julander J.G.; Tang W.W.; Shresta S.; Pierson T.C.; Ciaramella G.; Diamond M.S.; Modified mRNA vaccines protect against zika virus infection. Cell 2017,168(6),1114-1125.e10","journal-title":"Cell"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","volume":"39","author":"Chu L.","year":"2021","unstructured":"Chu L.; McPhee R.; Huang W.; Bennett H.; Pajon R.; Nestorova B.; Leav B.; A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021,39(20),2791-2799","journal-title":"Vaccine"},{"key":"ref=275","first-page":"31","author":"Oc\u00e1riz M.","year":"2021","unstructured":"Oc\u00e1riz M.; Zubeldia Ortu\u00f1o J.; Safety of new MRNA vaccines against COVID-19 in severe allergic patients. J Investig Allergol Clin Immunol 2021,31","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"Kim H.W.","year":"1969","unstructured":"Kim H.W.; Canchola J.G.; Brandt C.D.; Pyles G.; Chanock R.M.; Jensen K.; Parrott R.H.; Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969,89(4),422-434","journal-title":"Am J Epidemiol"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","volume":"133","author":"Kremsner P.G.","year":"2021","unstructured":"Kremsner P.G.; Mann P.; Kroidl A.; Leroux-Roels I.; Schindler C.; Gabor J.J.; Schunk M.; Leroux-Roels G.; Bosch J.J.; Fendel R.; Kreidenweiss A.; Velavan T.P.; Fotin-Mleczek M.; Mueller S.O.; Quintini G.; Sch\u00f6nborn-Kellenberger O.; Vahrenhorst D.; Verstraeten T.; Alves de Mesquita M.; Walz L.; Wolz O.O.; Oostvogels L.; De Boever F.; Desimpel A.; Esen M.; Fischer I.; Fl\u00fcgge J.; Geisenberger O.; Geldmacher C.; Held K.; Hoffmann L.; H\u00f6lscher M.; Huber K.; Jacobs B.; Joye J.; Kirschke J.; Klopp N.; Koehne E.; K\u00f6hler C.; Lalremruata A.; Lamsfus-Calle C.; Linh L.T.K.; Maes C.; Metaxa D.; Molnar M-L.; Mueller M.; M\u00fcller-Sch\u00f6ner G.; Quindel M.; Rappe S.; Schultze-Naumburg L.; Schumacher C.; Schuster S.; Thiel V.; Vejda S.; Waerlop G.; Westenberg C.; Wons K.; Zeder A.; Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. Wien Klin Wochenschr 2021,133(17-18),931-941","journal-title":"Wien Klin Wochenschr"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"Pallesen J.","year":"2017","unstructured":"Pallesen J.; Wang N.; Corbett K.S.; Wrapp D.; Kirchdoerfer R.N.; Turner H.L.; Cottrell C.A.; Becker M.M.; Wang L.; Shi W.; Kong W.P.; Andres E.L.; Kettenbach A.N.; Denison M.R.; Chappell J.D.; Graham B.S.; Ward A.B.; McLellan J.S.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci 2017,114(35),E7348-E7357","journal-title":"Proc Natl Acad Sci"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"17823","DOI":"10.1038\/s41598-018-36918-8","volume":"8","author":"Kirchdoerfer R.N.","year":"2018","unstructured":"Kirchdoerfer R.N.; Wang N.; Pallesen J.; Wrapp D.; Turner H.L.; Cottrell C.A.; Corbett K.S.; Graham B.S.; McLellan J.S.; Ward A.B.; Publisher correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep 2018,8(1),17823","journal-title":"Sci Rep"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","volume":"6","author":"Rauch S.","year":"2021","unstructured":"Rauch S.; Roth N.; Schwendt K.; Fotin-Mleczek M.; Mueller S.O.; Petsch B.; mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines 2021,6(1),57","journal-title":"NPJ Vaccines"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"Kim J.","year":"2021","unstructured":"Kim J.; Eygeris Y.; Gupta M.; Sahay G.; Self-assembled mRNA vaccines. Adv Drug Deliv Rev 2021,170,83-112","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1126\/science.372.6549.1381","volume":"372","author":"Cohen J.","year":"2021","unstructured":"Cohen J.; What went wrong with CureVac\u2019s mRNA vaccine? Science 2021,372(6549),1381-1381","journal-title":"Science"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.4161\/hv.28077","volume":"10","author":"Stenler S.","year":"2014","unstructured":"Stenler S.; Blomberg P.; Smith C.I.E.; Safety and efficacy of DNA vaccines. Hum Vaccin Immunother 2014,10(5),1306-1308","journal-title":"Hum Vaccin Immunother"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0264-410X(02)00450-4","volume":"21","author":"L\u00f3pez-Fuertes L.","year":"2002","unstructured":"L\u00f3pez-Fuertes L.; P\u00e9rez-Jim\u00e9nez E.; Vila-Coro A.J.; Sack F.; Moreno S.; Konig S.A.; Junghans C.; Wittig B.; Tim\u00f3n M.; Esteban M.; DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002,21(3-4),247-257","journal-title":"Vaccine"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/gt.2014.37","volume":"21","author":"Walters A.A.","year":"2014","unstructured":"Walters A.A.; Kinnear E.; Shattock R.J.; McDonald J.U.; Caproni L.J.; Porter N.; Tregoning J.S.; Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines. Gene Ther 2014,21(7),645-652","journal-title":"Gene Ther"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines7020037","volume":"7","author":"Liu M.A.","year":"2019","unstructured":"Liu M.A.; A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines 2019,7(2),37","journal-title":"Vaccines"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1525-0016(03)00168-0","volume":"8","author":"Chen Z.Y.","year":"2003","unstructured":"Chen Z.Y.; He C.Y.; Ehrhardt A.; Kay M.A.; Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003,8(3),495-500","journal-title":"Mol Ther"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.ymthe.2017.03.003","volume":"25","author":"Lu J.","year":"2017","unstructured":"Lu J.; Zhang F.; Fire A.Z.; Kay M.A.; Sequence-modified antibiotic resistance genes provide sustained plasmid-mediated transgene expression in mammals. Mol Ther 2017,25(5),1187-1198","journal-title":"Mol Ther"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3390\/ijms19113605","volume":"19","author":"Hobernik D.","year":"2018","unstructured":"Hobernik D.; Bros M.; DNA vaccines-how far from clinical use? Int J Mol Sci 2018,19(11),3605","journal-title":"Int J Mol Sci"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ijpharm.2016.11.008","volume":"515","author":"Cheraghi R.","year":"2016","unstructured":"Cheraghi R.; Nazari M.; Alipour M.; Majidi A.; Hosseinkhani S.; Development of a targeted anti-HER2 scFv Chimeric peptide for gene delivery into HER2-positive breast cancer cells. Int J Pharm 2016,515(1-2),632-643","journal-title":"Int J Pharm"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jcyt.2014.11.008","volume":"17","author":"Park E.","year":"2015","unstructured":"Park E.; Cho H.B.; Takimoto K.; Effective gene delivery into adipose-derived stem cells: Transfection of cells in suspension with the use of a nuclear localization signal peptide\u2013conjugated polyethylenimine. Cytotherapy 2015,17(5),536-542","journal-title":"Cytotherapy"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1242\/jcs.112.12.2033","volume":"112","author":"Ludtke J.J.","year":"1999","unstructured":"Ludtke J.J.; Zhang G.; Sebesty\u00e9n M.G.; Wolff J.A.; A nuclear localization signal can enhance both the nuclear transport and expression of 1 kb DNA. J Cell Sci 1999,112(12),2033-2041","journal-title":"J Cell Sci"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ijpharm.2009.08.029","volume":"382","author":"Opanasopit P.","year":"2009","unstructured":"Opanasopit P.; Rojanarata T.; Apirakaramwong A.; Ngawhirunpat T.; Ruktanonchai U.; Nuclear localization signal peptides enhance transfection efficiency of chitosan\/DNA complexes. Int J Pharm 2009,382(1-2),291-295","journal-title":"Int J Pharm"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0014-5793(99)00674-2","volume":"453","author":"Neves C.","year":"1999","unstructured":"Neves C.; Byk G.; Scherman D.; Wils P.; Coupling of a targeting peptide to plasmid DNA by covalent triple helix formation. FEBS Lett 1999,453(1-2),41-45","journal-title":"FEBS Lett"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.theriogenology.2012.03.027","volume":"78","author":"Duan B.","year":"2012","unstructured":"Duan B.; Cheng L.; Gao Y.; Yin F.X.; Su G.H.; Shen Q.Y.; Liu K.; Hu X.; Liu X.; Li G.P.; Silencing of fat-1 transgene expression in sheep may result from hypermethylation of its driven cytomegalovirus (CMV) promoter. Theriogenology 2012,78(4),793-802","journal-title":"Theriogenology"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jgm.516","volume":"6","author":"Brooks A.R.","year":"2004","unstructured":"Brooks A.R.; Harkins R.N.; Wang P.; Qian H.S.; Liu P.; Rubanyi G.M.; Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004,6(4),395-404","journal-title":"J Gene Med"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1128\/IAI.71.7.3844-3851.2003","volume":"71","author":"Siddiqui A.A.","year":"2003","unstructured":"Siddiqui A.A.; Phillips T.; Charest H.; Podesta R.B.; Quinlin M.L.; Pinkston J.R.; Lloyd J.D.; Paz M.; Villalovos R.M.; Pompa J.; Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): Adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003,71(7),3844-3851","journal-title":"Infect Immun"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1089\/hum.2015.075","volume":"26","author":"Krinner S.","year":"2015","unstructured":"Krinner S.; Heitzer A.; Asbach B.; Wagner R.; Interplay of promoter usage and intragenic CpG Content: Impact on GFP Reporter gene expression. Hum Gene Ther 2015,26(12),826-840","journal-title":"Hum Gene Ther"},{"key":"ref=299","year":"2023","unstructured":"Safety and immunogenicity study of GX-19, a COVID-19 preventive DNA vaccine in healthy adults. 2023"},{"key":"ref=300","year":"2023","unstructured":"Safety and immunogenicity study of GX-19N, a COVID-19 preventive DNA vaccine in healthy adults. 2023"},{"key":"ref=301","year":"2023","unstructured":"Study of COVID-19 DNA vaccine (AG0301-COVID19). 2023"},{"key":"ref=302","year":"2023","unstructured":"Study of COVID-19 DNA vaccine (AG0302-COVID19). 2023"},{"key":"ref=303","year":"2023","unstructured":"A clinical trial of a prophylactic plasmid DNA vaccine for COVID-19 [Covigenix VAX-001] in adults. 2023"},{"key":"ref=304","year":"2023","unstructured":"GLS-5310 vaccine for the prevention of SARS-CoV-2 (COVID-19). 2023"},{"key":"ref=305","year":"2023","unstructured":"Safety and immunogenicity of COVID-eVax, a candidate plasmid DNA vaccine for COVID-19, in healthy adult volunteers. 2023"},{"key":"ref=306","year":"2023","unstructured":"afety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. 2023"},{"key":"ref=307","year":"2023","unstructured":"Safety, immunogenicity, and efficacy of INO-4800 for COVID-19 in adults at high risk of SARS-CoV-2 exposure. 2023"},{"key":"ref=308","unstructured":"A phase III, randomized, multi-centre, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M\/s Cadila Healthcare LimitedAvailable from:"},{"key":"ref=309","year":"2023","unstructured":"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. 2023"},{"key":"ref=310","year":"2023","unstructured":"CORVax12: SARS-CoV-2 spike (S) protein plasmid DNA vaccine trial for COVID-19 (SARS-CoV-2) (CORVax12). 2023"},{"key":"ref=311","year":"2023","unstructured":"The safety and immunogenicity of a DNA-based vaccine (COVIGEN) in healthy volunteers (COVALIA). 2023"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14760584.2020.1843434","volume":"19","author":"Tafreshi S.H.","year":"2020","unstructured":"Tafreshi S.H.; Efficacy, safety, and formulation issues of the combined vaccines. Expert Rev Vaccines 2020,19(10),949-958","journal-title":"Expert Rev Vaccines"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","volume":"100","author":"Guimar\u00e3es L.E.","year":"2015","unstructured":"Guimar\u00e3es L.E.; Baker B.; Perricone C.; Shoenfeld Y.; Vaccines, adjuvants and autoimmunity. Pharmacol Res 2015,100,190-209","journal-title":"Pharmacol Res"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/17512433.2021.1903317","volume":"14","author":"Marmitt D.J.","year":"2021","unstructured":"Marmitt D.J.; Goettert M.I.; Rempel C.; Compounds of plants with activity against SARS-CoV-2 targets. Expert Rev Clin Pharmacol 2021,14(5),623-633","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","volume":"14","author":"Zhang L.","year":"2015","unstructured":"Zhang L.; Wang W.; Wang S.; Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines 2015,14(11),1509-1523","journal-title":"Expert Rev Vaccines"},{"key":"ref=316","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","volume":"15","author":"Li L.","year":"2016","unstructured":"Li L.; Petrovsky N.; Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016,15(3),313-329","journal-title":"Expert Rev Vaccines"},{"key":"ref=317","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S2666-5247(21)00177-4","volume":"2","author":"Lim W.W.","year":"2021","unstructured":"Lim W.W.; Mak L.; Leung G.M.; Cowling B.J.; Peiris M.; Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2021,2(9),e423","journal-title":"Lancet Microbe"},{"key":"ref=318","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"Tanriover M.D.","year":"2021","unstructured":"Tanriover M.D.; Do\u011fanay H.L.; Akova M.; G\u00fcner H.R.; Azap A.; Akhan S.; K\u00f6se \u015e.; Erdin\u00e7 F.\u015e.; Akal\u0131n E.H.; Tabak \u00d6.F.; Pulluk\u00e7u H.; Batum \u00d6.; \u015eim\u015fek Yavuz S.; Turhan \u00d6.; Y\u0131ld\u0131rmak M.T.; K\u00f6ksal \u0130.; Ta\u015fova Y.; Korten V.; Y\u0131lmaz G.; \u00c7elen M.K.; Alt\u0131n S.; \u00c7elik \u0130.; Bay\u0131nd\u0131r Y.; Karao\u011flan \u0130.; Y\u0131lmaz A.; \u00d6zkul A.; G\u00fcr H.; Unal S.; Kayaaslan B.; Hasano\u011flu \u0130.; Dalk\u0131ran A.; Aydos \u00d6.; \u00c7\u0131nar G.; Akdemir-Kalkan \u0130.; \u0130nkaya A.\u00c7.; Aydin M.; \u00c7akir H.; Y\u0131ld\u0131z J.; Kocab\u0131y\u0131k \u00d6.; Arslan S.; Nall\u0131 B.; Demir \u00d6.; Singil S.; Ataman-Hatipo\u011flu \u00c7.; Tuncer-Ertem G.; K\u0131n\u0131kl\u0131 S.; \u00d6nal U.; Mete B.; Dalgan G.; Ta\u015fbakan M.; Yamazhan T.; K\u00f6m\u00fcrc\u00fco\u011flu B.; Yaln\u0131z E.; Benli A.; Keskin-Sar\u0131ta\u015f \u00c7.; Ertosun M.G.; \u00d6zkan \u00d6.; Emre S.; Ar\u0131ca S.; Ku\u015f\u00e7u F.; Candevir A.; Ert\u00fcrk-\u015eengel B.; Ayvaz F.; Aksoy F.; Mermutluo\u011flu \u00c7.; Demir Y.; G\u00fcnl\u00fco\u011flu G.; Tural-\u00d6n\u00fcr S.; K\u0131l\u0131\u00e7-Toker A.; Eren E.; Otlu B.; Mete A.\u00d6.; Ko\u00e7ak K.; Ate\u015f H.; Koca-Kalkan \u0130.; Aksu K.; Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021,398(10296),213-222","journal-title":"Lancet"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"Voysey M.","year":"2021","unstructured":"Voysey M.; Clemens S.A.C.; Madhi S.A.; Weckx L.Y.; Folegatti P.M.; Aley P.K.; Angus B.; Baillie V.L.; Barnabas S.L.; Bhorat Q.E.; Bibi S.; Briner C.; Cicconi P.; Collins A.M.; Colin-Jones R.; Cutland C.L.; Darton T.C.; Dheda K.; Duncan C.J.A.; Emary K.R.W.; Ewer K.J.; Fairlie L.; Faust S.N.; Feng S.; Ferreira D.M.; Finn A.; Goodman A.L.; Green C.M.; Green C.A.; Heath P.T.; Hill C.; Hill H.; Hirsch I.; Hodgson S.H.C.; Izu A.; Jackson S.; Jenkin D.; Joe C.C.D.; Kerridge S.; Koen A.; Kwatra G.; Lazarus R.; Lawrie A.M.; Lelliott A.; Libri V.; Lillie P.J.; Mallory R.; Mendes A.V.A.; Milan E.P.; Minassian A.M.; McGregor A.; Morrison H.; Mujadidi Y.F.; Nana A.; O\u2019Reilly P.J.; Padayachee S.D.; Pittella A.; Plested E.; Pollock K.M.; Ramasamy M.N.; Rhead S.; Schwarzbold A.V.; Singh N.; Smith A.; Song R.; Snape M.D.; Sprinz E.; Sutherland R.K.; Tarrant R.; Thomson E.C.; T\u00f6r\u00f6k M.E.; Toshner M.; Turner D.P.J.; Vekemans J.; Villafana T.L.; Watson M.E.E.; Williams C.J.; Douglas A.D.; Hill A.V.S.; Lambe T.; Gilbert S.C.; Pollard A.J.; Aban M.; Abayomi F.; Abeyskera K.; Aboagye J.; Adam M.; Adams K.; Adamson J.; Adelaja Y.A.; Adewetan G.; Adlou S.; Ahmed K.; Akhalwaya Y.; Akhalwaya S.; Alcock A.; Ali A.; Allen E.R.; Allen L.; Almeida T.C.D.S.C.; Alves M.P.S.; Amorim F.; Andritsou F.; Anslow R.; Appleby M.; Arbe-Barnes E.H.; Ariaans M.P.; Arns B.; Arruda L.; Azi P.; Azi L.; Babbage G.; Bailey C.; Baker K.F.; Baker M.; Baker N.; Baker P.; Baldwin L.; Baleanu I.; Bandeira D.; Bara A.; Barbosa M.A.S.; Barker D.; Barlow G.D.; Barnes E.; Barr A.S.; Barrett J.R.; Barrett J.; Bates L.; Batten A.; Beadon K.; Beales E.; Beckley R.; Belij-Rammerstorfer S.; Bell J.; Bellamy D.; Bellei N.; Belton S.; Berg A.; Bermejo L.; Berrie E.; Berry L.; Berzenyi D.; Beveridge A.; Bewley K.R.; Bexhell H.; Bhikha S.; Bhorat A.E.; Bhorat Z.E.; Bijker E.; Birch G.; Birch S.; Bird A.; Bird O.; Bisnauthsing K.; Bittaye M.; Blackstone K.; Blackwell L.; Bletchly H.; Blundell C.L.; Blundell S.R.; Bodalia P.; Boettger B.C.; Bolam E.; Boland E.; Bormans D.; Borthwick N.; Bowring F.; Boyd A.; Bradley P.; Brenner T.; Brown P.; Brown C.; Brown-O\u2019Sullivan C.; Bruce S.; Brunt E.; Buchan R.; Budd W.; Bulbulia Y.A.; Bull M.; Burbage J.; Burhan H.; Burn A.; Buttigieg K.R.; Byard N.; Cabera Puig I.; Calderon G.; Calvert A.; Camara S.; Cao M.; Cappuccini F.; Cardoso J.R.; Carr M.; Carroll M.W.; Carson-Stevens A.; Carvalho Y.M.; Carvalho J.A.M.; Casey H.R.; Cashen P.; Castro T.; Castro L.C.; Cathie K.; Cavey A.; Cerbino-Neto J.; Chadwick J.; Chapman D.; Charlton S.; Chelysheva I.; Chester O.; Chita S.; Cho J-S.; Cifuentes L.; Clark E.; Clark M.; Clarke A.; Clutterbuck E.A.; Collins S.L.K.; Conlon C.P.; Connarty S.; Coombes N.; Cooper C.; Cooper R.; Cornelissen L.; Corrah T.; Cosgrove C.; Cox T.; Crocker W.E.M.; Crosbie S.; Cullen L.; Cullen D.; Cunha D.R.M.F.; Cunningham C.; Cuthbertson F.C.; Da Guarda S.N.F.; da Silva L.P.; Damratoski B.E.; Danos Z.; Dantas M.T.D.C.; Darroch P.; Datoo M.S.; Datta C.; Davids M.; Davies S.L.; Davies H.; Davis E.; Davis J.; Davis J.; De Nobrega M.M.D.; De Oliveira Kalid L.M.; Dearlove D.; Demissie T.; Desai A.; Di Marco S.; Di Maso C.; Dinelli M.I.S.; Dinesh T.; Docksey C.; Dold C.; Dong T.; Donnellan F.R.; Dos Santos T.; dos Santos T.G.; Dos Santos E.P.; Douglas N.; Downing C.; Drake J.; Drake-Brockman R.; Driver K.; Drury R.; Dunachie S.J.; Durham B.S.; Dutra L.; Easom N.J.W.; van Eck S.; Edwards M.; Edwards N.J.; El Muhanna O.M.; Elias S.C.; Elmore M.; English M.; Esmail A.; Essack Y.M.; Farmer E.; Farooq M.; Farrar M.; Farrugia L.; Faulkner B.; Fedosyuk S.; Felle S.; Feng S.; Ferreira Da Silva C.; Field S.; Fisher R.; Flaxman A.; Fletcher J.; Fofie H.; Fok H.; Ford K.J.; Fowler J.; Fraiman P.H.A.; Francis E.; Franco M.M.; Frater J.; Freire M.S.M.; Fry S.H.; Fudge S.; Furze J.; Fuskova M.; Galian-Rubio P.; Galiza E.; Garlant H.; Gavrila M.; Geddes A.; Gibbons K.A.; Gilbride C.; Gill H.; Glynn S.; Godwin K.; Gokani K.; Goldoni U.C.; Goncalves M.; Gonzalez I.G.S.; Goodwin J.; Goondiwala A.; Gordon-Quayle K.; Gorini G.; Grab J.; Gracie L.; Greenland M.; Greenwood N.; Greffrath J.; Groenewald M.M.; Grossi L.; Gupta G.; Hackett M.; Hallis B.; Hamaluba M.; Hamilton E.; Hamlyn J.; Hammersley D.; Hanrath A.T.; Hanumunthadu B.; Harris S.A.; Harris C.; Harris T.; Harrison T.D.; Harrison D.; Hart T.C.; Hartnell B.; Hassan S.; Haughney J.; Hawkins S.; Hay J.; Head I.; Henry J.; Hermosin Herrera M.; Hettle D.B.; Hill J.; Hodges G.; Horne E.; Hou M.M.; Houlihan C.; Howe E.; Howell N.; Humphreys J.; Humphries H.E.; Hurley K.; Huson C.; Hyder-Wright A.; Hyams C.; Ikram S.; Ishwarbhai A.; Ivan M.; Iveson P.; Iyer V.; Jackson F.; De Jager J.; Jaumdally S.; Jeffers H.; Jesudason N.; Jones B.; Jones K.; Jones E.; Jones C.; Jorge M.R.; Jose A.; Joshi A.; J\u00fanior E.A.M.S.; Kadziola J.; Kailath R.; Kana F.; Karampatsas K.; Kasanyinga M.; Keen J.; Kelly E.J.; Kelly D.M.; Kelly D.; Kelly S.; Kerr D.; Kfouri R.\u00c1.; Khan L.; Khozoee B.; Kidd S.; Killen A.; Kinch J.; Kinch P.; King L.D.W.; King T.B.; Kingham L.; Klenerman P.; Knapper F.; Knight J.C.; Knott D.; Koleva S.; Lang M.; Lang G.; Larkworthy C.W.; Larwood J.P.J.; Law R.; Lazarus E.M.; Leach A.; Lees E.A.; Lemm N-M.; Lessa A.; Leung S.; Li Y.; Lias A.M.; Liatsikos K.; Linder A.; Lipworth S.; Liu S.; Liu X.; Lloyd A.; Lloyd S.; Loew L.; Lopez Ramon R.; Lora L.; Lowthorpe V.; Luz K.; MacDonald J.C.; MacGregor G.; Madhavan M.; Mainwaring D.O.; Makambwa E.; Makinson R.; Malahleha M.; Malamatsho R.; Mallett G.; Mansatta K.; Maoko T.; Mapetla K.; Marchevsky N.G.; Marinou S.; Marlow E.; Marques G.N.; Marriott P.; Marshall R.P.; Marshall J.L.; Martins F.J.; Masenya M.; Masilela M.; Masters S.K.; Mathew M.; Matlebjane H.; Matshidiso K.; Mazur O.; Mazzella A.; McCaughan H.; McEwan J.; McGlashan J.; McInroy L.; McIntyre Z.; McLenaghan D.; McRobert N.; McSwiggan S.; Megson C.; Mehdipour S.; Meijs W.; Mendon\u00e7a R.N.\u00c1.; Mentzer A.J.; Mirtorabi N.; Mitton C.; Mnyakeni S.; Moghaddas F.; Molapo K.; Moloi M.; Moore M.; Moraes-Pinto M.I.; Moran M.; Morey E.; Morgans R.; Morris S.; Morris S.; Morris H.C.; Morselli F.; Morshead G.; Morter R.; Mottal L.; Moultrie A.; Moya N.; Mpelembue M.; Msomi S.; Mugodi Y.; Mukhopadhyay E.; Muller J.; Munro A.; Munro C.; Murphy S.; Mweu P.; Myasaki C.H.; Naik G.; Naker K.; Nastouli E.; Nazir A.; Ndlovu B.; Neffa F.; Njenga C.; Noal H.; No\u00e9 A.; Novaes G.; Nugent F.L.; Nunes G.; O\u2019Brien K.; O\u2019Connor D.; Odam M.; Oelofse S.; Oguti B.; Olchawski V.; Oldfield N.J.; Oliveira M.G.; Oliveira C.; Oosthuizen A.; O\u2019Reilly P.; Osborne P.; Owen D.R.J.; Owen L.; Owens D.; Owino N.; Pacurar M.; Paiva B.V.B.; Palhares E.M.F.; Palmer S.; Parkinson S.; Parracho H.M.R.T.; Parsons K.; Patel D.; Patel B.; Patel F.; Patel K.; Patrick-Smith M.; Payne R.O.; Peng Y.; Penn E.J.; Pennington A.; Peralta Alvarez M.P.; Perring J.; Perry N.; Perumal R.; Petkar S.; Philip T.; Phillips D.J.; Phillips J.; Phohu M.K.; Pickup L.; Pieterse S.; Piper J.; Pipini D.; Plank M.; Du Plessis J.; Pollard S.; Pooley J.; Pooran A.; Poulton I.; Powers C.; Presa F.B.; Price D.A.; Price V.; Primeira M.; Proud P.C.; Provstgaard-Morys S.; Pueschel S.; Pulido D.; Quaid S.; Rabara R.; Radford A.; Radia K.; Rajapaska D.; Rajeswaran T.; Ramos A.S.F.; Ramos Lopez F.; Rampling T.; Rand J.; Ratcliffe H.; Rawlinson T.; Rea D.; Rees B.; Rein\u00e9 J.; Resuello-Dauti M.; Reyes Pabon E.; Ribiero C.M.; Ricamara M.; Richter A.; Ritchie N.; Ritchie A.J.; Robbins A.J.; Roberts H.; Robinson R.E.; Robinson H.; Rocchetti T.T.; Rocha B.P.; Roche S.; Rollier C.; Rose L.; Ross Russell A.L.; Rossouw L.; Royal S.; Rudiansyah I.; Ruiz S.; Saich S.; Sala C.; Sale J.; Salman A.M.; Salvador N.; Salvador S.; Sampaio M.; Samson A.D.; Sanchez-Gonzalez A.; Sanders H.; Sanders K.; Santos E.; Santos Guerra M.F.S.; Satti I.; Saunders J.E.; Saunders C.; Sayed A.; Schim van der Loeff I.; Schmid A.B.; Schofield E.; Screaton G.; Seddiqi S.; Segireddy R.R.; Senger R.; Serrano S.; Shah R.; Shaik I.; Sharpe H.E.; Sharrocks K.; Shaw R.; Shea A.; Shepherd A.; Shepherd J.G.; Shiham F.; Sidhom E.; Silk S.E.; da Silva Moraes A.C.; Silva-Junior G.; Silva-Reyes L.; Silveira A.D.; Silveira M.B.V.; Sinha J.; Skelly D.T.; Smith D.C.; Smith N.; Smith H.E.; Smith D.J.; Smith C.C.; Soares A.; Soares T.; Sol\u00f3rzano C.; Sorio G.L.; Sorley K.; Sosa-Rodriguez T.; Souza C.M.C.D.L.; Souza B.S.D.F.; Souza A.R.; Spencer A.J.; Spina F.; Spoors L.; Stafford L.; Stamford I.; Starinskij I.; Stein R.; Steven J.; Stockdale L.; Stockwell L.V.; Strickland L.H.; Stuart A.C.; Sturdy A.; Sutton N.; Szigeti A.; Tahiri-Alaoui A.; Tanner R.; Taoushanis C.; Tarr A.W.; Taylor K.; Taylor U.; Taylor I.J.; Taylor J.; te Water Naude R.; Themistocleous Y.; Themistocleous A.; Thomas M.; Thomas K.; Thomas T.M.; Thombrayil A.; Thompson F.; Thompson A.; Thompson K.; Thompson A.; Thomson J.; Thornton-Jones V.; Tighe P.J.; Tinoco L.A.; Tiongson G.; Tladinyane B.; Tomasicchio M.; Tomic A.; Tonks S.; Towner J.; Tran N.; Tree J.; Trillana G.; Trinham C.; Trivett R.; Truby A.; Tsheko B.L.; Turabi A.; Turner R.; Turner C.; Ulaszewska M.; Underwood B.R.; Varughese R.; Verbart D.; Verheul M.; Vichos I.; Vieira T.; Waddington C.S.; Walker L.; Wallis E.; Wand M.; Warbick D.; Wardell T.; Warimwe G.; Warren S.C.; Watkins B.; Watson E.; Webb S.; Webb-Bridges A.; Webster A.; Welch J.; Wells J.; West A.; White C.; White R.; Williams P.; Williams R.L.; Winslow R.; Woodyer M.; Worth A.T.; Wright D.; Wroblewska M.; Yao A.; Zimmer R.; Zizi D.; Zuidewind P.; Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021,397(10269),99-111","journal-title":"Lancet"},{"key":"ref=320","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/M21-0111","volume":"174","author":"Connors M.","year":"2021","unstructured":"Connors M.; Graham B.S.; Lane H.C.; Fauci A.S.; SARS-CoV-2 vaccines: Much accomplished, Much to Learn. Ann Intern Med 2021,174(5),687-690","journal-title":"Ann Intern Med"},{"key":"ref=321","year":"2021","unstructured":"Evidence assessment: Sinopharm\/BBIBP COVID-19 vaccine. WHOAvailable from:  (accessed on 28 October 2022)2021"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-2600(21)00075-8","volume":"9","author":"Williams T.C.","year":"2021","unstructured":"Williams T.C.; Burgers W.A.; SARS-CoV-2 evolution and vaccines: Cause for concern? Lancet Respir Med 2021,9(4),333-335","journal-title":"Lancet Respir Med"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"e0250780","DOI":"10.1371\/journal.pone.0250780","volume":"16","author":"Van Egeren D.","year":"2021","unstructured":"Van Egeren D.; Novokhodko A.; Stoddard M.; Tran U.; Zetter B.; Rogers M.; Pentelute B.L.; Carlson J.M.; Hixon M.; Joseph-McCarthy D.; Chakravarty A.; Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS One 2021,16(4),e0250780","journal-title":"PLoS One"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jiph.2021.12.014","volume":"15","author":"Malik J.A.","year":"2022","unstructured":"Malik J.A.; Ahmed S.; Mir A.; Shinde M.; Bender O.; Alshammari F.; Ansari M.; Anwar S.; The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. J Infect Public Health 2022,15(2),228-240","journal-title":"J Infect Public Health"},{"key":"ref=325","doi-asserted-by":"publisher","first-page":"101606","DOI":"10.1016\/j.bjid.2021.101606","volume":"25","author":"Mohammadi M.","year":"2021","unstructured":"Mohammadi M.; Shayestehpour M.; Mirzaei H.; The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis 2021,25(4),101606","journal-title":"Braz J Infect Dis"},{"key":"ref=326","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1126\/science.abg7404","volume":"371","author":"Altmann D.M.","year":"2021","unstructured":"Altmann D.M.; Boyton R.J.; Beale R.; Immunity to SARS-CoV-2 variants of concern. Science 2021,371(6534),1103-1104","journal-title":"Science"},{"key":"ref=327","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","volume":"184","author":"Hoang T.N.","year":"2021","unstructured":"Hoang T.N.; Pino M.; Boddapati A.K.; Viox E.G.; Starke C.E.; Upadhyay A.A.; Gumber S.; Nekorchuk M.; Busman-Sahay K.; Strongin Z.; Harper J.L.; Tharp G.K.; Pellegrini K.L.; Kirejczyk S.; Zandi K.; Tao S.; Horton T.R.; Beagle E.N.; Mahar E.A.; Lee M.Y.H.; Cohen J.; Jean S.M.; Wood J.S.; Connor-Stroud F.; Stammen R.L.; Delmas O.M.; Wang S.; Cooney K.A.; Sayegh M.N.; Wang L.; Filev P.D.; Weiskopf D.; Silvestri G.; Waggoner J.; Piantadosi A.; Kasturi S.P.; Al-Shakhshir H.; Ribeiro S.P.; Sekaly R.P.; Levit R.D.; Estes J.D.; Vanderford T.H.; Schinazi R.F.; Bosinger S.E.; Paiardini M.; Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 2021,184(2),460-475.e21","journal-title":"Cell"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"Cantini F.","year":"2020","unstructured":"Cantini F.; Niccoli L.; Matarrese D.; Nicastri E.; Stobbione P.; Goletti D.; Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020,81(2),318-356","journal-title":"J Infect"},{"key":"ref=329","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"Lopez Bernal J.","year":"2021","unstructured":"Lopez Bernal J.; Andrews N.; Gower C.; Gallagher E.; Simmons R.; Thelwall S.; Stowe J.; Tessier E.; Groves N.; Dabrera G.; Myers R.; Campbell C.N.J.; Amirthalingam G.; Edmunds M.; Zambon M.; Brown K.E.; Hopkins S.; Chand M.; Ramsay M.; Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021,385(7),585-594","journal-title":"N Engl J Med"},{"key":"ref=330","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1038\/s41467-021-24909-9","volume":"12","author":"Ikegame S.","year":"2021","unstructured":"Ikegame S.; Siddiquey M.N.A.; Hung C.T.; Haas G.; Brambilla L.; Oguntuyo K.Y.; Kowdle S.; Chiu H.P.; Stevens C.S.; Vilardo A.E.; Edelstein A.; Perandones C.; Kamil J.P.; Lee B.; Neutralizing activity of sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun 2021,12(1),4598","journal-title":"Nat Commun"},{"key":"ref=331","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12916-022-02509-8","volume":"20","author":"Barchuk A.","year":"2022","unstructured":"Barchuk A.; Cherkashin M.; Bulina A.; Berezina N.; Rakova T.; Kuplevatskaya D.; Stanevich O.; Skougarevskiy D.; Okhotin A.; Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: A test-negative case-control study. BMC Med 2022,20(1),312","journal-title":"BMC Med"},{"key":"ref=332","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/d41586-021-00268-9","volume":"590","author":"Callaway E.","year":"2021","unstructured":"Callaway E.; Mallapaty S.; Novavax offers first evidence that COVID vaccines protect people against variants. Nature 2021,590(7844),17","journal-title":"Nature"},{"key":"ref=333","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijtb.2021.03.010","volume":"68","author":"Matta S.","year":"2021","unstructured":"Matta S.; Rajpal S.; Chopra K.K.; Arora V.K.; Covid-19 vaccines and new mutant strains impacting the pandemic. Indian J Tuberc 2021,68(2),171-173","journal-title":"Indian J Tuberc"},{"key":"ref=334","unstructured":"Centers for disease control and preventiion CDCAvailable from: (accessed on 27 November 2022).","journal-title":"Centers for disease control and preventiion"},{"key":"ref=335","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1128\/JVI.00632-13","volume":"87","author":"de Wispelaere M.","year":"2013","unstructured":"de Wispelaere M.; LaCroix A.J.; Yang P.L.; The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol 2013,87(13),7367-7381","journal-title":"J Virol"},{"key":"ref=336","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41401-020-00556-6","volume":"42","author":"Yang L.","year":"2021","unstructured":"Yang L.; Pei R.; Li H.; Ma X.; Zhou Y.; Zhu F.; He P.; Tang W.; Zhang Y.; Xiong J.; Xiao S.; Tong X.; Zhang B.; Zuo J.; Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin 2021,42(8),1347-1353","journal-title":"Acta Pharmacol Sin"},{"key":"ref=337","doi-asserted-by":"publisher","first-page":"o1052","DOI":"10.1136\/bmj.o1052","volume":"377","author":"Mahase E.","year":"2022","unstructured":"Mahase E.; Covid-19: Mix and match booster vaccination approach offers best protection, study reports. BMJ 2022,377,o1052","journal-title":"BMJ"},{"key":"ref=338","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"Mathieu E.","year":"2021","unstructured":"Mathieu E.; Ritchie H.; Ortiz-Ospina E.; Roser M.; Hasell J.; Appel C.; Giattino C.; Rod\u00e9s-Guirao L.; A global database of COVID-19 vaccinations. Nat Hum Behav 2021,5(7),947-953","journal-title":"Nat Hum Behav"},{"key":"ref=339","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jama.2022.11844","volume":"328","author":"Larkin H.D.","year":"2022","unstructured":"Larkin H.D.; Mix-and-match COVID-19 boosters after inactivated virus vaccine. JAMA 2022,328(3),234-234","journal-title":"JAMA"},{"key":"ref=340","doi-asserted-by":"publisher","first-page":"31935","DOI":"10.1021\/acsomega.2c02794","volume":"7","author":"Puhl A.C.","year":"2022","unstructured":"Puhl A.C.; Gomes G.F.; Damasceno S.; Fritch E.J.; Levi J.A.; Johnson N.J.; Scholle F.; Premkumar L.; Hurst B.L.; Lee-Montiel F.; Veras F.P.; Batah S.S.; Fabro A.T.; Moorman N.J.; Yount B.L.; Dickmander R.J.; Baric R.S.; Pearce K.H.; Cunha F.Q.; Alves-Filho J.C.; Cunha T.M.; Ekins S.; Vandetanib blocks the cytokine storm in SARS-CoV-2-infected mice. ACS Omega 2022,7(36),31935-31944","journal-title":"ACS Omega"},{"key":"ref=341","doi-asserted-by":"publisher","first-page":"e0005540","DOI":"10.1371\/journal.pntd.0005540","volume":"11","author":"Nelson E.A.","year":"2017","unstructured":"Nelson E.A.; Dyall J.; Hoenen T.; Barnes A.B.; Zhou H.; Liang J.Y.; Michelotti J.; Dewey W.H.; DeWald L.E.; Bennett R.S.; Morris P.J.; Guha R.; Klumpp-Thomas C.; McKnight C.; Chen Y.C.; Xu X.; Wang A.; Hughes E.; Martin S.; Thomas C.; Jahrling P.B.; Hensley L.E.; Olinger G.G.; White J.M.; The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl Trop Dis 2017,11(4),e0005540","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=342","doi-asserted-by":"publisher","first-page":"20803","DOI":"10.1073\/pnas.2007837117","volume":"117","author":"Kang Y.L.","year":"2020","unstructured":"Kang Y.L.; Chou Y.; Rothlauf P.W.; Liu Z.; Soh T.K.; Cureton D.; Case J.B.; Chen R.E.; Diamond M.S.; Whelan S.P.J.; Kirchhausen T.; Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc Natl Acad Sci 2020,117(34),20803-20813","journal-title":"Proc Natl Acad Sci"},{"key":"ref=343","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"Bergelson J.M.","year":"1997","unstructured":"Bergelson J.M.; Cunningham J.A.; Droguett G.; Kurt-Jones E.A.; Krithivas A.; Hong J.S.; Horwitz M.S.; Crowell R.L.; Finberg R.W.; Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997,275(5304),1320-1323","journal-title":"Science"},{"key":"ref=344","doi-asserted-by":"publisher","first-page":"10862","DOI":"10.1128\/JVI.00928-12","volume":"86","author":"Li H.","year":"2012","unstructured":"Li H.; Rhee E.G.; Masek-Hammerman K.; Teigler J.E.; Abbink P.; Barouch D.H.; Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 2012,86(19),10862-10865","journal-title":"J Virol"},{"key":"ref=345","first-page":"e01474","volume":"93","author":"Nesti\u0107 D.","year":"2018","unstructured":"Nesti\u0107 D.; Uil T.G.; Ma J.; Roy S.; Vellinga J.; Baker A.H.; Custers J.; Majhen D.; \u03b1v\u03b23 integrin is required for efficient infection of epithelial cells with human adenovirus type 26. J Virol 2018,93(1),e01474-e01418","journal-title":"J Virol"},{"key":"ref=346","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.3390\/ijerph18157859","volume":"18","author":"Riad A.","year":"2021","unstructured":"Riad A.; Sch\u00fcnemann H.; Attia S.; Peri\u010di\u0107 T.; \u017duljevi\u0107 M.; J\u00fcrisson M.; Kalda R.; Lang K.; Morankar S.; Yesuf E.; Mekhemar M.; Danso-Appiah A.; Sofi-Mahmudi A.; P\u00e9rez-Gaxiola G.; Dziedzic A.; Ap\u00f3stolo J.; Cardoso D.; Marc J.; Moreno-Casbas M.; Wiysonge C.; Qaseem A.; Gryschek A.; Tadi\u0107 I.; Hussain S.; Khan M.; Klugarova J.; Pokorna A.; Ko\u0161\u010d\u00edk M.; Klugar M.; COVID-19 vaccines safety tracking (CoVaST): Protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines\u2019 side effects. Int J Environ Res Public Health 2021,18(15),7859","journal-title":"Int J Environ Res Public Health"},{"key":"ref=347","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/cid\/ciab438","volume":"74","author":"Chodick G.","year":"2022","unstructured":"Chodick G.; Tene L.; Rotem R.S.; Patalon T.; Gazit S.; Ben-Tov A.; Weil C.; Goldshtein I.; Twig G.; Cohen D.; Muhsen K.; The effectiveness of the two-dose BNT162b2 vaccine: Analysis of real-world data. Clin Infect Dis 2022,74(3),472-478","journal-title":"Clin Infect Dis"},{"key":"ref=348","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14785\/lymphosign-2021-0020","volume":"8","author":"Roifman C.M.","year":"2021","unstructured":"Roifman C.M.; Vong L.; COVID-19 vaccination for patients with primary immunodeficiency. LymphoSign Journal 2021,8(2),37-45","journal-title":"LymphoSign Journal"},{"key":"ref=349","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1099\/jgv.0.001047","volume":"99","author":"Sisk J.M.","year":"2018","unstructured":"Sisk J.M.; Frieman M.B.; Machamer C.E.; Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 2018,99(5),619-630","journal-title":"J Gen Virol"},{"key":"ref=350","doi-asserted-by":"publisher","first-page":"e151477","DOI":"10.1172\/jci.insight.151477","volume":"6","author":"Racine-Brzostek S.E.","year":"2021","unstructured":"Racine-Brzostek S.E.; Yee J.K.; Sukhu A.; Qiu Y.; Rand S.; Barone P.D.; Hao Y.; Yang H.S.; Meng Q.H.; Apple F.S.; Shi Y.; Chadburn A.; Golden E.; Formenti S.C.; Cushing M.M.; Zhao Z.; Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight 2021,6(20),e151477","journal-title":"JCI Insight"},{"key":"ref=351","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1080\/14760584.2021.1977630","volume":"20","author":"Jamiruddin R.","year":"2021","unstructured":"Jamiruddin R.; Haq A.; Khondoker M.U.; Ali T.; Ahmed F.; Khandker S.S.; Jawad I.; Hossain R.; Ahmed S.; Rahman S.R.; Mustafi M.; Kaitsuka T.; Mie M.; Tomizawa K.; Kobatake E.; Haque M.; Adnan N.; Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh. Expert Rev Vaccines 2021,20(12),1651-1660","journal-title":"Expert Rev Vaccines"},{"key":"ref=352","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jama.2021.3199","volume":"325","author":"Creech C.B.","year":"2021","unstructured":"Creech C.B.; Walker S.C.; Samuels R.J.; SARS-CoV-2 vaccines. JAMA 2021,325(13),1318-1320","journal-title":"JAMA"},{"key":"ref=353","doi-asserted-by":"publisher","first-page":"e1010821","DOI":"10.1371\/journal.ppat.1010821","volume":"18","author":"Tang P.C.H.","year":"2022","unstructured":"Tang P.C.H.; Ng W.H.; King N.J.C.; Mahalingam S.; Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic? PLoS Pathog 2022,18(9),e1010821","journal-title":"PLoS Pathog"},{"key":"ref=354","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1414216","volume":"376","author":"Regules J.A.","year":"2017","unstructured":"Regules J.A.; Beigel J.H.; Paolino K.M.; Voell J.; Castellano A.R.; Hu Z.; Mu\u00f1oz P.; Moon J.E.; Ruck R.C.; Bennett J.W.; Twomey P.S.; Guti\u00e9rrez R.L.; Remich S.A.; Hack H.R.; Wisniewski M.L.; Josleyn M.D.; Kwilas S.A.; Van Deusen N.; Mbaya O.T.; Zhou Y.; Stanley D.A.; Jing W.; Smith K.S.; Shi M.; Ledgerwood J.E.; Graham B.S.; Sullivan N.J.; Jagodzinski L.L.; Peel S.A.; Alimonti J.B.; Hooper J.W.; Silvera P.M.; Martin B.K.; Monath T.P.; Ramsey W.J.; Link C.J.; Lane H.C.; Michael N.L.; Davey R.T.; Thomas S.J.; A recombinant vesicular stomatitis virus ebola vaccine. N Engl J Med 2017,376(4),330-341","journal-title":"N Engl J Med"},{"key":"ref=355","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"Xia S.","year":"2020","unstructured":"Xia S.; Duan K.; Zhang Y.; Zhao D.; Zhang H.; Xie Z.; Li X.; Peng C.; Zhang Y.; Zhang W.; Yang Y.; Chen W.; Gao X.; You W.; Wang X.; Wang Z.; Shi Z.; Wang Y.; Yang X.; Zhang L.; Huang L.; Wang Q.; Lu J.; Yang Y.; Guo J.; Zhou W.; Wan X.; Wu C.; Wang W.; Huang S.; Du J.; Meng Z.; Pan A.; Yuan Z.; Shen S.; Guo W.; Yang X.; Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA 2020,324(10),951-960","journal-title":"JAMA"},{"key":"ref=356","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"Xia S.","year":"2021","unstructured":"Xia S.; Zhang Y.; Wang Y.; Wang H.; Yang Y.; Gao G.F.; Tan W.; Wu G.; Xu M.; Lou Z.; Huang W.; Xu W.; Huang B.; Wang H.; Wang W.; Zhang W.; Li N.; Xie Z.; Ding L.; You W.; Zhao Y.; Yang X.; Liu Y.; Wang Q.; Huang L.; Yang Y.; Xu G.; Luo B.; Wang W.; Liu P.; Guo W.; Yang X.; Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis 2021,21(1),39-51","journal-title":"Lancet Infect Dis"},{"key":"ref=357","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s40249-021-00924-2","volume":"10","author":"Feng Y.","year":"2021","unstructured":"Feng Y.; Chen J.; Yao T.; Chang Y.; Li X.; Xing R.; Li H.; Xie R.; Zhang X.; Wei Z.; Mu S.; Liu L.; Feng L.; Wang S.; Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: A randomized, parallel, controlled clinical trial. Infect Dis Poverty 2021,10(1),138","journal-title":"Infect Dis Poverty"},{"key":"ref=358","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","volume":"21","author":"Han B.","year":"2021","unstructured":"Han B.; Song Y.; Li C.; Yang W.; Ma Q.; Jiang Z.; Li M.; Lian X.; Jiao W.; Wang L.; Shu Q.; Wu Z.; Zhao Y.; Li Q.; Gao Q.; Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1\/2 clinical trial. Lancet Infect Dis 2021,21(12),1645-1653","journal-title":"Lancet Infect Dis"},{"key":"ref=359","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","volume":"39","author":"Fadlyana E.","year":"2021","unstructured":"Fadlyana E.; Rusmil K.; Tarigan R.; Rahmadi A.R.; Prodjosoewojo S.; Sofiatin Y.; Khrisna C.V.; Sari R.M.; Setyaningsih L.; Surachman F.; Bachtiar N.S.; Sukandar H.; Megantara I.; Murad C.; Pangesti K.N.A.; Setiawaty V.; Sudigdoadi S.; Hu Y.; Gao Q.; Kartasasmita C.B.; A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: An interim analysis in Indonesia. Vaccine 2021,39(44),6520-6528","journal-title":"Vaccine"},{"key":"ref=360","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1080\/22221751.2021.1937328","volume":"10","author":"Liao Y.","year":"2021","unstructured":"Liao Y.; Zhang Y.; Zhao H.; Pu J.; Zhao Z.; Li D.; Fan S.; Yu L.; Xu X.; Wang L.; Jiang G.; Liu L.; Li Q.; Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine. Emerg Microbes Infect 2021,10(1),1112-1115","journal-title":"Emerg Microbes Infect"},{"key":"ref=361","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1080\/22221751.2021.1996210","volume":"10","author":"Yue L.","year":"2021","unstructured":"Yue L.; Zhou J.; Zhou Y.; Yang X.; Xie T.; Yang M.; Zhao H.; Zhao Y.; Yang T.; Li H.; Xiang H.; Wang J.; Lu S.; Liu H.; Zhao H.; Wei X.; Zhang Y.; Xie Z.; Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern. Emerg Microbes Infect 2021,10(1),2125-2127","journal-title":"Emerg Microbes Infect"},{"key":"ref=362","doi-asserted-by":"publisher","first-page":"789","DOI":"10.24272\/j.issn.2095-8137.2021.343","volume":"42","author":"Xie X.","year":"2021","unstructured":"Xie X.; Han J.B.; Ma G.; Feng X.L.; Li X.; Zou Q.C.; Deng Z.H.; Zeng J.; Emerging SARS-CoV-2 B.1.621\/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool Res 2021,42(6),789-791","journal-title":"Zool Res"},{"key":"ref=363","doi-asserted-by":"publisher","first-page":"927306","DOI":"10.3389\/fmicb.2022.927306","volume":"13","author":"Heidary M.","year":"2022","unstructured":"Heidary M.; Kaviar V.H.; Shirani M.; Ghanavati R.; Motahar M.; Sholeh M.; Ghahramanpour H.; Khoshnood S.; A comprehensive review of the protein subunit vaccines against COVID-19. Front Microbiol 2022,13,927306","journal-title":"Front Microbiol"},{"key":"ref=364","doi-asserted-by":"publisher","first-page":"701501","DOI":"10.3389\/fimmu.2021.701501","volume":"12","author":"Mart\u00ednez-Flores D.","year":"2021","unstructured":"Mart\u00ednez-Flores D.; Zepeda-Cervantes J.; Cruz-Res\u00e9ndiz A.; Aguirre-Sampieri S.; Sampieri A.; Vaca L.; SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol 2021,12,701501","journal-title":"Front Immunol"},{"key":"ref=365","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","volume":"170","author":"Pollet J.","year":"2021","unstructured":"Pollet J.; Chen W.H.; Strych U.; Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev 2021,170,71-82","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=366","year":"2022","unstructured":"A Phase I\/II clinical trial in healthy people aged 18 years and above. 2022"},{"key":"ref=367","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","volume":"21","author":"Yang S.","year":"2021","unstructured":"Yang S.; Li Y.; Dai L.; Wang J.; He P.; Li C.; Fang X.; Wang C.; Zhao X.; Huang E.; Wu C.; Zhong Z.; Wang F.; Duan X.; Tian S.; Wu L.; Liu Y.; Luo Y.; Chen Z.; Li F.; Li J.; Yu X.; Ren H.; Liu L.; Meng S.; Yan J.; Hu Z.; Gao L.; Gao G.F.; Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 2021,21(8),1107-1119","journal-title":"Lancet Infect Dis"},{"key":"ref=368","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","volume":"386","author":"Dai L.","year":"2022","unstructured":"Dai L.; Gao L.; Tao L.; Hadinegoro S.R.; Erkin M.; Ying Z.; He P.; Girsang R.T.; Vergara H.; Akram J.; Satari H.I.; Khaliq T.; Sughra U.; Celi A.P.; Li F.; Li Y.; Jiang Z.; Dalimova D.; Tuychiev J.; Turdikulova S.; Ikram A.; Flores Lastra N.; Ding F.; Suhardono M.; Fadlyana E.; Yan J.; Hu Z.; Li C.; Abdurakhmonov I.Y.; Gao G.F.; Efficacy and safety of the rbd-dimer\u2013based Covid-19 vaccine zf2001 in adults. N Engl J Med 2022,386(22),2097-2111","journal-title":"N Engl J Med"},{"key":"ref=369","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","volume":"399","author":"Bravo L.","year":"2022","unstructured":"Bravo L.; Smolenov I.; Han H.H.; Li P.; Hosain R.; Rockhold F.; Clemens S.A.C.; Roa C.; Borja-Tabora C.; Quinsaat A.; Lopez P.; L\u00f3pez-Medina E.; Brochado L.; Hern\u00e1ndez E.A.; Reynales H.; Medina T.; Velasquez H.; Toloza L.B.; Rodriguez E.J.; de Salazar D.I.M.; Rodr\u00edguez C.A.; Sprinz E.; Cerbino-Neto J.; Luz K.G.; Schwarzbold A.V.; Paiva M.S.; Carlos J.; Montellano M.E.B.; de Los Reyes M.R.A.; Yu C.Y.; Alberto E.R.; Panaligan M.M.; Salvani-Bautista M.; Buntinx E.; Hites M.; Martinot J.B.; Bhorat Q.E.; Badat A.; Baccarini C.; Hu B.; Jurgens J.; Engelbrecht J.; Ambrosino D.; Richmond P.; Siber G.; Liang J.; Clemens R.; Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: A phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2022,399(10323),461-472","journal-title":"Lancet"},{"key":"ref=370","doi-asserted-by":"publisher","first-page":"970045","DOI":"10.3389\/fcvm.2022.970045","volume":"9","author":"Dong Y.","year":"2022","unstructured":"Dong Y.; Liu X.; Yang C.; Qi Q.; Shi W.; Li Y.; Zuo M.; Wang S.; Bi H.; Ma R.; Zhang G.; Cong B.; Case report: Myocarditis following COVID-19 protein subunit vaccination. Front Cardiovasc Med 2022,9,970045","journal-title":"Front Cardiovasc Med"},{"key":"ref=371","year":"2023","unstructured":"KRR1 small subunit processome component homolog [Homo sapiens (human)]. Available from:(accessed on 9 December 2022) 2023"},{"key":"ref=372","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","volume":"18","author":"Robert-Guroff M.","year":"2007","unstructured":"Robert-Guroff M.; Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007,18(6),546-556","journal-title":"Curr Opin Biotechnol"},{"key":"ref=373","doi-asserted-by":"publisher","first-page":"e0006870","DOI":"10.1371\/journal.pntd.0006870","volume":"12","author":"Wang C.","year":"2018","unstructured":"Wang C.; Dulal P.; Zhou X.; Xiang Z.; Goharriz H.; Banyard A.; Green N.; Brunner L.; Ventura R.; Collin N.; Draper S.J.; Hill A.V.S.; Ashfield R.; Fooks A.R.; Ertl H.C.; Douglas A.D.; A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Negl Trop Dis 2018,12(10),e0006870","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=374","doi-asserted-by":"publisher","first-page":"e163202","DOI":"10.1172\/JCI163202","volume":"132","author":"Mahla R.S.","year":"2022","unstructured":"Mahla R.S.; Dustin L.B.; Lessons from a large-scale COVID-19 vaccine trial. J Clin Invest 2022,132(18),e163202","journal-title":"J Clin Invest"},{"key":"ref=375","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","volume":"377","author":"Kennedy S.B.","year":"2017","unstructured":"Kennedy S.B.; Bolay F.; Kieh M.; Grandits G.; Badio M.; Ballou R.; Eckes R.; Feinberg M.; Follmann D.; Grund B.; Gupta S.; Hensley L.; Higgs E.; Janosko K.; Johnson M.; Kateh F.; Logue J.; Marchand J.; Monath T.; Nason M.; Nyenswah T.; Roman F.; Stavale E.; Wolfson J.; Neaton J.D.; Lane H.C.; Phase 2 placebo-controlled trial of two vaccines to prevent ebola in liberia. N Engl J Med 2017,377(15),1438-1447","journal-title":"N Engl J Med"},{"key":"ref=376","doi-asserted-by":"publisher","first-page":"e2118895119","DOI":"10.1073\/pnas.2118895119","volume":"119","author":"Hoff N.A.","year":"2022","unstructured":"Hoff N.A.; Bratcher A.; Kelly J.D.; Musene K.; Kompany J.P.; Kabamba M.; Mbala-Kingebeni P.; Dighero-Kemp B.; Kocher G.; Elliott E.; Reilly C.; Halbrook M.; Ilunga Kebela B.; Gadoth A.; Ngoie Mwamba G.; Tambu M.; McIlwain D.R.; Mukadi P.; Hensley L.E.; Ahuka-Mundeke S.; Rutherford G.W.; Muyembe-Tamfum J.J.; Rimoin A.W.; Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. Proc Natl Acad Sci 2022,119(6),e2118895119","journal-title":"Proc Natl Acad Sci"},{"key":"ref=377","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","volume":"20","author":"Koch T.","year":"2020","unstructured":"Koch T.; Dahlke C.; Fathi A.; Kupke A.; Kr\u00e4hling V.; Okba N.M.A.; Halwe S.; Rohde C.; Eickmann M.; Volz A.; Hesterkamp T.; Jambrecina A.; Borregaard S.; Ly M.L.; Zinser M.E.; Bartels E.; Poetsch J.S.H.; Neumann R.; Fux R.; Schmiedel S.; Lohse A.W.; Haagmans B.L.; Sutter G.; Becker S.; Addo M.M.; Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: An open-label, phase 1 trial. Lancet Infect Dis 2020,20(7),827-838","journal-title":"Lancet Infect Dis"},{"key":"ref=378","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/mtm.2016.30","volume":"3","author":"Afkhami S.","year":"2016","unstructured":"Afkhami S.; Yao Y.; Xing Z.; Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev 2016,3,16030","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=379","doi-asserted-by":"publisher","first-page":"e34884","DOI":"10.1371\/journal.pone.0034884","volume":"7","author":"Steffensen M.A.","year":"2012","unstructured":"Steffensen M.A.; Jensen B.A.H.; Holst P.J.; Bassi M.R.; Christensen J.P.; Thomsen A.R.; Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses. PLoS One 2012,7(4),e34884","journal-title":"PLoS One"},{"key":"ref=380","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","volume":"20","author":"Folegatti P.M.","year":"2020","unstructured":"Folegatti P.M.; Bittaye M.; Flaxman A.; Lopez F.R.; Bellamy D.; Kupke A.; Mair C.; Makinson R.; Sheridan J.; Rohde C.; Halwe S.; Jeong Y.; Park Y.S.; Kim J.O.; Song M.; Boyd A.; Tran N.; Silman D.; Poulton I.; Datoo M.; Marshall J.; Themistocleous Y.; Lawrie A.; Roberts R.; Berrie E.; Becker S.; Lambe T.; Hill A.; Ewer K.; Gilbert S.; Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020,20(7),816-826","journal-title":"Lancet Infect Dis"},{"key":"ref=381","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","volume":"26","author":"Martin J.E.","year":"2008","unstructured":"Martin J.E.; Louder M.K.; Holman L.A.; Gordon I.J.; Enama M.E.; Larkin B.D.; Andrews C.A.; Vogel L.; Koup R.A.; Roederer M.; Bailer R.T.; Gomez P.L.; Nason M.; Mascola J.R.; Nabel G.J.; Graham B.S.; A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008,26(50),6338-6343","journal-title":"Vaccine"},{"key":"ref=382","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"Modjarrad K.","year":"2019","unstructured":"Modjarrad K.; Roberts C.C.; Mills K.T.; Castellano A.R.; Paolino K.; Muthumani K.; Reuschel E.L.; Robb M.L.; Racine T.; Oh M.; Lamarre C.; Zaidi F.I.; Boyer J.; Kudchodkar S.B.; Jeong M.; Darden J.M.; Park Y.K.; Scott P.T.; Remigio C.; Parikh A.P.; Wise M.C.; Patel A.; Duperret E.K.; Kim K.Y.; Choi H.; White S.; Bagarazzi M.; May J.M.; Kane D.; Lee H.; Kobinger G.; Michael N.L.; Weiner D.B.; Thomas S.J.; Maslow J.N.; Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 2019,19(9),1013-1022","journal-title":"Lancet Infect Dis"},{"key":"ref=383","doi-asserted-by":"publisher","first-page":"e01372-19","DOI":"10.1128\/mBio.01372-19","volume":"10","author":"Strange D.P.","year":"2019","unstructured":"Strange D.P.; Jiyarom B.; Pourhabibi Zarandi N.; Xie X.; Baker C.; Sadri-Ardekani H.; Shi P.Y.; Verma S.; Axl promotes zika virus entry and modulates the antiviral state of human sertoli cells. MBio 2019,10(4),e01372-19","journal-title":"MBio"},{"key":"ref=384","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1089\/10430349950018021","volume":"10","author":"O\u2019Riordan C.R.","year":"1999","unstructured":"O\u2019Riordan C.R.; Lachapelle A.; Delgado C.; Parkes V.; Wadsworth S.C.; Smith A.E.; Francis G.E.; PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999,10(8),1349-1358","journal-title":"Hum Gene Ther"},{"key":"ref=385","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"Tatsis N.","year":"2004","unstructured":"Tatsis N.; Ertl H.C.J.; Adenoviruses as vaccine vectors. Mol Ther 2004,10(4),616-629","journal-title":"Mol Ther"},{"key":"ref=386","doi-asserted-by":"publisher","first-page":"100432","DOI":"10.1016\/j.dmpk.2021.100432","volume":"42","author":"Sakurai F.","year":"2022","unstructured":"Sakurai F.; Tachibana M.; Mizuguchi H.; Adenovirus vector-based vaccine for infectious diseases. Drug Metab Pharmacokinet 2022,42,100432","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=387","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/sj.gt.3301858","volume":"9","author":"Sailaja G.","year":"2002","unstructured":"Sailaja G.; HogenEsch H.; North A.; Hays J.; Mittal S.K.; Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther 2002,9(24),1722-1729","journal-title":"Gene Ther"},{"key":"ref=388","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1080\/21645515.2021.1944742","volume":"17","author":"Rahman M.A.","year":"2021","unstructured":"Rahman M.A.; Islam M.S.; Early approval of COVID-19 vaccines: Pros and cons. Hum Vaccin Immunother 2021,17(10),3288-3296","journal-title":"Hum Vaccin Immunother"},{"key":"ref=389","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","volume":"29","author":"Greaney A.J.","year":"2021","unstructured":"Greaney A.J.; Starr T.N.; Gilchuk P.; Zost S.J.; Binshtein E.; Loes A.N.; Hilton S.K.; Huddleston J.; Eguia R.; Crawford K.H.D.; Dingens A.S.; Nargi R.S.; Sutton R.E.; Suryadevara N.; Rothlauf P.W.; Liu Z.; Whelan S.P.J.; Carnahan R.H.; Crowe J.E.; Bloom J.D.; Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 2021,29(1),44-57.e9","journal-title":"Cell Host Microbe"},{"key":"ref=390","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4161\/onci.19727","volume":"1","author":"Kreiter S.","year":"2012","unstructured":"Kreiter S.; Castle J.C.; T\u00fcreci \u00d6.; Sahin U.; Targeting the tumor mutanome for personalized vaccination therapy. OncoImmunology 2012,1(5),768-769","journal-title":"OncoImmunology"},{"key":"ref=391","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"Petsch B.","year":"2012","unstructured":"Petsch B.; Schnee M.; Vogel A.B.; Lange E.; Hoffmann B.; Voss D.; Schlake T.; Thess A.; Kallen K.J.; Stitz L.; Kramps T.; Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012,30(12),1210-1216","journal-title":"Nat Biotechnol"},{"key":"ref=392","doi-asserted-by":"publisher","first-page":"718753","DOI":"10.3389\/fbioe.2021.718753","volume":"9","author":"Liang Y.","year":"2021","unstructured":"Liang Y.; Huang L.; Liu T.; Development and delivery systems of mRNA vaccines. Front Bioeng Biotechnol 2021,9,718753","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=393","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0972-6748.328833","volume":"30","author":"Chaudhury S.","year":"2021","unstructured":"Chaudhury S.; Ali T.; Mujawar S.; Sowmya A.V.; Saldanha D.; Dangers of mRNA vaccines. Ind Psychiatry J 2021,30(3(S1)),291","journal-title":"Ind Psychiatry J"},{"key":"ref=394","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1586\/erv.09.84","volume":"8","author":"Cai Y.","year":"2009","unstructured":"Cai Y.; Rodriguez S.; Hebel H.; DNA vaccine manufacture: Scale and quality. Expert Rev Vaccines 2009,8(9),1277-1291","journal-title":"Expert Rev Vaccines"},{"key":"ref=395","doi-asserted-by":"publisher","first-page":"18885","DOI":"10.1002\/anie.202008319","volume":"59","author":"Ye T.","year":"2020","unstructured":"Ye T.; Zhong Z.; Garc\u00eda-Sastre A.; Schotsaert M.; De Geest B.G.; Current status of COVID-19 (Pre)clinical vaccine development. Angew Chem Int Ed 2020,59(43),18885-18897","journal-title":"Angew Chem Int Ed"},{"key":"ref=396","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1586\/erv.09.132","volume":"8","author":"Dupuy L.C.","year":"2009","unstructured":"Dupuy L.C.; Schmaljohn C.S.; DNA vaccines for biodefense. Expert Rev Vaccines 2009,8(12),1739-1754","journal-title":"Expert Rev Vaccines"},{"key":"ref=397","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/imm.12467","volume":"145","author":"Niezold T.","year":"2015","unstructured":"Niezold T.; Storcksdieck genannt Bonsmann M.; Maaske A.; Temchura V.; Heinecke V.; Hannaman D.; Buer J.; Ehrhardt C.; Hansen W.; \u00dcberla K.; Tenbusch M.; DNA vaccines encoding DEC205-targeted antigens: Immunity or tolerance? Immunology 2015,145(4),519-533","journal-title":"Immunology"},{"key":"ref=398","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1586\/erv.09.43","volume":"8","author":"Roper R.L.","year":"2009","unstructured":"Roper R.L.; Rehm K.E.; SARS vaccines: where are we? Expert Rev Vaccines 2009,8(7),887-898","journal-title":"Expert Rev Vaccines"},{"key":"ref=399","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/biology9060141","volume":"9","author":"Pandey S.","year":"2020","unstructured":"Pandey S.; Yadav B.; Pandey A.; Tripathi T.; Khawary M.; Kant S.; Tripathi D.; Lessons from SARS-CoV-2 pandemic: Evolution, disease dynamics and future. Biology 2020,9(6),141","journal-title":"Biology"},{"key":"ref=400","doi-asserted-by":"publisher","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"Tseng C.T.","year":"2012","unstructured":"Tseng C.T.; Sbrana E.; Iwata-Yoshikawa N.; Newman P.C.; Garron T.; Atmar R.L.; Peters C.J.; Couch R.B.; Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012,7(4),e35421","journal-title":"PLoS One"},{"key":"ref=401","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"Agrawal A.S.","year":"2016","unstructured":"Agrawal A.S.; Tao X.; Algaissi A.; Garron T.; Narayanan K.; Peng B.H.; Couch R.B.; Tseng C.T.K.; Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016,12(9),2351-2356","journal-title":"Hum Vaccin Immunother"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230825094341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220323\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230825094341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T07:19:18Z","timestamp":1703229558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220323\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":401,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026623666230825094341","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}